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The RAC1 specific GEF, DOCK4, has been identified as an essential component in the 
Rho GTPase signalling pathway, imperative for correct vascular patterning and lumenisation 
during sprouting angiogenesis in vitro. As RAC1 has been previously implicated in the 
signalling events involved in vascular regrowth within a hypoxic environment, it was 
hypothesized that DOCK4 may be an important effector in the response to vascular injury 
and oxygen deprivation. To test this hypothesis, a DOCK4 depleted endothelial co-culture 
assay was carried out in both hypoxic and normoxic conditions. DOCK4 driven activation of 
RAC1 has been demonstrated under VEGF signalling, however FGF2 signalling pathways have 
also been strongly implicated in vascular response to blood vessel injury and hypoxia. 
Therefore, co-culture assays were carried out to assess sprouting angiogenesis with DOCK4 
knockdown in response to FGF2 supplementation. Further, a heterozygous DOCK4 depleted 
murine model in ischemia studies using a model of HLI was employed together with LDI 
monitoring of vascular response and regrowth, comparing the response of heterozygous 
Dock4 KO mice and their WT littermate controls.  
DOCK4 interacts with the CDC42 GEF DOCK9 but the molecular basis of the 
interaction is unknown, as is the role of GEF heterodimerization in cell signalling. This study 
aims to further understand the function of DOCK4 within a pathological sprouting 
angiogenesis while also investigating the mechanism of interaction between DOCK4 and 
DOCK9.  
The two pro-angiogenic growth factors VEGFA and FGF2 drive different phenotypical 
growth responses during sprouting angiogenesis in vitro. DOCK4 was demonstrated as being 
an important component of FGF2 stimulated angiogenesis under hypoxia, indicating DOCK4 
as important for mechanisms involved in the angiogenic response to ischemia. The specific 
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site of DOCK9 which interacts with the SH3 domain of DOCK4 was not elucidated during this 
study, however it was determined that DOCK9 proline rich regions identified as PRR 2, 3, 4, 
and 9 were unlikely to be involved in the interaction. The small molecule inhibitor QL-47 was 
demonstrated to be a potent anti-angiogenic compound with VEGFA stimulated ECs being 
particularly sensitive to QL-47. However, it is highly unlikely that the anti-angiogenic effects 
are due to disruption of the DOCK4-DOCK9 interaction, as the p.C628 cysteine residue was 
found to not be involved in DOCK4 SH3 domain interaction.  
Understanding how Rho GTPases are regulated and mechanisms underpinning their 
activity will progress the understanding of events that drive blood vessel growth while 
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The overarching aim of this thesis is to expand upon the understanding of the RhoG 
pathway (RhoG-DOCK4-RAC-DOCK9-CDC42) and its role in the process of angiogenesis. 
DOCK4 and its interaction with DOCK9 are the central components of the pathway, as 
together they drive some of the hallmarks of angiogenic growth, filopodia formation and 
sprouting (Abraham et al., 2015).  
1 
1 Introduction 
1.1 The mammalian vascular system 
The mammalian vascular system serves as a multifunctioning network of tubes, or 
hollow cords, which enables flow of blood for maintenance of cellular homeostasis, 
distribution of essential nutrients and oxygen in concert with removal of metabolic waste 
and carbon dioxide. It also allows the trafficking of growth factors (GFs), cytokines, hormones 
and immune cells around the body (Wacker and Gerhardt, 2011b). The vascular system is 
essential in maintenance of homeostasis of ionic concentration, physiological pH, body 
temperature, and glucose concentration (Wacker and Gerhardt, 2011b). 
The cardiovascular system is an enclosed organ system composed of a contractile 
four chambered muscular pump, the heart, and a complex network of multicellular tubes 
organized into three subsystems based on structure and function; the arterial system, 
venous system, and the lymphatic system (Carmeliet, 2000), as is seen in figure 1.1.  
The arterial system delivers blood from the heart to the other organs, tissues, and 
limbs of the body. Blood pumped from the right ventricle of the heart and flows through the 
pulmonary artery, allowing for oxygenation of the blood in concert with removal of carbon 
dioxide. Oxygenated blood then flows into the left atrium of the heart where it is pumped 
into the left ventricle. The left ventricle contracts to force the blood to flow through the 
aorta, the largest of the arteries. Blood flows at high pressure through the aorta into arteries, 
arterioles, and capillaries of decreasing diameter to the other organs, brain, and tissues of 





   
Figure 1-1 The human circulatory system 
Diagram of the human circulatory system: the heart, arteries, veins and capillaries. 
Arteries possess three structural layers: the Tunica Adventitia, Tunica Media, and Tunica Intima. 
The Tunica Adventitia is the outer layer of arteries and consists of connective tissue, collagen, 
and elastic fibres. The middle layer, the Tunica Media, contains smooth muscle cells and elastic 
fibres. The Tunica Intima is the inner most layer of the arteries and is comprised of endothelial 
cells. There are three distinct types of arteries: elastic arteries, muscular arteries, and arterioles. 
Veins also have three layers; the Tunica Adventitia, Tunica Media, and the Tunica Intima. The 
Tunica Media of veins possesses an irregular covering of vascular smooth-muscle cells and 
pericytes. In the lumen of veins also lie valves which act to prevent the backflow of blood through 
the less pressurized vascular structures. Capillaries are small, thin vessels comprised of a single 
layer of flattened ECs with no muscular layer. There are three types of capillaries: continuous, 
fenestrated, and discontinuous. 
 
3 
The venous system allows blood to flow from the periphery, tissues, and organs 
through vessels which increase in diameter from venules to veins and then into the vena 
cava, the largest of the veins. Through the vena cava blood flows back to the heart, entering 
through the right atrium (Udan et al., 2013). 
The lymphatic system serves as a system of vessels that provide passage for 
interstitial fluid to flow from the organs and tissue to re-enter circulation through the 
subclavian vein (Udan et al., 2013). 
The vessels forming the three subsystems possess unique composition allowing for 
their distinct function. Within humans and rodents the cardiovascular system is the first 
organ formed during embryogenesis (Udan et al., 2013). Formation of the precursor 
structures of the cardiovascular system begins during the early stages of embryo 
development through a process called vasculogenesis (Galan Moya et al., 2009). Once 
formed the vascular structures may further specialize to adopt characteristics essential for 
the vessel’s physiological function within its specified organ or tissue.  
Dysregulation of endothelial cells (ECs) due to vascular injury or cellular dysfunction 
can contribute towards many pathological conditions including vascular disorders: 
atherosclerosis, peripheral artery disease, hypertension, and inflammatory disorders such as 
sepsis and inflammatory syndromes to name a few (Galley and Webster, 2004; 
Vanlandewijck et al., 2018). 
1.2 Blood vessels 
Vascular structures may display some variability in functional characteristics to allow 
for specialization within the context of their location. Despite these differences, human 
blood vessels retain the same histological organization of a single layer of ECs, with a luminal-
abluminal polarity, located on the intima of all vessels. The layer of ECs form into hollow 
cords with the abluminal side of the EC layer connected to vascular basement membrane 
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(Lammert and Axnick, 2012) and a layer mural cells, smooth muscle cells and pericytes, at 
the external side of the basement membrane (Lammert and Axnick, 2012). Once blood 
vessels have fully formed and blood flow is established, ECs exhibit features of planar cell 
polarity in response to blood flow (Lizama and Zovein, 2013). 
 The endothelium 
The endothelium is a heterogeneous and multi-functional disseminated organ which 
not only forms vascular structure but is vital in maintenance of a non-thrombogenic blood-
tissue interface responsible for regulating blood flow, vascular tone, thrombosis, 
thrombolysis, and platelet adherence (Cines et al., 1998). ECs which form the endothelium 
also function in secretory, synthetic, metabolic, and immunologic roles in addition to forming 
a semi-permeable barrier (Cines et al., 1998).  
 Growth of blood vessels 
In the healthy adult, vasculature and ECs are largely quiescent with the exception of 
during pregnancy, the menstrual cycle, and wound healing (Adams and Alitalo, 2007; Rizov 
et al., 2017). ECs may remodel their morphology, to form new vessel under pathological 
conditions, such as tissue ischemia, in order to meet the metabolic needs of the tissue (Egami 
et al., 2006).  
1.2.2.1 Vasculogenesis 
The vascular system first forms through vasculogenesis, a process initiated when 
endothelial precursor cells differentiate from blast-like bi-potential cells called angioblasts 
(Carmeliet, 2000), as depicted in figure 1.1. The ventral floor of the dorsal aorta gives rise to 
mesenchymal cells. The pluripotent mesenchymal cells differentiate into angioblasts that in 
turn differentiate into intermediate pre-ECs; cells capable of differentiating into either a 
committed haematopoietic cell line or ECs. ECs may also display plasticity to 
transdifferentiate into mesenchymal cells and intimal smooth muscle cells. Once the EC 
phenotype has been acquired, further specialisation may take place to adapt the cell to the 
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specific type and location of the vascular structure (Choi et al., 1998; Galley and Webster, 
2004). 
Forming vascular structures recruit smooth muscle expressing mural cells, such as 
vascular smooth muscle cell (VSMC) and pericytes. These cells form the smooth muscle layer 
which envelopes vascular structures on the external surfaces of the basement membrane at 
the abluminal side of the endothelium (Drake et al., 1998; Hirschi and D'Amore, 1996). The 
phenotypical features and organisation of mural cells associated with a vascular structure 




Figure 1-2 Mechanisms of vascular growth 
During embryogenesis the primitive capillary plexus is formed through 
differentiation and expansion of angioblasts derived from the mesoderm, which assemble 
into cords, forming the beginning of vascular structures. Further remodelling, expansion, 
and recruitment of smooth muscle cells and pericytes giving rise to blood vessels and 
lymphatic vessels through the process of angiogenesis and lymphangiogenesis respectively. 
Image taken with permission from Adams & Alitalo (2007). 
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1.2.2.2 Mural cells 
Mural cells provide scaffold to vascular structures and are responsible for 
contraction and dilation of blood vessels. Mural cells directly contact ECs to co-regulate 
vascular function via paracrine signalling and direct physical contact. Direct physical contact 
between mural cells and ECs allow for mechanical signalling through contractile forces via 
junction complexes between the two cell types; which include (but are not limited to) β-
catenin-based adherent junctions, N-cadherin, cell-adhesion molecules, and extracellular 
matrix (ECM) components (Gerhardt et al., 2003; Vanlandewijck et al., 2018).  
VSMCs have been associated with larger vessels and have not been observed to 
embed into the basement membrane of vascular structures, a characteristic of pericytes 
(Gerhardt et al., 2003). Arterioles are coated with a thick and continuous layer of VSMCs and 
elastic and collagenous fibres (Cleaver and Melton, 2003; Vanlandewijck et al., 2018) that 
control contraction and relaxation of arterioles.  
Pericytes form an intermittent single cell layer over capillaries and post-capillary 
venules, and anchor to ECs through adhesion plaques. Unlike VSMC, pericytes embed into 
the basement membrane of vascular structures, allowing direct contact between pericytes 
and the endothelium. Pericytes extend longitudinal cytoplasmic projections along the length 
of blood vessels, to allow for integration of signalling along the vessel and may connect 
multiple capillaries within the vasculature (Rucker et al., 2000). Pericytes may also develop 
contacts between discontinuities in the vessel basement membrane, through peg-and-
socket contacts (Rucker et al., 2000; Vanlandewijck et al., 2018). 
 Vascular structures 
There are a number of different types of vascular structures which form the 
circulatory system, to allow for circulation of blood in tune to the beat of the heart. The 
differences in structure of each vessel type aids in the particular function required for 
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maintaining circulation of blood to and from the heart, regulation of blood pressure, 
exchange of gases and substances, and movement of immune cells.  
1.2.3.1 Arteries 
Arteries are the largest of the vascular structures and are constructed of 
concentrically arranged smooth-muscle cells, which form elastic vessel walls made to 
withstand higher blood pressures (Shepherd, 1983; Aaronson et al., 2012). Arteries possess 
three structural layers: the Tunica Adventitia, Tunica Media, and the Tunica Intima. The 
Tunica Adventitia is the outer layer of arteries and consists of connective tissues, collagen, 
and elastic fibres. The middle layer, the Tunica Media, contains the smooth muscle cells and 
elastic fibres, this layer regulates vascular contraction, relaxation, and vascular tone 
(Shepherd, 1983; Aaronson et al., 2012). The Tunica Intima is the inner most layer of the 
arteries and is comprised of ECs. The Tunica Intima lies directly in contact with the arterial 
blood flowing. A hollow lumen lies throughout the centre of the arteries, through which 
blood flows (Shepherd, 1983; Aaronson et al., 2012). The lumen of arteries are typically 
smaller than that of veins, a structural feature specialised to aid in the high pressure of blood 
flow from the heart (Shepherd, 1983; Aaronson et al., 2012).  
There are three distinct types of arteries: elastic arteries, muscular arteries, and 
Arterioles. Elastic arteries, the aorta and pulmonary artery, have thin vessel walls with a high 
level of elastin to aid in expansion and recoil of the vessels in response to the high-pressured 
flow of blood from the heart. Muscular arteries contain a smooth muscle rich wall capable 
of modifying blood flow through the vessel via contraction and relaxation of the muscular 
layer. Arterioles are the smallest of the arterial vessels which contain concentric rings of 
smooth muscle within the tunica media layer and connect blood flow from other arteries to 




Veins retain a similar structure to that of arteries with the same three layers; the 
Tunica Adventitia, Tunica Media, and the Tunica Intima (Shepherd, 1983; Aaronson et al., 
2012). However, the Tunica Media layer of veins is considerable thinner when compared to 
arteries. The cellular structure of the Tunica Media also differs between the two vascular 
sub-groups, with the intermediate layer of arteries primarily being formed by a thick layer of 
VSMCs and veins possessing an irregular covering of VSMCs and pericytes (Aaronson et al., 
2012). 
Throughout the lumen of veins also lie valves which act to prevent the backflow of 
blood through the less pressurised vascular structures (Aaronson et al., 2012). 
1.2.3.3 Capillaries 
Capillaries are small, thin vessels comprised of a single layer of flattened ECs with no 
muscular layer. There are three types of capillaries continuous, fenestrated, and 
discontinuous (Shepherd, 1983; Aaronson et al., 2012; Bennett et al., 1959). While capillaries 
do not have an adventia layer, continuous capillaries possess intermittent pericytes. 
Fenestrated capillaries possess fenestrations, or pores, which aid in movement of larger 
molecules. Discontinuous capillaries are only found in the liver. The structure formed 
between the ECs and hepatocytes creates clefts through which macromolecules and blood 
cells to pass through (Galley and Webster, 2004; Vanlandewijck et al., 2018).  
Capillaries connect arterioles to venules and facilitate passive diffusion and 
pinocytosis of nutrients and cellular wastes between the blood and the tissue cells. The 
absence of the muscular layer, thinness of the capillary walls, and distribution of intercellular 
junctions, aid in movement of substances and white blood cells between circulation and 
tissues (Galley and Webster, 2004; Vanlandewijck et al., 2018). 
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1.2.3.4 Collateral arteries 
Collateral arteries are narrow arterioles which provide circulation interconnections 
between nearby arteries or arterioles (Antoniucci et al., 2002; Schaper, 2009; Faber et al., 
2014; Simons and Eichmann, 2015). Networks of native collateral arteries function to divert 
blood flow in instances of arterial occlusion, allowing for continuation of circulation to the 
affected tissue and organ (Heil et al., 2006; Schaper, 2009; Simons and Eichmann, 2015; 
Ramo et al., 2016). Once blood flow to the collateral circulation has been initiated, sheer 
force of the blood flow drives arteriogenesis of the collateral arteries to develop into efficient 
conductance arteries (Ramo et al., 2016). The number and patterning of pre-existing 
collateral arteries prior to an occlusion greatly affects the adequacy of the diversion of blood 
flow to the affected tissue/organ (Ramo et al., 2016). 
1.2.3.5 Lymphatic vessels 
Lymphatic vessels make up the lymphatic component of the vascular system and are 
functionally and structurally unique from the blood vessel circulatory element of the vascular 
system. They are structurally unique from blood vessels, with features which aide in their 
function to uptake fluid, macromolecules, and cells. Lymphatic vessels are formed of a single 
layer of attenuated, non-fenestrated, ECs (Schmid-Schönbein, 1990; Aukland and Reed, 
1993).  
The lymphatic system serves to aid in multiple biological functions; primarily in 
regulation of fluid and fluid pressure within the interstitium, movement of fluid and 
macromolecules to and from blood circulation, as well as immunological functions involving 







1.3 Mechanisms of blood vessel growth 
 Sprouting angiogenesis 
Expansion and remodelling of the vascular system beyond vasculogenesis is 
propagated via angiogenesis; either through sprouts branching (as seen in figure 1.3) from 
pre-existing blood vessels (sprouting angiogenesis) or through splitting of existing vessels to 
a larger number via intussusception (Adams and Alitalo, 2007). In adults, angiogenesis occurs 
typically in response to nutrient and oxygen deprivation, tissue damage, or in response to 
aberrant cell signalling arising from pathological stimuli (Egami et al., 2006; Potente et al., 
2011). Parenchymal cells respond to hypoxia by secreting pro-angiogenic GFs such as 
vascular endothelial growth factor A (VEGFA; described in detail in section 1.3.6.1). 
During sprouting angiogenesis, quiescent ECs lining blood vessels excrete protease 
to degrade the basement membrane, break away from the vessel wall, and alter their 
morphology while they rapidly proliferate and invade the surrounding tissue to form new 
sprouts (Blanco and Gerhardt, 2013). Under pro-angiogenic signalling, ECs coordinate in a 
migratory hierarchy of leading ‘tip cells’ and trailing ‘stalk cells’ dependent upon local 
chemotactic gradients and juxtacrine Notch signalling (Jakobsson et al., 2010). At the 
angiogenic front this organization of cells is malleable, with tip cells and stalk cells frequently 
changing position (Jakobsson et al., 2010). 
VEGFA stimulation of the VEGF-receptor 2 on ECs induces a Delta-Notch signalling 
response which prompts a tip-cell phenotype (Jakobsson et al., 2010; Hellstrom et al., 2007). 
Within mammals the Notch signalling pathway regulates angiogenesis through multiple 
Notch receptors (Notch1-4) and their interactions with multiple membrane bound ligands: 
Delta-like (DLL1, 3, 4) and Jagged (Jag-12) (Lawson et al., 2002; Iruela-Arispe, 2017). VEGFA 
driven Notch receptor-ligand interaction drives proteolytic cleavage of the Notch receptor 
and release of the intracellular domain which relocates to the nucleus to function as a 
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transcription factor, binding to DNA and modulating gene expression (Lawson et al., 2002; 
Iruela-Arispe, 2017). 
Expression of Delta-like-4 (Dll4) stimulates Notch receptors on neighbouring ECs, 
initiating neighbouring cells to adopt a stalk cell morphology through suppression of VEGF-
receptor 2 production (Adair and Montani, 2010). Stalk cells display a much higher level of 
proliferation with lower migratory behaviour than that of tip cells (Adair and Montani, 2010).  
Tip-cells produce multiple filopodia at the distal end of the cord (as depicted in figure 
1.3) which probe the extracellular environment for growth cues aiding in organised and 
guided growth through detection of a gradient of pro and anti-growth signalling cues 
(Gerhardt et al., 2003; Wacker and Gerhardt, 2011b). Upon the meeting of two EC sprouts, 
the growths connect and join to create an enclosed vessel in a process termed anastomosis 
(Wacker and Gerhardt, 2011b). ECs wrap and form a polarised luminal-abluminal 
organization which initiates cord hollowing and subsequent lumenisation of the newly 




Figure 1-3 Basic schematic diagram of sprouting angiogenesis 
During sprouting angiogenesis quiescent ECs within a blood vessel (1) respond to 
binding of an extracellular ligand or cue to a transmembrane receptor (2). This initiates tip 
cell selection and filopodia production at the leading edge of the tip cell (3). Intracellular 
signalling event within the tip cell convey a signal to adjacent cells, prompting a stalk 
phenotype in the neighbouring cells (4). Stalk cells rapidly proliferate to establish an 
elongated cord of cells (5). Depletion of GF (6; or contact with other growing cords) is 
hypothesized to results in extension of lateral filopodia (7). Luminal-abluminal polarity is 
established within ECs of the cell cord, initiating lumenisation. 
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 Endothelial cell filopodia 
Filopodia are actin-rich cytoplasmic protrusions found on actively motile cells in 3D 
spaces, they are also found in ECs and were initially observed on tip cells. EC filopodia probe 
the surrounding environment for chemical and mechanical signals and direct migration 
towards chemotactic signals such as VEGF. The interaction between filopodia and the ECM 
produces points of cell-ECM attachment allowing generation of tension necessary for 
propulsion towards the direction of migration (Blanco and Gerhardt, 2013). Interactions 
between filopodia and chemotactic cues promote rapid extension and directional growth of 
the vessel sprouts while guiding correct patterning of the newly forming vessels (DeLisser, 
2011).  
Recently filopodia have been described at lateral sites (Abraham et al., 2015) which 
develop along a tubule and give rise to lateral sprouts (DeLisser, 2011). Lateral filopodia are 
thus required for the dynamic remodelling of newly forming vessels and correct patterning 
prior to lumen formation (DeLisser, 2011). Once lateral junctions between ECs establish, ECs 
may polarize and initiate lumen formation. The formation of filopodia requires changes of 
the actin cytoskeleton with rapid F-actin polymerisation proceeded by actin contraction 
within the projections (Blanco and Gerhardt, 2013).  
While filopodia promote sprouting both in vivo and in 3D tissue culture models 
(DeLisser, 2011; Hetheridge et al., 2011), lamellipodia have been shown to promote EC 
migration in a 2D substratum. Interestingly when filopodia are inhibited, lamellipodia-like 
structures may promote the growth of blood vessels in vivo (Gerhardt et al., 2003). 
 Lumen Formation 
Once the blood vessels have expanded through the process of filopodia-driven 
sprout formation, the blood vessels have to form enclosed tubes to allow blood flow and 
gain functionality. During angiogenic sprouting, ECs migrate as cords that form a hollow 
interior, or lumen, as they grow through and invade the surrounding matrix (Iruela-Arispe 
15 
and Davis, 2009). The process of lumen formation is complex and the cellular and molecular 
mechanisms are only partially understood. Multiple mechanisms have been described, 
including cord hollowing, cell wrapping, cell hollowing, budding, and cavitation (Lammert 
and Axnick, 2012). Of those mechanisms cell and cord hollowing are those that have been 
investigated in greater detail. Cell hollowing entails formation of an intracellular vacuole 
which expands through neighbouring ECs in a cord, giving rise to the lumen (Lizama and 
Zovein, 2013). Cord hollowing involves either the invagination of unicellular membranes; a 
hollow centre forming between multicellular cords (Iruela-Arispe and Davis, 2009); or 
formation of a lumen at sites of lateral EC-cell adhesions (Strilic et al., 2009).  
Before lumen formation may take place, ECs must acquire polarity through 
recruitment of proteins to the apical membrane. One such protein is the glycoprotein 
podocalyxin, the accumulation of which at the apical domain marks initiation of the process 
of lumen formation (Sigurbjornsdottir et al., 2014). This establishment of luminal-abluminal 
polarity results in accumulation of a negative charge in the apical surface and opening of the 
lumen via electrostatic repulsion (Sigurbjornsdottir et al., 2014; Debruin et al., 2014; Gebala 
et al., 2016). Cord hollowing has been more widely accepted as the process by which lumens 
form in vivo, although the latest studies in zebrafish show that within intersegmental vessels 
the apical membrane expands through both laterally adjacent, and single cells to form the 
lumen (Gebala et al., 2016). 
 Blood vessel elongation 
During angiogenesis, growth of blood vessels proceeds not only through 
proliferation of ECs and development of new sprouts but also through elongation of a 
developing tubule that fuses with other growing or established blood vessel. Elongation may 
take place at the single cell level, or results from proliferation of cells arranged in a cord 
(Gebala et al., 2016). Cell elongation occurs through internally driven remodelling of the 
cytoskeleton which allows cells to grow in a directional fashion (Gebala et al., 2016). 
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Interestingly, brain microvascular cells resist cell elongation and minimize lateral cell-cell 
junctions in response to curvature and sheer stress, resulting in the characteristic radial 
arrangement of cells, as opposed to axial, within the brain micro-vessels (Merks et al., 2006). 
Therefore, the ability of ECs to elongate can have profound effects on the structure and 
function of blood vessels (Merks et al., 2006). Little is known about the molecular 
mechanisms underlying blood vessel elongation, at the single or multi-cellular level. Within 
a 3D organotypic angiogenesis model tubules stimulated with the GF fibroblast growth factor 
(FGF) develop an elongated phenotype (Scarcia M, unpublished data), however it is not 
known whether this is due to cells becoming more elongated, or that cells proliferate more 
at the axial orientation. However, other studies have described FGF as inducing both 
proliferation of ECs and elongation of individual cells (Lee and Kay, 2006; Ornitz and Itoh, 
2015). 
 Arteriogenesis 
Arteriogenesis describes a mechanism through which pre-existing collateral 
arterioles (described in 1.2.3.4) remodel from narrow vessels with little to no blood flow to 
become large conducting arteries, in response to sheer stress following occlusion of a 
secondary supply blood vessel (Antoniucci et al., 2002; Schaper, 2009; Faber et al., 2014). 
Unlike angiogenesis, arteriogenesis is initiated by mechanical forces and has thus far been 
shown to occur without stimulation of hypoxic factors (Heil et al., 2006; Grant and Karsan, 
2018). Sheer stress has been seen to drive monocyte recruitment to the collateral arteries, 
leading to monocyte and endothelial secretion of GFs cytokines and proteases; driving matrix 
degradation, proliferation of smooth muscle, and enlargement of the collateral arteries 
(Ramo et al., 2016). 
 Growth factor signalling  
Chemical stimulation which drives the growth of blood vessels integrates the activity 
of a diverse repertoire of proteins including GF signalling molecules, cell surface receptors, 
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integrins, and prostaglandins, just to name a few of the many components driving the 
complex process of blood vessel growth (Ucuzian et al., 2010; Simons et al., 2016). The GF 
signalling pathways, VEGF and FGF, are two pathways that have been described to drive 
angiogenesis in similar but unique ways. Canonical VEGF signalling has been well described 
in the context of embryogenesis and development, in addition to the vascular response to 
hypoxia (Ucuzian et al., 2010; Simons et al., 2016). VEGF signalling has been implicated in 
driving tip/stalk cell selection. Canonical FGF signalling has been strongly implicated in 
response to wound healing and drives a highly proliferative endothelial phenotype (Ornitz 
and Itoh, 2015). This section will overview the two signalling pathways in the context of 






Figure 1-4 Schematic diagram of canonical VEGF signalling mechanisms in ECs 
Binding of a VEGF ligand leading to homodimerisation of VEGF receptors driving 
intracellular tyrosine kinase activity of the receptor. Activated VEGF receptor leads to 
activation of signalling pathways Src, Erk, Rho GTPase, PI3K/AKT, and P38/MAPK. 
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1.3.6.1 Vascular endothelial growth factor 
VEGF signalling is complex, with the potential to stimulate multiple cell surface 
receptors and subsequent activation and integration of a vast number of cell signalling 
pathways. For the aforementioned reasons, only VEGF characteristics and signalling 
components relevant to this report and the primary VEGF signalling components shall be 
discussed in detail within this introduction. 
VEGFs are a sub-group of the platelet-derived GF family of cysteine-knot GFs 
(Ucuzian et al., 2010; Simons et al., 2016). VEGF is an EC mitogen that acts as a major 
regulator of blood vessel formation through vasculogenesis, angiogenesis, and 
arteriogenesis, in addition to maintenance and function of vascular structures (Ucuzian et 
al., 2010; Simons et al., 2016). 
During sprouting angiogenesis VEGF binds to the VEGF receptor of the ECs and 
controls directional vascular growth through a chemotactic gradient, created via VEGF 
secreted by oxygen deprived cells (Gerhardt et al., 2003). Both VEGF and the VEGFR 
expression are upregulated within angiogenic sprout tip cells, with VEGF antibody inhibition 
leading to significant decrease in micro-vessel sprouting (Gerhardt et al., 2003; Brown et al., 
1996b). 
There are several variants of VEGF, vertebrate VEGFs A–D, placenta GF (PlGF), 
Parapoxvirus VEGFE and snake venom VEGFF. Each variant differs in their affinity for the 
different VEGF receptor subtype, of which there are 3, as well as their ability to bind co-
receptors and initiate homodimerisation/heterodimerisation of receptor complex formation 
(Simons et al., 2016). The type of VEGF molecule driving a signalling response dictates the 
activity and complex formation of the target receptor, thus regulating the downstream 
cellular response to binding of the VEGF ligand (Simons et al., 2016). 
VEGFA is the classical VEGFR activating ligand, and is often referred to simply as 
VEGF. VEGFA has been strongly characterised as a primary component in proliferation, 
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survival, and migration of ECs (Simons et al., 2016). VEGFA has multiple isoforms, each 
resulting from alternative splicing of the same gene product. Each isoform varies in their 
ability to activate the VEGF receptor, due to the differences in their affinity for binding co-
receptors, such as neuropilin (NRP) family members NRP1 and NRP2 and to heparin sulfate 
proteoglycans (HSPGs) (Simons et al., 2016). 
VEGF receptors act as receptor tyrosine kinases and binding of a VEGF ligand leads 
to homodimerisation of VEGF receptors driving intracellular tyrosine kinase activity of the 
receptor (as is seen in figure 1.4). Activated VEGF receptor leads to activation of signalling 
pathways Src, Erk, Rho GTPase, PI3K/AKT, and P38/MAPK (Iruela-Arispe, 2017). 
Each sub-type of the VEGFR greatly differ in effect following ligand binding (Iruela-
Arispe, 2017). There are numerous VEGF receptor subtypes with VEGFR1, VEGFR2, and 
VEGFR3 being the best characterised. VEGFR1 is a negative regulator of angiogenesis which 
is expressed by blood vascular ECs, macrophages, trophoblasts, tumour cells, and other cell 
types (Wu et al., 2006; Tsuchida et al., 2008) and can exist in a membrane bound or secreted 
form. VEGFA, VEGFB, and PIGF are the known canonical ligands which bind to VEGFR1.  
VEGF binds to VEGFR1 with a higher affinity than to VEGFR2, however VEGFR1 has 
not been seen to activate a downstream signalling response and is therefore assumed to act 
as a decoy receptor, potentially sequestering free VEGF molecules (Hiratsuka et al., 1998; 
Iruela-Arispe, 2017). Constitutive knockout of VEGFR1 in a murine model is embryonic lethal 
on day E9 due to excessive EC overgrowth (Fong et al., 1995). VEGFR2 is expressed on blood 
vascular ECs and to a lesser degree on the surface of lymphatic vascular ECs (Simons et al., 
2016). VEGFR2 is known as the primary endothelial receptor responsible for conferring the 
mitogenic signal induced by VEGF. VEGFR2 is canonically activated by VEGFA and processed 
VEGFC and VEGFD. VEGFR2 may also be non-canonically activated via multiple mechanisms: 
Shear stress due to changes in blood flow; the bone morphogenic protein antagonist 
gremlins, which has been seen to bind VEGFR2 with a similar affinity of VEGF and is able to 
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stimulate similar downstream activity (Mitola et al., 2010); Galectin-1, a β-galactoside-
binding protein, which prompts phosphorylation of VEGFR2 extending cell surface retention 
of the receptor, with inhibition of galectin-1 greatly reducing tumour associated 
angiogenesis; Lactate has been observed to upregulate expression of VEGF and VEGFR2 
(Kumar et al., 2007) as well as upregulating the ligands which activate the latter (Ruan and 
Kazlauskas, 2013); Low density lipoproteins (LDL) may negatively affect VEGFR2 activity, with 
presence of LDL leading to a reduced endothelial response to VEGFA and a decrease in 
VEGFR2 expression. Unlike VEGFR1, constitutive VEGFR2 deletion in a murine model is 
embryonic lethal on day E9 due to insufficient EC lineage commitment (Simons et al., 2016; 
Sakurai et al., 2005; Takahashi et al., 2001). 
1.3.6.2 VEGFR2 functions and pathways activated 
Of all receptors capable of binding VEGF, VEGFR2 has the second highest binding 
affinity for VEGF, second only to VEGFR1. While VEGF binds to VEGFR1 with a significantly 
higher affinity than to VEGFR2, the tyrosine kinase (TK) activity of VEGF bound VEGFR2 is 10-
fold stronger than the TK activity of VEGF stimulated VEGFR1. Activated VEGFR2 transduces 
a strong positive angiogenic signal to the EC (Shalaby et al., 1995) indicating VEGF-VEGFR2 
as the primary signal transducer of angiogenesis stimulation (Shibuya, 2013). 
Endothelial VEGFR2 activation stimulates a multitude of intracellular signalling 
pathways, some of which have been better characterised than others. Activated VEGFR2 
preferentially signals to phospholipase Cγ (PLCγ), protein kinase C (PKC) and p42/44 mitogen-
activated protein kinases (MAPK) (Shibuya, 2013) and is essential for vasculogenesis during 
embryogenesis (Sakurai et al., 2005) and EC proliferation (Xia et al., 1996; Takahashi and 
Shibuya, 1997; Takahashi et al., 1999). The VEGFR2-PLC-γ-PKC pathway regulates EC 
proliferation and migration through activation of the protein kinase D (PKD)-histone-
deacetylase 7 (HDAC7) pathway (Wang et al., 2008). Sase et al. (2009) demonstrated that 
differentiation of endothelial stem cells to ECs strongly depends on the VEGFR2- PLC-γ 
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pathway, while zebrafish mutants of the PLC-γ1 gene results in lethal deficiency of 
arteriogenesis (Sase et al., 2009; Lawson et al., 2002).  
VEGFR2 activation controls vaso-motion, barrier function, and cell survival through 
regulation of phosphatidylinositol-3-kinase (PI3K)/Akt and mammalian target of rapamycin 
(mTOR) signalling pathways (Zhuang et al., 2013) while also partaking in regulation of von 
Willebrand factor (vWF) release from ECs, an essential component of the coagulation system 
(Xiong et al., 2009). Activation of the VEGFR2 also mediates tip cell selection in initiation of 
sprouting angiogenesis, leading to modulation of Notch signalling and initiation of the stalk 
cell phenotype of adjacent ECs which proliferate along a newly forming sprout. This 
regulation is a characteristic not described in an FGF signalling context and demonstrates the 
clear differences the two signalling pathways drive during angiogenesis (Xiong et al., 2009). 
Activated VEGFR2 has also been described to regulate signalling via the Rho family 
of small GTPases driving changes to the actin cytoskeleton; activity necessary for regulation 
of cell shape, polarity, junction conformation, migration, and cellular growth in response to 
growth signalling cues (Rodrigues and Granger, 2015). Luke Hoeppner et al (2015) described 
how in vitro VEGF-VEGFR2 driven activation for the small RhoGTPase RhoC promotes a 
proliferating and a migratory phenotype. RhoC binds to and stabilises nuclear localised β-
catenin; prompting an increase in expression of the cell cycle intermediate cyclin D. 
However, RhoC was also described to inhibit migration in a MAPKs and myosin light chain 2 
dependent manner and downregulate the PLCγ calcium (Ca2+) endothelial nitric oxide 
synthase (eNOS) cascade, leading to decreased vascular permeability (Hoeppner et al., 
2015). 
During sprouting angiogenesis VEGF-VEGFR2 driven activation of the small Rho 
family GTPases ras-related C3 botulinum toxin substrate (RAC) and cell division control 
protein 42 homolog (CDC42) drive directional migration and correct vascular patterning via 
regulation of the actin polymerisation required for lateral filopodia production, along cords 
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of newly forming vascular sprouts, in addition to lumen formation of the newly forming 
vessels (Abraham et al., 2015).  
VEGFR2 has also been indicated in control of many other signalling pathways 
including: Src, p38 MAPK, STATs and G protein-coupled receptor (GPCR)-dependent 
signalling (Simons et al., 2016). 
VEGFR3 is highly expressed on the cell surface of lymphatic ECs and blood vascular 
ECs (Simons et al., 2016). VEGFR3 binds and transduces signals from the ligands VEGFC and 
VEGFD. VEGFR3 may also be non-canonically activated by sheer stress (Byzova et al., 2000; 
West et al., 2012). VEGFR3 constitutive deletion within a murine model is embryonically 





Figure 1-5 Schematic diagram of canonical FGF signalling mechanisms in ECs 
Binding of an FGF ligand leading to homodimerisation of FGF receptors drives 
intracellular tyrosine kinase activity of the receptor. Activated FGF receptor stimulates 
activation of signalling pathways RAC/MAP kinase, PI3K/AKT, Rho GTPase RAC1 and CDC42, 












1.3.6.3 Fibroblast Growth Factor 
The FGF family of GFs and their receptors have been implicated in many 
developmental and post developmental processes affecting multiple tissues and organs 
throughout the body. During embryogenesis and development, FGF signalling regulates 
tissue patterning, organogenesis, branching morphogenesis, and limb development. Within 
the vascular system, FGF acts as a potent endothelial mitogen (Gospodarowicz et al., 1977; 
Maciag et al., 1981; Thornton et al., 1983) which is stored within the vascular basement 
membrane and acts as an angiogenic factor during vascular development and progression 
(Ucuzian et al., 2010; Javerzat et al., 2002).  
There are four FGF receptors (FGFR), with each subtype differing in kinase domain 
and ligand binding affinity (Trueb et al., 2013; Beenken and Mohammadi, 2009). As depicted 
in figure 1.5, binding of an FGF ligand leading to homodimerised FGF receptor molecules 
drives intracellular TK activity of the receptor. Activated FGFR stimulates activation of 
signalling pathways RAC/MAP kinase, PI3K/AKT, Rho GTPase RAC1 and CDC42, PLCγ/PKC, 
and STAT 1,3,4 (Beenken and Mohammadi, 2009; Dailey et al., 2005).  
Stimulation of FGFRs primarily leads to intracellular regulation of two main 
intracellular substrates; PLCγ1 and FGFR substrate 2 (FRS2; (Beenken and Mohammadi, 
2009)). Phosphorylation of FGFRs leads to PLCγ phosphorylation and activation. FRS2 
associates with a juxtamembrane region of FGFR to drive constitutive activation of the FRS2, 
inducing activation of the Ras–mitogen-activated protein kinase (MAPK) and 
phosphoinositide 3-kinase–Akt signalling pathways (Beenken and Mohammadi, 2009; Dailey 
et al., 2005).  
FGF ligands also signal through the low-affinity heparin sulphate transmembrane 
proteoglycan, syndecan 4 (Kitamura et al., 2008). FGF stimulation of S4 independently of FGF 
receptors is due to the receptor’s ability to activate PKC (Horowitz et al., 1999; Partovian et 
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al., 2008). FGF activated S4 associates with a ubiquitous cytoplasmic protein, synectin (Gao 
et al., 2000). 
The family of FGFs consists of 22 structurally similar signalling ligands, FGF1 -FGF23, 
of which 18 eighteen (FGF1-FGF10 and FGF15-FGF22) have been identified as ligands capable 
of binding to FGF receptor tyrosine kinases (Smallwood et al., 1996; Olsen et al., 2003). 
Similarly to VEGF, FGF proteins also possess heparin binding affinity (Shing et al., 1984). Due 
to the vast and varied activity of the FGF family of ligands and receptors, only FGF 
characteristics and signalling components relevant to this report and the primary FGF 
signalling components shall be discussed in detail within this introduction.  
The FGF ligands FGF1 and FGF2, regulate vascular tone and thus blood pressure 
(Cuevas et al., 1991) and have been implicated in regulating NOS activity (Cuevas et al., 
1996). Mice with FGF1 or FGF2 depletion are viable with no known defects and maintain 
normal vascularization (Miller et al., 2000) potentially due to redundancy, or action of 
alternative angiogenic GFs in their absence. 
FGF1 is capable of binding to all FGF-receptor subtypes, a characteristic unique to 
FGF1. FGF1 is a potent angiogenic mitogen (Blaber et al., 1996) under the condition of 
hypoxia, and is able to drive the FGF1 proliferation and differentiation of the endothelial and 
smooth muscle cells necessary for construction of an arterial vessel (Stegmann, 1998; 
Khurana and Simons, 2003). FGF1 has been implicated in driving a protective response in 
cardiac ischemia, with higher levels of FGF1 found within pericardial fluid following an 
ischemic cardiac event (Iwakura et al., 2000). FGF1 treatment within cardiovascular disorders 
have also demonstrated FGF1 function in collateral artery growth, capillary proliferation 
(Schumacher et al., 1998) and in improving perfusion within the lower extremities following 
ischemia (Comerota et al., 2002; Nikol et al., 2008). FGF1 has also been implicated in nerve 
repair following injuries (Cheng et al., 1996; Takahashi and Shibuya, 1997; Lin et al., 2005; 
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Cheng et al., 2004). In vitro, FGF1 induces microvascular branching within cultured ECs (Uriel 
et al., 2006).  
During wound healing FGF1 and FGF2 stimulate the proliferation of fibroblasts and 
ECs, necessary for angiogenesis, and developing granulation tissue (Ornitz and Itoh, 2001). 
FGF2 plays a role in a broad spectrum of processes, regulating multiple mitogenic 
and cell survival activities (Ornitz and Itoh, 2001). FGF2 is a more potent stimulator of 
angiogenesis than either VEGF or PDGF (but not FGF1) and promotes angiogenesis through 
stimulating proliferation and physical organization of ECs into tube-like structures (Ornitz 
and Itoh, 2001).  
FGF2 function has been implicated in embryonic development, morphogenesis, 
tissue repair, and functions in regulating migration and proliferation of ECs, mitogenesis of 
smooth muscle cells and fibroblasts, anti-apoptotic responses, adipogenesis, and 
inflammation (Ware and Simons, 1997; Yanagisawa-Miwa et al., 1992; Scholz et al., 2001; 
Hutley et al., 2004; Keller et al., 2008). 
In vivo, FGF2 plays a role in migration and proliferation of ECs (Ware and Simons, 
1997), and has been implicated in the development of large collateral vessels with adventitia 
(Scholz et al., 2001). Use of FGF2 as a treatment following cardiac ischemia has been 
demonstrated to reduce the size of ischemic regions in the myocardium, reduce the 
frequency of angina (Unger et al., 2000; Laham et al., 1999), and has also been established 
to improves peripheral circulation of people suffering from claudication; pain within the 
lower limbs due to obstruction of blood flow (Lazarous et al., 2000). FGF2 inhibition in 
tumours has been shown to impede vascularisation (Wang and Becker, 1997) but does not 
impact on microvessel density in tumours (Presta et al., 2005). 
FGF1 and FGF2 induced vascular growth develops features distinctly different when 
compare to VEGF induced vascular growth; with a marked reduction in fenestrations, and 
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thus permeability, of blood vessels produced under FGF driven vascular growth (Cao et al., 
2004; Hori et al., 2017). 
1.3.6.4 FGF stimulation of RhoG, RAC1, and CDC42 activity 
FGF2 binding to syndecan-4 drives RAC1 activation in a RhoG dependent mechanism 
(these Rho GTPases are described in detail in section 1.4), through initiating release of RhoG 
from an inhibitory ternary protein complex S4–synectin–RhoGDI1 (a RhoGTPase inhibitory 
protein described in section 1.4). FGF stimulation of RhoG activation of RAC1 leads to the 
activation of PKC in rat fat pad ECs (Elfenbein et al., 2009). 
FGF2 stimulated endothelial activation of PI3K induces the reorganization of actin 
cytoskeleton to the cortex, and stimulation of changes in cell morphology, to induce and 
elongated phenotype in a Rho GTPase dependent manner (Lee and Kay, 2006). 
Jeong Goo Lee and EunDuck P. Kay (2006) demonstrated that FGF2 stimulation of 
cultured corneal ECs, a type of non-vascular ECs, drives formation of protrusive processes in 
a CDC42/RAC1 dependent manner, in parallel with Rho inactivation. All FGF2 driven Rho 
GTPase regulation was observed to be blocked through administration of a PI 3-kinase 
inhibitor, LY294002.  
RAC1 and CDC42 have also been demonstrated to be required for internalisation of 
FGF2 in complex with syndecan-4 on the surface of smooth muscle cells in vitro (Tkachenko 
et al., 2004). FGF2 bound syndecan-4 interacts with dextran during endocytosis of the 
complex. In vitro dominant negative RAC1 within smooth muscle cells blocks internalisation 
of FGF2 and syndecan-4. Smooth muscle cells with dominant-negative CDC42 blocked 
endocytosis of FGF2, syndecan-4 and dextran (Tkachenko et al., 2004).  
With consideration to the literature it can thus be considered that FGF signalling in 
angiogenesis drives EC proliferation and elongation during wound healing. The FGF 
stimulation of EC elongation occurs in a RAC1 and CDC42 specific context. As DOCK4 is an 
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activator of RAC1, DOCK4 may serve as a potential component in conferring the cellular 
response to FGF.  
 Peripheral artery disease 
Peripheral artery disease (PAD) describes a pathologically driven reduction in blood 
flow to the lower extremities and, within the Western world, is a predominant cause of 
mortality (Ferraro et al., 2010; Rissanen et al., 2001). In severe cases, PAD may manifest as 
critical limb ischemia (CLI), which often results in a requirement for limb amputation. Limb 
ischemia has been attributed to insufficient neovascularisation following blood vessel 
occlusion (Carmeliet, 2003). While patients suffering from PAD may receive physical therapy 
(Gardner and Poehlman, 1995; Robeer et al., 1998), treatment is aimed to reduce underlying 
pathological instigators of PAD (i.e. atherosclerosis), or surgical procedures to introduce a 
catheter or stimulate re-vascularisation (Norgren et al., 2007). Despite the use of these 
interventions there is currently no effective treatments for CLI (Aviles et al., 2003).   
FGF signalling ligands and receptors have been indicated as critical for 
neovascularisation following injury and have been indicated as potential therapeutics for 
treating CLI (Ferraro et al., 2010; Bobek et al., 2006).  
Sunday S. Oladipupo et al (2014) utilised both FGFR1 and FGFR2 deficient mice to 
demonstrate that FGF signalling via either of the FGFR1 or FGFR2 TKs is not required for 
embryonic vascular development or maintenance of vascular integrity under homeostatic 
conditions. However, depletion of FGFR1/2 led to impairment of neovascularisation 
following injury to the skin or cornea. Analysis of post-injured murine skin samples indicated 
a heightened level of FGF2, VEGF, and PIGF, this finding was attributed to disruption of 
feedback mechanisms regulating levels of gene expression. This finding indicates FGF 
signalling through the FGFR1/2 primarily functions within neovascularisation during wound 
healing.  
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Bernadette Ferraro et al. (2010) found electroporation-mediated intradermal 
delivery of plasmid FGF2 (pFGFE+) treatment of hind limb ischemia (HLI) in rats, following 
occlusion of the femoral artery, was observed to significantly increase blood flow to the 
affected hind limb (Ferraro et al., 2010). This study supported the earlier work of Fujii, et al. 
(2008) which demonstrated that intramuscular injection of an FGF2 expressing plasmid 
greatly enhanced hind limb perfusion to an ischemic limb via VEGF driven enhancement of 
placental GF signalling (Fujii et al., 2008). Together these findings implicate FGF as an 
important mediator of the vascular response to tissue ischemia. Further, understanding the 
mechanisms involved in regulating downstream vascular signalling events activated by FGF 
signalling may lend insight into potential therapeutic targets for treatment of pathological 
peripheral ischemia.  
1.4 The Rho family of small GTPases 
The Ras homolog (Rho) family of low molecular weight proteins form a distinct group 
of proteins within the large Ras superfamily of regulatory guanine tri-phosphate (GTP) 
hydrolases (Sadok and Marshall, 2014). In parallel with other GTPase proteins, each family 
member possesses a conserved 20kDa GTP-binding domain (Sadok and Marshall, 2014). 
Activation of Rho GTPases arises through alternation in binding of GTP/GDP (guanine di-
phosphate) inducing a switch-like control mechanism in activating or deactivating the Rho 
GTPase respectively, as is seen in figure 1.6 (Cherfils and Zeghouf, 2013). Once activated, Rho 
GTPases modulate multiple downstream targets that are involved in the organisation of the 
actin cytoskeleton and the microtubule network. 
Guanine nucleotide exchange factors (GEFs) induce activation of GTPases through 
release of GDP enabling binding of GTP (Cherfils and Zeghouf, 2013). There are two distinct 
groups of Rho GEFs, both of which have GDP exchange activities but no sequence homology. 
Diffuse B-cell lymphoma (Dbl)-family GEFs mediate nucleotide exchange through a Dbl 
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homology-pleckstrin homology (DH-PH) domain (Cherfils and Zeghouf, 2013). The PH domain 
can be auto inhibitory and also permits binding to phospholipids allowing for localisation at 
the plasma membrane (Meller et al., 2008; Sadok and Marshall, 2014). 
The DOCK180 family make up the second group of Rho GEFs. DOCK180 proteins 
possess DOCK homology region (DHR) 1 and 2 domains. The DHR2 domain controls 
nucleotide exchange, while the DHR1 domain is thought to control plasma membrane 
localisation (Cote and Vuori, 2007; Patel et al., 2011). The majority of DOCK180 proteins lack 
a PH domain with the exception of three members: DOCK9, DOCK10, and DOCK11 (Meller et 
al., 2008). DOCK1 proteins possess an SH3 domain (SH3 domains are described in section 
1.4.6.4) capable of binding adaptor proteins containing a proline-rich motifs such as ELMO 
(Patel et al., 2011). GEF proteins will be described in more detail in section 1.4.6.  
32 
Alternation in binding of the Rho GTPase to GTP/ or GDP induces a switch-like control 
mechanism in activating or deactivating the Rho GTPase respectively. Once activated Rho 
GTPases modulate multiple downstream targets that are involved in the organisation of the 
actin cytoskeleton and the microtubule network. GEFs induce activation of GTPases through 
mediating release of GDP enabling the binding of GTP. GAPs drive inactivation of Rho-
GTPases via stimulation of GTP hydrolysis. GAPs catalyse the intrinsic GTPase activity of Rho 







Figure 1-6 Schematic diagram of RAC1 activation and inactivation 
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GTPase activating proteins (GAPs) drive inactivation of Rho-GTPases via stimulation 
of GTP hydrolysis (Sadok and Marshall, 2014). Rho guanine nucleotide dissociation inhibitors 
(GDIs) are also capable of regulating Rho-GTPase activity through binding to the C-terminal 
prenyl group, and retaining the GTPase in the cytoplasm (Sadok and Marshall, 2014; Etienne-
Manneville and Hall, 2002). Interestingly, the Rho GAP, RhoGDI 1, acts as a chaperone to 
multiple Rho proteins, acting to facilitate correct folding and prevent ubiquitination and 
degradation (Etienne-Manneville and Hall, 2002). 
It must also be noted that atypical Rho-GTPase proteins remain continually bound 
to a GTP molecule, effectively rendering the protein permanently activated yet under the 
control of alternative mechanism (Sadok and Marshall, 2014). 
The switch-like control mechanisms of the Rho-GTPase proteins enables integration 
of a fast acting and local stimulus. The existence of over 70 GEFs and 80 GAPs, which have 
thus far been identified (Sadok and Marshall, 2014; Hall, 2012), allows for diverse and 
complex fine tuning of Rho GTPase protein activation and localisation. The extensive 
repertoire of GEFs, GAPs, and GDIs lend to the Rho GTPase capacity to modulate and 
integrate multiple signals and their involvement in numerous cellular responses. 
Multiple signalling transduction pathways (MAPK, PI3K, PLCγ, and Rho-family of 
small GTPase) have been noted to regulate the dynamic plasticity of ECs (Etienne-Manneville 
and Hall, 2002). Of the many signalling molecules involved, the Rho family of small GTPases 
have been found to be integral in transmitting extracellular stimuli and converting them to 
cellular responses during angiogenesis (Etienne-Manneville and Hall, 2002). In ECs, Rho-
GTPases are primarily essential in regulating actin cytoskeletal dynamics thereby controlling 
cell migration, adhesion to the ECM, and lumen formation. They are also important in cell 
polarity, maintenance of endothelial barrier integrity, and may influence angiogenic 
metabolism, transcription factor activity, and transportation pathways as reviewed in 
Etienne-Manneville & Hall (2002). 
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 Actin cytoskeleton  
The cytoskeleton of a cell is a network of fibrous elements found within the 
cytoplasm which provides morphological diversity, cellular structure, and migratory 
capabilities. The cytoskeleton is comprised of microtubules, actin microfilaments, and 
intermediate filaments (Fletcher & Mullins, 2010). Networks of highly dynamic actin 
filaments are typically found beneath the cell cortex and consist of globular proteins (G-actin) 
assembled into long double helix filaments (F-actin; (Fletcher and Mullins, 2010)).  
Actin filament remodelling is dynamic and tightly regulated through complex 
mechanisms. Growth of actin filaments occurs through addition of G-actin monomers onto 
either the fast growing barbed end of the F-actin filaments, or the pointed slow growth end 
of F-actin filaments, via polymerization (Fletcher and Mullins, 2010). Depolymerisation 
occurs through cleaving of G-actin from either end of the F-actin filaments (Holmes et al., 
1990; Oda and Maéda, 2010). Existing actin filaments are maintained in a caped state, with 
uncapping and nucleation of the barbed end required for initiation of polymerisation. Three 
major classes of actin nucleators have been identified: the Arp2/3 complex, formins, and 
tandem actin-binding domain nucleators (Weston et al., 2012). 
Nucleation-promoting factors (NPFs) of the Wiskott–Aldrich syndrome protein 
(WASP)/WASP-family verprolin-homologous protein (WAVE) family activates and binds the 
F-actin bound Arp2/3 complex in conjunction with also binding G-actin monomers 
(Chesarone and Goode, 2009). This complex formation initiates creation of a nucleation core 
prompting actin nucleation and polymerisation of a new actin filament from a pre-existing 
actin filaments (Chesarone and Goode, 2009). The Arp2/3 complex also catalyses the 
production of branched F-actin filaments via increasing the number of barbed ends through 
binding to the side of filaments at the pointed end, forming the base of a new branch (Egile 
et al., 2005). 
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The Formin family of proteins also bind to the barbed ends of actin filaments to 
prompt the formation of linear actin filaments (Chesarone and Goode, 2009).  
Cofilin is an actin binding protein capable of initiating actin nucleation via 
depolymerisation of actin filaments. Cofilin cleaves actin monomers from actin filaments, 
creating barbed ends aiding nucleation and actin polymerisation (Ichetovkin et al., 2002; 
Andrianantoandro et al., 2006). Gelsolin also drives depolymerisation of F-actin and 
increases the number of free pointed ends, with a considerably higher binding affinity than 
that of cofilin (Ressad et al., 1998). 
The actin binding capping protein blocks actin polymerisation, terminating filament 
elongation, through binding to the F-actin barbed ends (Caldwell et al., 1989; Cooper and 
Pollard, 1985; Jo et al., 2015). 
 RhoA, RAC1, and CDC42 
Of the 20 known Rho family members, member A (RhoA), RAC, and CDC42 have been 
the most extensively studied, with these three considered to be hallmark family members 
(Sadok and Marshall, 2014). These three proteins have been noted through numerous 
studies to each regulate different aspects of cell shape changes through interactions with 
the cytoskeleton (Sadok and Marshall, 2014). CDC42 and RAC1 may regulate activation of 
one another, dependent on the signalling context, whereas RAC1 and RhoA often act in 
opposition (Machacek et al., 2009). The three canonical Rho GTPases RhoA, RAC1 and CDC42 
act in co-ordination with one another to regulate cytoskeleton dynamics.  
Within fibroblasts, the three Rho GTPases have been observed to fluctuate in activity 
within sub-minute times of one another and at a micro-meter length scales apart (Martin et 
al., 2016). RAC and/or CDC42 influence migration in distinctly different ways despite sharing 
some common GEF activators, indicating that RAC and CDC42 are activated within different 
sub-cellular locations simultaneously while acting upon distinctly different downstream 
targets (Cook et al., 2013). The mechanisms occurring downstream of each Rho-GTPase may 
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differ greatly dependent on the proteins through which they interact and their localisation 
within the cell (Cook et al., 2013). 
1.4.2.1 RhoA 
In the most basic sense, RhoA drives bundling of actin filaments into contractile 
stress fibers, increases cell contractility, and initiates assembly of focal adhesions. RhoA is 
most commonly recognised as the Rho-GTPase responsible for inducing contractility at the 
trailing edge of a migrating cell in 2-D motility. However, RhoA has also been implicated in 
events occurring at the leading edge of migrating cells (Wacker and Gerhardt, 2011b). 
There are multiple recognised mechanisms through which RhoA promotes EC 
migration. RhoA activation of the downstream target ROCK is the most studied activity of 
RhoA (Wacker and Gerhardt, 2011b). RhoA-ROCK signalling enables actomyosin contractility 
through phosphorylation of myosin light chain in addition to phosphorylating and inhibiting 
myosin phosphatase (Wacker and Gerhardt, 2011b). RhoA activation of the formin, mDia, 
also initiates actomyosin contractility and force generation (Sadok and Marshall, 2014). 
During initiation of cell migration, recruitment of RhoA from cell junctions to the leading 
edge of the cell, in a Rab-13-dependent manner, allows for activation of RhoA induced by 
the RhoGEF Syx. The p110α subunit of PI3K may also influence migration through RhoA 
signalling (Wacker and Gerhardt, 2011a). 
Reorganisation of the actin cytoskeleton may be further controlled through RhoA-
ROCK signalling via ROCK phosphorylation of LIM-Kinase, leading to phosphorylation of the 
actin-regulatory protein cofilin (a protein responsible for actin capping and 
depolymerisation) thus reducing accumulation of F-actin (Arber et al., 1998; Olson et al., 
1995). 
Rho signalling via ROCK has also been described in regulating EC protrusion and 
branching. ROCK activation during sprouting through stiffer ECM results in enhanced 
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directional growth and reduced EC branching (Fischer et al., 2009; Wacker and Gerhardt, 
2011a). 
1.4.2.2 RAC1 
RAC1 is ubiquitously expressed signal transducer which integrates signals from 
numerous cell signalling pathways (see figure 1.7) following stimulation of receptor kinases, 
G protein-coupled receptors, or integrins (Bosco et al., 2009). RAC1 has been implicated to 
be fundamental in several cellular functions and has been well described as a primary 
regulator of actin cytoskeletal reorganisation, axonal guidance, as well as cell migration and 
cell transformation. RAC1 has also been implicated in the induction of DNA synthesis and 
superoxide production (Bosco et al., 2009). 
RAC1 interacts with multiple proteins involved in various aspects of cytoskeletal 
dynamics including cytoskeleton remodelling, microtubule stability, and gene transcription 
(Bosco et al., 2009). Activated RAC1 binds a number of effector molecules such as IQ Motif 
Containing GTPase Activating Protein 1 (IQGAP), IRSp53/WAVE, PAK, and mixed-lineage 
protein kinases 2 and 3(MLK2/3) (Bosco et al., 2009). WASP family of verprolin-homologous 
proteins and the formin family of proteins promote actin nucleation downstream of RAC1 
(Galan Moya et al., 2009). RAC1 may also activate cofilin and gesolin, driving actin capping 
and depolymerisation. RAC1 control of spectrin activation drives membrane-associated actin 
binding (Galan Moya et al., 2009). The described RAC1 targets may also cooperate in 
exportation of proteins to expanding filaments thus further promoting migration.  
RAC1 effectors, protein family of p21 activating kinases (PAK), bind RAC1-GTP 
potently stimulating PAK kinase activity and leading to cytoskeletal dynamics, adhesion, and 
transcription (Frost et al., 1996; Brown et al., 1996a).. RAC1 driven activation of PAK leads to 
c-Jun N-terminal kinase (JNK) activation (Westwick et al., 1997) and MLK2/3 driven activation 
of the JNK pathway through RAC1 mediated nuclear (Nagata et al., 1998; Teramoto et al., 
1996). RAC1 is also involved in canonical JNK regulated Wnt-signalling to the TCF 
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transcription factor (Wu et al., 2008). Also, RAC1 leads to activation of PAK transmembrane 
guanylyl cyclase activity and the second messenger cGMP production (Guo et al., 2007).  
RAC1 may also antagonise RhoA driven actomyosin contractility via signalling 
through PAK. RAC1-GTP activity may also drive stabilisation of cell-cell contacts through 
targeting the scaffold protein Ras GTPase-activating-like protein (IQGAP). RAC1 bound 
IQGAP1 displacing α-catenin from the cadherin-catenin cellular adhesion complex through 
binding β-catenin (Noritake et al., 2005). 
RAC1 accumulates at the leading edge of migrating cells and was initially identified 
as driving cytoskeletal changes and formation of actin-rich lamellae at the leading edge of 
fibroblasts in response to microtubule growth. RAC1 also promoted neurite extension 
through prompting lamellipodia formation within the neural growth cone (Kozma et al., 
1995). E-cadherin stimulated RAC1 activity is also fundamental in actin recruitment to 
epithelial cell-cell adherens junctions (Vasioukhin et al., 2000; Ehrlich et al., 2002). RAC1 also 
drives actin polymerisation in stimulated blood platelets, lymphocytes, mast cells, and ECs 
(Hall, 1998) and is also involved in endocytosis/trafficking, and pinocytosis within dendritic 
cells (Nobes and Marsh, 2000).  
RAC1 also prompts actin nucleation and polymerisation through IRSp53 dependent 
N-WASP activation of the Arp2/3 complex (Miki et al., 2000). RAC1 signalling is crucial within 
immune defence via its involvement in phagocytosis; RAC1 regulates polymerisation of actin 
fibres at membrane sites of micro-organism and particle uptake (Etienne-Manneville and 
Hall, 2002); RAC1 partakes in activation of NADPH oxidase within phagocytic cells leading to 
the superoxide ions production required to kill bacteria (Bokoch, 1995; Abo et al., 1992); 
RAC1 regulates macrophage cell immunoglobulin-receptor mediated phagocytosis; RAC1 
also activates MAPK and JNK pathways enabling an inflammatory response (Caron and Hall, 
1998). 
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RAC1 is also a prominent regulator of NADPH-dependent membrane oxidase (NOX), 
a primary source of reactive oxygen species (ROS). Through ROS production RAC1 signalling 
is also involved in senescence, p53 activity, and genomic stability (Debidda et al., 2006; 
Joneson and Bar-Sagi, 1998; Cheng et al., 2006) with double negative RAC1 fibroblasts unable 
to generate ROS (Irani et al., 1997).  
RAC1 signalling may also induce cellular changes in gene transcription through 
activation of the activator protein-1 (AP1) transcription factors via activating nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFkB), JNK, and MAPK (Caron, E, 1998). This 
modulation of transcription by RAC1 has been described to induce G1/S progression of the 
cell cycle through upregulating cell cycle proteins such as cyclin D1 and c-myc (Olson et al., 
1995; Chiariello et al., 2001). RAC1 is essential for the growth of major blood vessels, 
developmental angiogenesis and formation of lymphatic vessels (D'Amico et al., 2009; Tan 









Figure 1-7 RAC1 signal transduction 
RAC1 transduces external stimulus transmitted through receptor kinases, G protein-
coupled receptors, or integrins via GEFs. GTP bound RAC1 targets effector molecules such as 
IQGAP, IRSp53/WAVE, PAK, and MLK2/3, prompting intracellular activities such as cytoskeleton 







CDC42 possess similar feature to RAC1 in that this small cyclic GTPase has many 
downstream effectors yet is highly specific in activity, integrating signals concerning specific 
functions transduced via distinct pathways. This is regulated through the diverse repertoire 
of GEFs which drive CDC42 activation downstream of surface receptors. CDC42 signalling is 
crucial for regulating changes to cell morphology, as well as cell cycle progression, cell 
migration, and endocytosis (Barry et al., 2015). 
CDC42s principal function is in conveying signals from the external environment 
prompting modification of the actin-cytoskeleton. CDC42 is also a predominant signalling 
transducer in establishing correct cell polarity in response to external signalling cues 
(Etienne-Manneville and Hall, 2002). CDC42’s ability to modulate the actin cytoskeleton is 
directed via multiple downstream targets including; Pak2, Pak4; cofilin; N-WASP and Arp2/3 
complex; IRSp53/Mena complex; Myosin light-chain kinase (MLCK); myotonic dystrophy 
kinase-related CDC42 binding kinase (MRCK); and IQGAP (Govek et al., 2005; Etienne-
Manneville, 2004).  
During migration CDC42 exerts much of its effects towards filopodia formation and 
has typically been described as an upstream regulator of RAC activation; with the exception 
of RAC1 dependent CDC42 activation under the control of VEGF stimulated RhoG activity 
within sprouting angiogenesis (Abraham et al., 2015). CDC42 function in regulating formation 
of filopodia has been attributed to its signalling via N-WASP and Pak2/4-mediated non-
muscle myosin IIA heavy chain (NMIIA) signalling (Etienne-Manneville, 2004). CDC42 
activates N-WASP in an IRSp53/Mena complex dependent mechanism inducing Arp2/3 
activation and subsequent actin nucleation and polymerisation (Lim et al., 2008). 
CDC42 may also act to inhibit myosin light chain phosphatase (MYPT), an activity 
more commonly associated with RhoA-ROCK signalling, via activation of MRCK (Zhao and 
Manser, 2015). Thus, CDC42 activation can cooperate with RhoA-ROCK in instigating cell 
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motility (Machacek et al., 2009; Zhao and Manser, 2015). However, the ability for one 
pathway to dominate control of MLC2 phosphorylation dictates the cell morphology 
displayed by the cell during migration, with Rho signalling prompting a more rounded 
morphology and CDC42 signalling instilling the more elongated morphology (Wilkinson et al., 
2005), as is seen in EC angiogenic migration.  
In quiescent ECs, CDC42 activity has been observed to influence intercellular gaps 
between adjacent cells and between cell-ECM (Zihni and Terry, 2015; Etienne-Manneville, 










Figure 1-8 CDC42 signal transduction pathways 
CDC42 transduces external stimulus transmitted through T-cell receptor, tyrosine 
kinase receptors, G-protein coupled receptors, integrins, Cadherins, and Nectins are all 
capable of transmitting extracellular stimulus inducing CDC42 activation via GEF. GTP bound 
CDC42 targets effector molecules such as IRSp53/Mena complex, WASP, PAKs, Par6/aPKC 
and IQGAP prompting intracellular activities such as cytoskeleton remodelling, microtubule 












RhoG is a ubiquitously expressed member of the RAC1 subfamily of RhoGTPase and 
has primarily been described to function within cell migration and regulation of 
macropinocytosis and caveolar endocytosis (Ellerbroek et al., 2004; Prieto-Sanchez et al., 
2006). RhoG stimulates a cellular migratory morphology through activation of RAC1 (Cote 
and Vuori, 2007). DOCK180 activation of RhoG leads to binding of the adapter protein ELMO 
and subsequent activation of RAC1 (Katoh et al., 2006; Katoh and Negishi, 2003). 
RhoG has been found to be regulated by a number of GEFs. TRIO driven activation 
of RhoG has been found to promote GF-induced neurite outgrowth in PC12 cells (Estrach et 
al., 2002). Within ECs the RhoG specific GEF, SGEF (Src homology 3 domain-containing 
guanine nucleotide exchange factor), stimulates RhoG activation of RAC1 in a VEGF 
dependent signalling pathway. RhoG activation of RAC1 signals via the RAC1 specific GEF 
DOCK4 (Cote and Vuori, 2007). DOCK4 driven RAC1 activation downstream of RhoG initiates 
CDC42 activation via DOCK9 activation, leading to actin cytoskeleton rearrangement and pro-
growth and migratory endothelial phenotype during sprouting angiogenesis (Abraham et al., 
2015). RhoG activation also induces macropinocytosis within fibroblasts (Ellerbroek et al., 
2004) and apical cup assembly in ECs. Dbs, ECT2, VAV2 and VAV3 GEFs have also been 
implicated in RhoG activation (Wennerberg et al., 2002; Schuebel et al., 1998; Movilla and 
Bustelo, 1999). 
 Rho GTPase signalling in EC filopodia formation 
During the initiation of migration stimulation of Rho GTPase signalling downstream 
of pro-angiogenic factors is a pivotal stage in inducing the dynamic remodelling of cell shape 
during angiogenic sprouting (Wacker and Gerhardt, 2011b). Filopodia are cytoplasmic rich 
actin projections which extend out from the cell to probe the extracellular space for growth 
signalling cues (Krugmann, 2001). Filopodia are present in abundance at the leading edge of 
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tip cells but have also been observed to a lesser degree along the elongating stalk of newly 
developing cords of ECs (Abraham et al., 2015). 
During filopodia production, CDC42 induces F-actin bundles through activating actin-
associated proteins, including fascin, formin (mDia2) and Ena/VASP (Mattila and 
Lappalainen, 2008; Chhabra and Higgs, 2007). CDC42 also regulate filopodia in a RhoG 
dependent manner (Abraham et al., 2015). In vitro CDC42 instigates actin polymerisation 
through cooperation with WASP and Pak2/4-mediated NMIIA signalling (Barry et al., 2015) 
which results in activation of Arp2/3 actin nucleation complex (Rohatgi et al., 1999).  
RAC1 has also been found to be essential in filopodia formation through activation 
of CDC42 (Abraham et al., 2015). Abraham, et al (2015) observed disruption of lateral 
filopodia formation following RAC1 knockdown in a tissue culture organotypic angiogenesis 
assay. Suppression of lateral filopodia was also seen in ECs following knockdown of DOCK4, 
a known RAC1 GEF (Abraham et al., 2015). Reduction of lateral filopodia prevented lumen 
formation within sprouting vessels, resulting in elongated unbranched sprouts. Knockdown 
of either RAC1 or DOCK4 appeared to have little effect on tip filopodia, indicating that 
different control mechanisms are involved in the development of the two types of filopodia. 
Interestingly Phng LK et al. (2013) reported that in vivo inhibition of actin polymerisation with 
latrunculin B reduced the presence of tip cell filopodia and speed of EC migration while 
guidance was unaffected (Phng et al., 2013). 
1.1 Rho GTPase signalling in blood vessel lumen formation 
In addition to their role in protrusive activity and EC migration, CDC42 and RAC1 are 
also necessary for lumen formation (Wacker and Gerhardt, 2011b). Studies performed in 
tissue culture in 3D collagen matrices have shown that RAC1 and CDC42 are required for 
changes in EC polarity during lumen formation taking place through the process of cell 
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hollowing (Lizama and Zovein, 2013), which entails formation an intracellular vacuole which 
expands through other cells giving rise to the lumen. 
RAC1 stimulation of PAK2, in addition to CDC42 activation of Pak2, Pak4, Par3, and 
Par6 all influence lumen formation, potentially in a protein kinase C dependent manner (Koh 
et al., 2008; Iruela-Arispe and Davis, 2009). Koh et al (2008) also describe potential 
interactions between CDC42, RAC1 and polarity protein complexes in driving lumen 
formation during cell hollowing. CDC42’s ability to regulate vascular lumen formation in vitro 
has been linked to CDC42-Par3-Par4-PKC atypical complex (Koh et al., 2008; Hoang et al., 
2011); the four proteins form a quaternary complex, with loss of any of the four components 
of the complex disrupting lumen formation (Koh et al., 2008). Knockdown of Pak2 and Pak3 
disrupt formation lumens (Hoang et al., 2011; Barry et al., 2015). CDC42 may further promote 
lumenisation through phosphorylation and inhibition of glycogen synthase kinase-3β (GSK-
3β) (Hoang et al., 2011). 
Barry et al (2015) found deletion of CDC42, in Tie2-Cre driver line mouse model, 
blocked angiogenic tubulogenesis while the deletion was lethal due to blood vessel defects. 
Additionally, EC specific RAC1 knockout in Cre/Flox mice has been seen to disrupt correct 
formation of major blood vessels and resulted in an absence of small-branched vessels (Tan 
et al., 2008; D'Amico et al., 2009). The EC RAC1 knockout is embryonic lethal at mid-gestation 
(Sugihara et al., 1998). 
Abraham et al (2015) described delineation of the Rho-GTPase pathway downstream 
of VEGF signalling essential for lateral filopodia formation, a process potentially imperative 
for lumenisation (as seen in figure 1.9). VEGF signalling resulting in activation of SGEF, a GEF 
which targets and activates RhoG, initiating a pathway which results in RAC1 activation (via 
binding of an ELMO and DOCK4 complex) and CDC42 activation downstream of RAC1 





Figure 1-9 RhoG signalling in angiogenesis 
Schematic diagram of intracellular signal transduction downstream of activated 
VEGF and FGF. (A) VEGF stimulation induce filopodia formation and sprouting angiogenesis. 
The Rho GEF SGEF activates RhoG, which in turn activates Rac GEF DOCK4 allowing binding 
of DOCK4 to ELMO. DOCK4-ELMO then translocate to the plasma membrane to activate 
Rac1. Abraham et al. (2015) described formation of an ELMO-DOCK4-DOCK9 complex 
capable of activating Cdc42 and stimulating filopodia formation. (B) Previous work in the 




 RhoGTPase in EC elongation 
Little is known in regard to Rho GTPase activity in driving EC elongation. However, 
RAC1 has been implicated in driving EC elongation downstream of the GEF Tiam-1 through a 
TNF-α-mediated re-arrangement of F-actin (Cain et al., 2010). Recently, Jiahui Cao et al. 
(2017) described a RAC1 dependent mechanism which, in cooperation with microtubules, 
drives cell elongation following VEGF stimulation of ECs. This RAC1 dependent signal 
transduction led to an increase in cell perimeter and decrease in junctional concentration of 
VE-cadherin. RAC1 activity stimulated formation of an actin-driven junction-associated 
intermittent lamellipodia (JAIL) via regulation of the WASP/WAVE/ARP2/3 complex, thus 
implicating RAC1 as a potential prominent component within EC elongation (Cao et al., 
2017).  
SiRNA mediated knockdown of cingulin-like 1 was found to impair the elongated 
phenotype via loss in Tiam-1 driven Rac1 activation (Chrifi et al., 2017). Marghe Scarcia 
(Thesis, 2013) found supplementing EC in vitro with FGF2 propagated EC elongation through 
initiating Trio driven RhoG activation.  
 Guanine nucleotide exchange factors 
GEFs, as previously described in section 1.4, can be grouped into two separate 
categories due to their distinct functional domains. Atypical DOCK1 related GEFs, as depicted 
in figure 1.10, are characterised by their evolutionary conserved DOCK homology region1 
(DHR1); which has been described to bind phospholipids, and DOCK homology region 2 
(DHR2), a domain which has been observed to bind target Rho GTPases and drive activation 
(Cote and Vuori, 2007; Meller et al., 2005; Brugnera et al., 2002).  
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Figure 1-10 Schematic diagram of DOCK protein functional domains 
DOCK1-related proteins are classified by their domain organisation and sequence 
similarity into four sub-groups: DOCKA (DOCK1, DOCK2, and DOCK5), DOCKB (DOCK3, and 
DOCK4), DOCKC (DOCK6, DOCK7, and DOCK8), and DOCKD (DOCK9, DOCK10, and DOCK11. 
DOCKA subgroup each possess an SH3 domain, helical region, DHR1, DHR2, PBR, and proline rich 
motif. DOCKB subgroup each possess an SH3 domain, DHR1, DHR2, and proline rich motif. 
DOCKC subgroup each contain only the DHR1 and DHR2 domains. DOCKD subgroup are the only 
DOCK proteins to contain a PH domain in addition to DHR1 and DHR2 domains.  
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1.4.5.1 The DOCK atypical GEF activity 
The DOCK atypical GEFs bear a mechanism of Rho GTPase activation that is distinct 
from the Dbl GEFs (as described in section 1.4). The DHR2 domain of DOCK proteins contain 
a conserved nucleotide sensor region with an essential valine residue within an insert in the 
α10 helix of the DHR2 domain. The specific valine residue binds to its target GDP-bound Rho 
GTPase and drives exclusion of an Mg2+ ion from the nucleotide pocket. The nucleotide free 
Rho GTPase can then bind a GTP molecule, in addition to activating the Rho GTPase this also 
induces conformational changes to the DOCK GEF through displacement of the DOCK a10 
helix insert resulting in the release of the activated GTPase (Yang et al., 2009; Gadea and 
Blangy, 2014). 
DOCK180-related proteins can be further classified by their domain organisation and 
sequence similarity into four sub-groups (see figure 1.-10): DOCKA (DOCK1, DOCK2, and 
DOCK5), DOCKB (DOCK3, and DOCK4), DOCKC (DOCK6, DOCK7, and DOCK8), and DOCKD 
(DOCK9, DOCK10, and DOCK11) (Cote and Vuori, 2007; Laurin and Côté, 2014).  
The DOCKA (DOCK1, DOCK2, and DOCK5) and DOCKB (DOCK3 and DOCK4) 
subfamilies both possess a SH3 domain, DHR1 domain, and DHR2 domain. DOCKA and 
DOCKB proteins also have a proline rich region (PRR) at the carboxyl terminus, which binds 
Crk proteins (Gadea and Blangy, 2014). DOCKA proteins also have a polybasic region (PBR) 
and helical region. Both DOCKA and DOCKB have been identified as DOCK proteins able to 
drive RAC1 activation.  
The DOCKC (DOCK6, DOCK7, and DOCK8), and DOCKD (DOCK9, DOCK10, and 
DOCK11) subfamilies lack both the SH3 domain and the proline-rich region but do have a 
pleckstrin homology domain at the amino-terminus. DOCKD subgroup of DOCK180 family 
proteins have been identified as CDC42 activating GEFs (Hiramoto-Yamaki et al., 2010; Côté 
and Vuori, 2002; Côté and Vuori, 2006). DOCKC subgroup of GEFs have been described as 
possessing dual specificity driving activation of both RAC1 and CDC42 (Harada et al., 2012; 
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Kulkarni et al., 2011; Miyamoto et al., 2013; Watabe-Uchida et al., 2006; Gadea and Blangy, 
2014). 
1.4.5.2 DOCK homology region1 
 The DHR1 domain of DOCK GEFs is approximately 200 amino acid residues and has 
been implicated in protein complex localisation to the plasma membrane. Côté et al. (2005) 
described the DHR1 domain of DOCK1 as capable of interacting with Phosphatidylinositol 
(3,4,5)-trisphosphate within the plasma membrane, driving localisation of a protein complex 
involved in RAC1 activation to the leading edge of migrating cells. Deletion of the DHR1 
region of DOCK1 did not disrupt DHR2 domain RAC1 loading but prevented the localisation 
of DOCK1 to the leading edge of the cell, impeding cell migration (Côté et al., 2005). 
1.4.5.3 DOCK homology region2 
 The DHR2 domain of DOCK GEFs are approximately 500 amino acid residues that 
bind in high specificity to either RAC1 or CDC42, driving Rho GTPase activation. Amino acid 
residue variances of the DHR2 domains between the different subgroups of DOCK GEFs 
facilitates the specificity in Rho GTPase targeting.  
 Crystal structural analysis of the DOCK2 (Kulkarni et al., 2011; Hanawa-Suetsugu et 
al., 2012; Ferrandez et al., 2017) and DOCK9 DHR2/GTPase complexes has demonstrated that 
the DHR2 is a symmetrical dimer comprised of three lobes: lobes A, B, and C. Lobe A of the 
DHR2 region was determined to be required for dimerisation of DOCK proteins. Lobe B and 
lobe C were seen to form the catalytic pocket which interact with the GTPase nucleotide-
sensing switch. Lobe B and C were determined to bear unique functions in GTPase activation 
with lobe B binding to and opening switch 1 of the GTPase nucleotide sensing switch. Lobe 
C drives GDP dissociation by binding to switch 2 and inserting a nucleotide sensor loop into 
the nucleotide-binding site (Kulkarni et al., 2011; Hanawa-Suetsugu et al., 2012; Ferrandez 
et al., 2017; Yang et al., 2009). 
52 
 Kulkami et al. 2011 described explicit differences between the amino acid sequences 
of RAC1 and CDC42, which enable specific binding of the DOCK2 DHR2 domain and DOCK9 
DHR2 domain, respectively. A phenylalanine or tryptophan at Rho GTPase residue 56 of the 
β3 strand, and an alanine or lysine at residue 27 drives Rho GTPase interaction within a 
region of the GEF DHR2 domain called switch 1 (Kulkarni et al., 2011). This finding 
demonstrated that DOCK proteins bind to their target Rho GTPase in a highly specific manner 
that is determined by the amino acid sequence of their DHR2 domain and target Rho GTPase.   
1.4.5.4 SH3 domain 
 The DOCKA and DOCKB subfamilies possess a SRC Homology 3 (SH3) domain at the 
amino-terminus. SH3 domains have been identified in approximately 250 proteins and are 
associated with aiding a large number of signalling pathways (Pollard et al., 2016). SH3 
domains are short peptide sequences, approximately 60 amino acids, which drive weak and 
transient interactions with proline-rich regions of interacting proteins. Aromatic residues 
within the SH3 domain shallow grove bind polyproline regions of proteins which form left 
handed type II polyproline helices (Pollard et al., 2016). 
 The SH3 domain of DOCK1 acts in an auto-inhibitory mechanism through weak 
interaction with the protein’s own DHR2 domain. The inhibitory conformation can be 
overcome through binding of the adaptor molecule, ELMO (Engulfment and Motility) (Gadea 
and Blangy, 2014). The SH3 domain of DOCK1 has been described as a site capable of binding 
the three isoforms of ELMO (Gadea and Blangy, 2014); ELMO acts as an adaptor molecule 
that couples RAC to specific downstream effectors (Katoh et al., 2006). 
1.4.5.5 Pleckstrin-homology (PH) domains  
 Pleckstrin-homology (PH) domains are found in the DOCKD sub-group of DOCK GEFs 
and also within Dbl GEFs, downstream of the DH domain. PH domains form weak interactions 
with phosphoinositide of the plasma membrane. Within the context of Dbl GEFs, the binding 
of PH domain to phosphoinositide of the plasma membrane has been suggested to facilitate 
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allosteric changes within the DH–PH array instigating Rho GTPase nucleotide exchange. 
However, it is also plausible that PH domain-phosphoinositide binding may function to guide 
precise subcellular localisation of Dbl proteins and engagement of membrane-bound 
GTPases. PH domains of the DOCKD group of GEFs may also function in localisation of DOCKD 
proteins to the plasma membrane (Rossman et al., 2005).  
1.4.5.6 Proline rich regions 
 Proline rich regions describe amino acid sequences with multiple proline residues 
within close proximity to one another (Yu et al., 1994; Alexandropoulos et al., 1995). 
Members of the DOCKA and B subfamilies possess a proline-rich region downstream of the 
DHR2 domain. DOCK9 was also determined to possess 11 PRRs with 9 of the 11 containing 
the typical PxxP or PxxxP motif which forms a continuous hydrophobic patch which 
preferentially binds to the amino acid sequence of SH3 domains. 
1.4.5.7 PBR 
 A polybasic region (PBR) within DOCK1 and DOCK2 was initially thought to bind PIP3, 
but more recent data suggest that it binds the signalling lipid phosphatidic acid (PA) 
(Kobayashi et al., 2001; Nishikimi et al., 2009; Sanematsu et al., 2013). 
1.4.5.8 DOCK9 
 DOCK9 signalling has yet to be well characterised, but has thus far been identified as 
a CDC42 specific GEF (Meller et al., 2002), however a recent study characterising the 
phenotype driven by over expression of DOCK9 in HeLa cells implicated DOCK9 in inducing 
RAC1 activation and membrane ruffling (Ruiz-Lafuente et al., 2018). DOCK9 expression drives 
filopodia production when expressed within cells. DOCK9 activity has been described as 
necessary within neuronal development (Kuramoto et al., 2009), angiogenesis (Abraham et 
al., 2015), and has been implicated in a number of diseases. DOCK9 is also expressed in 
steady-state circulating human CD3+ T cells, although the function of this expression has not 
yet been described (Ruiz-Lafuente et al., 2018). 
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 Variants in the DOCK9 gene have been implicated in bi-polar disorder (Detera-
Wadleigh et al., 2007). DOCK9 variant c.2262A>C has been associated in the development of 
the ocular degenerative disease Keratoconus (Karolak et al., 2016). DOCK9 has also been 
detected as a biomarker of tuberculosis (de Araujo et al., 2016). During the late stages of 
neuronal development DOCK9 is highly expressed in the hippocampus and cerebral cortex 
and activates CDC42, through which DOCK9 acts as a prominent regulator of dendritic 
growth in hippocampal neurons (Kuramoto et al., 2009). DOCK9 is able to homodimerise via 
the DHR2 domain (Meller et al., 2004) and is also able to auto-inhibit through binding of the 
DHR1 domain to the DHR2 domain, the mechanism through which DOCK9 overcomes auto-
inhibition is not yet known (Meller et al., 2008). Within angiogenesis DOCK9 driven CDC42 
activation is imperative for lateral filopodia of growing vascular sprouts (Abraham et al., 
2015).  
1.4.5.9 DOCK4 
 DOCK4 signalling is complex and has been described as an active component in 
multiple different cell signalling pathways within various cell types. DOCK4 activity has been 
termed as both pro and anti-oncogenic. DOCK4 has also been designated as required for 
correct growth of neuronal and ECs, with mutations within DOCK4 being implicated in a 
number of neurological diseases. 
 The pro-oncogenic potential of mutated DOCK4 was identified through a mouse 
model genetic based screening study (Yajnik et al., 2003). DOCK4 mutation Pro1718Leu was 
detected in prostate and ovarian cancers and led to DOCK4 being ineffective in activating 
Rap1 GTPase, however, the Pro1718Leu mutation led to an increase in RAC1 and CDC42 
activation (Yajnik et al., 2003). The change in Rho GTPase signalling prompted by DOCK4 
mutation Pro1718Leu, was seen to disrupt correct localisation of β-catenin to the sites of 
adherens junctions and resulted in the disruption of formation of intercellular junctions, 
leading to a loss of contact inhibition within cultured cells (Yajnik et al., 2003). In addition to 
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disrupting the formation of intercellular junctions, the DOCK4 Pro1718Leu mutation drove 
formation of filopodia protrusions (Yajnik et al., 2003). Together the characteristics driven 
by the DOCK4 mutation led to a tumour invasive phenotype which was also confirmed within 
a nude mouse model. Through this study, the tumour suppressor effect of wild type (WT) 
DOCK4 was also demonstrated through the use of a cancer invasion mouse model assay, 
during which cancer cells expressing WT DOCK4 were significantly less capable of invasion 
and metastasis when compared to tumours established from cell expressing DOCK4 
Pro1718Leu mutant (Yajnik et al., 2003). 
 DOCK4 has also been described to have oncogenic potential within breast cancer, 
leading to an increased invasive potential of breast cancer cells. Hiramoto-Yamaki et al., 
(2010) established evidence describing a mechanism through which RhoG activation within 
breast cancer cells drives a complex formation at the tip of cortactin-rich protrusions 
between ELMO2, DOCK4, and a member of the Eph receptor family, EphA2. The formation 
of the ELMO2-DOCK4-EphA2 complex was seen to induce formation of protrusions within 
breast cancer cell, increasing cell mobility in a RAC1 dependent manner (Hiramoto-Yamaki 
et al., 2010).  
 Further evidence linking to the pro-ongogenic activity of DOCK4 was described by 
Jia-Ray Yu et al (2015) through investigation of TGF-β driven RAC1 activation via inducing an 
increase in DOCK4 expression. TGF-β initiated increase in DOCK4 expression occurs 
downstream of the Smad signalling pathway, prompting an increase in tumour cell 
extravasation and metastasis. TGF-β-induced DOCK4 expression within lung 
adenocarcinoma induces an epithelial to mesenchymal transition independent increase in 
cell protrusion, motility, and invasion (Yu et al., 2015). 
 Upadhyay et al have previously demonstrated in vitro that pro-oncogenic Wnt 
signalling may induce RAC1 activation via GSK3-β driven β-catenin stabilization, through 
interaction with and phosphorylation of DOCK4. Activity which led to DOCK4 driven 
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stabilisation of the cellular levels of β-catenin via DOCK4 interaction with the β-catenin 
degradation protein complex; Adenomatosis Polyposis Coli (APC), Axin, and GSK3-β proteins 
(Upadhyay et al., 2008).  
 While activation of Wnt signalling during cancer progression has been described as 
driving a more aggressive phenotype (Polakis, 2000), DOCK4 involvement within the Wnt 
signalling pathway was later established to have a tumour suppressor effect (Yajnik et al., 
2003). 
 Debruyne et al. demonstrated that β-catenin induces an anti-proliferative 
mechanism via a feed forward loop to increase and accumulate its own nuclear activity 
through multiple mechanisms which regulate DOCK4 expression (Debruyne et al., 2018). 
GSK3-β activation and β-catenin transcriptional activity is required for DOCK4 mRNA and 
protein expressions (Debruyne et al., 2018). β-catenin directly binds to the 5’ regulatory 
sequence of the DOCK4 gene, regulating transcriptional activity of DOCK4. DOCK4 is also 
required for expression and transcriptional activity of β-catenin, thus creating a β-catenin 
driven feed-forward loop. Interaction of active GSK3-β with, and phosphorylation of, DOCK4 
induces β-catenin stabilisation and nuclear accumulation, activity which is driven by miR-302 
(Debruyne et al., 2018). β-catenin/DOCK4/miR-302 regulatory circuitry has been described 
as promoting a non-proliferative state with higher levels of DOCK4 expression leading to 
repression of glioblastoma multiform (GBM) proliferation stemness markers. Thus, GBM 
patients with increased DOCK4 expression possess a better survival prognosis (Debruyne et 
al., 2018).  
 The DOCK4 isoform (DOCK4-Ex49) is expressed within the brain, eye, and inner ear. 
Within the inner ear, this DOCK4 isoform has been found to regulate actin cytoskeleton 
organisation in stereocilia, via a RAC-DOCK4-ABP harmonin-activated signalling pathway 
(Yan et al., 2006). 
57 
 DOCK4 regulates essential processes during neural development and differentiation 
(Ueda et al., 2013; Xiao et al., 2013). DOCK4 driven RAC activation has also been proven to 
be imperative for the formation of dendritic spines within hippocampal neurons via DOCK4 
interaction with the actin-binding protein cortactin (Ueda et al., 2013).  
During neuron differentiation, the SH3 domain of DOCK4, but not the proline-rich C-
terminus, drives modulation of actin-enriched protrusions on the neurites leading to 
differentiation and extension and the establishment of the axon-dendrite polarity and the 
arborisation of dendrites (Xiao et al., 2013).  
 Further genetic based screening studies also identified DOCK4 as a candidate gene 
with mutations within the DOCK4 gene being associated with several neurological disorders, 
including autism (Pagnamenta et al., 2010), dyslexia (Pagnamenta et al., 2010) and 
schizophrenia (Alkelai et al., 2012). Microdeletion DOCK4 mutants lacking the GEF domain 
led to defective neuronal polarisation and neurite overgrowth, a phenotype which has been 
linked to autism and dyslexia (Xiao et al., 2013). A maternally inherited microdeletion 
encompassed chr7:110,663,978-111,257,682 leading to a DOCK4-IMMP2L fusion transcript 
was identified within people with autism spectrum disorder (Pagnamenta et al., 2010). 
Alkelai et al. (2012) identified a SNP (rs2074127) positioned within the DOCK4 gene (intron 
6) to be frequently present in a study group which represented schizophrenic people from 
within a Jewish population.    
 With the mounting evidence associated with DOCK4 functionality within multiple 
cell types, it is apparent that DOCK4 serves as a multi-functional protein important for 
numerous cell signalling pathways. However, evidence is still limited in the ability to decipher 
how, when, and under what context is DOCK4 expressed, activated, and regulated.  
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 Role of DOCK4 in vascular patterning and interaction with DOCK9 and generation of 
DOCK9 mutants in proline-rich regions 
The function of the RAC1 GEF DOCK4 within EC biology was investigated by Dr. 
Mavria’s research group. This work published within Nature Communications (Abraham et 
al., 2015) outlined the requirement of DOCK4 functionality for VEGF driven sprouting 
angiogenesis. Within an organotypic angiogenesis model, EC depletion of DOCK4 lead to a 
loss in stalk cell filopodia along the lateral edge of endothelial cords, but not filopodia 
extending from the tip cells during VEGF stimulated angiogenesis. This loss of lateral filopodia 
was accompanied by a reduction in branching and thus less dynamic endothelial structures. 
DOCK4 depletion also reduced the ability for EC cords to form a lumen (Abraham et al., 2015). 
Together these results suggest a role for DOCK4 in correct vascular patterning and formation 
of new functional vessels through sprouting angiogenesis under VEGF stimulated 
angiogenesis (Abraham et al., 2015). However, the role of DOCK4 activation of Rac1 within 
FGF stimulated angiogenesis is unknown, as is the requirement for DOCK4 activity within 
vascular biology in vivo. 
In order to further explore the function of DOCK4 signalling within mammalian 
biology the signalling context through which DOCK4 functions, and the protein complexes 
formed with DOCK4 while the protein is active, will allow for a deeper understanding into 
the relevance of DOCK4 for vascular biology. Investigating the effect of DOCK4 depletion 
within a murine model will also generate insight into the requirement for DOCK4 in 
mammalian physiology. However, a complete ablation of DOCK4 results in embryonic 
lethality. Thus, a heterozygous deletion, resulting in a 50% reduction of DOCK4 expression, 
would provide a robust model for exploring the biological effect of reduced DOCK4 bio-
availability.  
As VEGFA and FGF2 signalling pathways are both capable of initiating angiogenesis, 
yet both prompt growth of phenotypically different endothelial sprouts, and each control 
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angiogenesis under differing signalling context (i.e. during development and in response to 
hypoxia (Ucuzian et al., 2010; Simons et al., 2016) vs during wound healing (Ornitz and Itoh, 
2015), respectively, elucidating the control mechanisms which regulate DOCK4 activity will 
deepen the current knowledge of the mechanisms through which ECs respond to growth 
cues, while also giving insight into the signalling context through which DOCK4 functions.  
Abraham et al. (2015) also demonstrated a heterodimerisation between DOCK4 and 
the CDC42 specific GEF, DOCK9. The site of DOCK4 required for this interaction was 
determined to be the SH3 domain of DOCK4, indicating that DOCK4 binds a PRR of DOCK9, 
however, the PRR region of DOCK9 involved in this interaction was not determined.  
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Figure 1-11 Identification of DOCK9 PRRs  
(A) The GEF DOCK9 possess 11 proline PRR. Nine PRR have the typical PxxP or PxxxP 
motif. The small molecule QL-47 binds DOCK9 at the cysteine residue within PRR 3. (B) The 
predicted model of DOCK4 and DOCK9 interaction. The GEF DOCK4 homodimerises through bind 
of the DHR2 domains. DOCK4 SH3 domain also interacts with the adaptor protein, ELMO. DOCK4 
and DOCK9 interact via the SH3 domain of DOCK4 and an unknown region of DOCK9, predicate 








1. DOCK4 signalling is required for FGF2 driven angiogenesis. 
2. The SH3 domain of DOCK4 interacts with a PRR of DOCK9. 
3. DOCK4 expression is required for recovery from HLI in a murine model. 
1.6 Aims 
The overarching aim of this thesis is to understand the function of DOCK4 within 
pathological sprouting angiogenesis with consideration to the potential involvement of 
DOCK4 within FGF2 signalling. This thesis also investigates the mechanism of interaction 
between DOCK4 and DOCK9 within the RhoG signalling pathway (RhoG-DOCK4-RAC-DOCK9-
CDC42) and its role in angiogenesis.  
Aim 1. To investigate the role of DOCK4 in FGF2 signalling using an in vitro co-culture model. 
Aim 2. To elucidate the molecular basis of the DOCK4-DOCK9 interaction using Co-IP and 
chromatography. 
Aim 3. To investigate whether DOCK4 influences vascular response and recovery under 










2 Materials and methods  
All materials used were purchased from Sigma-Aldrich or Thermo Scientific unless 
indicated otherwise in the text. Common laboratory standard solutions can be found in Table 
2-1 at the end of this chapter. 
All experimental work presented within this thesis was carried out by Leander 
Stewart, with the exception of the point mutagenesis generation of DOCK9 PxxP plasmids, 
as described in section 2.4 carried out by Ms. Anne Sanford. Hind limb surgical procedures, 
as described in section 2.28, were performed by Dr. Nadira Yuldasheva. 
2.1 Primary cells and cell lines   
Human Umbilical Vein Endothelial Cells (HUVECs) and Angiokit-tested (AGK) Human 
Dermal Fibroblasts (HDFs) were purchased from TCS cellworks. Human Embryonic Kidney 
Cells 293T (HEK 293T) cells were purchased from Clontech Laboratories.  
2.2 Coating of tissue culture plates  
Collagen I coating for the culture of HEK 293T cells after thawing: Plastic bottomed 
T-75cm2 flasks were coated with 5mL of 50μg/mL Collagen I rat-tail (BD Biosciences); 5mg/mL 
stock of Collagen rat tail I was diluted in 0.02M glacial acetic acid. Coated plates were 
incubated at room temperature for 1 hour, and then washed three times with PBS.  
Fibronectin coating for the culture HEK 293T in immunoprecipitation (IP) 
experiments: 100mm plastic plates were coated with 4ml of 10μg/mL fibronectin solution; 
1mg/ml stock human plasma Fibronectin (Sigma-Aldrich) diluted in Phosphate Buffered 
Saline solution (PBS). Dishes were incubated at 37ᵒC for 3 hours before excess solution was 
removed and plates washed 3 times with PBS.  
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2.3 Cell culture conditions  
HEK 293T cells, stored in liquid nitrogen at passage 4 and passage 7, were thawed 
and seeded onto collagen I coated T-75 cm2 flasks. HEK 293T were maintained in high glucose 
Dulbecco’s modified eagle medium (DMEM) containing 10% v/v foetal bovine serum (FBS), 
supplemented with 1% v/v L-Glutamine, and 1% v/v penicillin-streptomycin.  
Media was changed every 48 hours. Upon reaching 80% confluence cells were 
trypsinised, using 0.5% v/v Trypsin/EDTA, and split at a ratio of 1:6 and seeded onto T- 
150cm2 flasks.  
HUVEC were purchased at passage 2 and used in co-culture assays until passage 5. 
Cells were stored in liquid nitrogen and once thawed were seeded onto T-75cm2 flasks and 
maintained in Large Vessel Endothelial Medium (LVEM, TCS cellworks) supplemented with 
100μg/mL of penicillin and endothelial growth supplements. HUVEC LVEM was replenished 
every 48 hours. Upon reaching 80% confluence HUVEC were washed in PBS and trypsinised 
using 0.5% v/v Trypsin/EDTA. Cells were split in a 1:5 ratio onto T-75cm2 flasks.  
AGK HDF were cultured in high glucose DMEM containing 10% FBS, supplemented 
with 1% v/v L- Glutamine, and penicillin-streptomycin.  
All cell culture work was carried out using aseptic techniques within a sterile HEPA 
filtration NuAire CellGuard class II biological safety cabinet and all cells were grown a 
humidified chamber at 37ᵒC with 5% CO2.  
2.4 Plasmids  
All plasmids used within this thesis are described in Table 2.2. Plasmid maps of each 
construct can be found in Appendix 7.1.2.  
PEF4 Myc-Flag–DOCK9 (Meller et al., 2008) was obtained from Professor Martin 
Schwartz, University of Virginia, USA. pC3 EGFP-DOCK4 and pBABE puro Flag-DOCK4 were 
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obtained from Dr Vijay Yanik, Harvard Medical School, Massachusetts, USA. Plasmid pC3 
EGFP-DOCK4 harbours a kanamycin resistance gene, for antibiotic selection in bacterial 
cultures. pEF4 Myc-Flag-DOCK9 and pBABE puro Flag-DOCK4 harbour an ampicillin 
resistance gene for antibiotic selection in bacterial cultures. 
DOCK9 point mutants (proline-alanine) were previously developed in the laboratory 
(by Ms. Anne Sanford) using the pEF4 Myc-Flag–DOCK9 construct by means of the 
StratageneQuickchange II XL site- directed mutagenesis kit. 
For expression of truncated DOCK4 proteins (as described table 2.1) human DOCK4 
complementary DNA fragments were isolated from a pBABE puro Flag-DOCK4 plasmid and 
cloned into the pOPIN-F vector (Addgene). For the expression of full length or truncated 
DOCK9 proteins (as described table 2.1), fragments of the human DOCK9 complementary 
DNA was isolated from a pEF4 Myc-Flag-DOCK9-His plasmid and cloned into a pOPIN-F 
vector. Vector pOPINF harbours a C-terminal His tag, resulting in all expressed peptides being 
tagged at the C-terminal with the His tag. Constructs based on pOPIN-F harbor an ampicillin 
resistance gene for antibiotic selection. The pOPIN-F constructs also harbor a CMV enhancer, 
Chicken β -Actin promoter, T7 promoter/lac operator and ORFs Lef-2603 and 1629 for 
expression within mammalian cells, bacteria and insect cells. Primers used for sequencing 











DOCK4 primers Forward primer sequences  
pOPIN vector sticky ends in lower case 
text 
Reverse primer sequences 
pOPIN vector sticky ends in 































DOCK9 primers Forward primer sequences  
pOPIN vector sticky ends in lower case 
text 
Reverse primer sequences 
pOPIN vector sticky ends in 























Table 2-1 Primers for nucleotide amplification for cloning of human DOCK4 and human 
DOCK9 gene sequences into plasmid constructs for protein expression. DOCK4 and DOCK9 
gene sequences isolated from pBABE puro Flag-DOCK4 and pEF4 Myc-Flag-DOCK9, 




Plasmid Gene Vector Antibiotic 
selection gene 
pC3 EGFP-DOCK4 DOCK4 pC3 EGFP  Kanamycin 
pBABE puro Flag-
DOCK4 
DOCK4 pBABE puro Ampicillin 
pEF4 Myc-Flag-
DOCK9 
DOCK9 pEF4 Ampicillin 
pOPINF DOCK4-
SH3  





pOPINF HIS6-3C-POI Ampicillin 












pOPINF HIS6-3C-POI Ampicillin 
pGIPz Lentiviral packaging plasmid Ampicillin 
psPAX Lentiviral packaging plasmid Ampicillin 
pMD2.G VSV G pMD2.G Ampicillin 






DOCK4 and DOCK9 DNA fragments were PCR amplified from the pBABE puro Flag-
DOCK4 and pEF4 Myc-Flag-DOCK9, respectively, with a Q5 high-fidelity DNA polymerase and 
master mix (1x Q5 reaction buffer, 200μM dNTPs, 0.02U/μl Q5 high-fidelity polymerase, 1x 
Q5 high-fidelity enhancer, <1ng plasmid DNA, nuclease-free water). PCRs were carried using 
a Veriti™ 96-Well Thermal Cycler. Conditions are as follows: 30 sec denaturation at 98ᵒC, 35 
cycles of 5 sec, 30 sec annealing with temperature optimised for each primer pair (see table 
2.1), elongation at 72ᵒC for 4mins for full length DOCK9 constructs and 30 sec for all other 
constructs), 2 min final extension at 72ᵒC.  
2.5 PCR clean-up 
15μl of PCR product per reaction was purified using a Monarch® PCR & DNA Cleanup 
Kit in accordance with manufacturer’s protocol. 
2.6 Cloning 
DOCK4 SH3 domain amplified from pBABE puro Flag-DOCK4, DOCK9 PH-PCIP domain 
amplified from pEF4 Myc-Flag-DOCK9) and DOCK9 p.PCIP627-630 domain amplified from 
pEF4 Myc-Flag-DOCK9 by PCR were sub-cloned into a modified a pOPINF HIS6-3C-POI vector, 
which had been ligated by the restriction enzymes NcoI and MscI. Full length DOCK9 was 
sub-cloned into pOPIN3SC HIS6-SUMO-3C-POI. Sub-cloning was carried out using a NEB 
builder HiFi DNA assembly kit. All primers described within this section are listed within Table 
2.1. 
2.7 Bacterial transformation and plasmid preparation  
BL21 pLYsS E.coli competent cells were quickly thawed on ice. 1μl of DNA was added 
to 50μl of E.coli then incubated on ice for 30 minutes. Cells were then heat shocked at 42ᵒC 
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for 45 seconds then placed on ice for 2 minutes. Cells were supplemented with 250μl of 
super optimal broth and placed on a shaking incubator at 37ᵒC for 1 hour. The pEF4 Myc-
Flag–DOCK9 plasmids contain an ampicillin selectable marker thus were streaked onto 
lysogeny broth (LB) agar plates prepared with 100μg/ml of ampicillin. BC21 bacteria 
transformed with pC3 EGFP-DOCK4 and pC3 EGFP-EV (empty vector) plasmids were cultured 
on LB agar containing 50μg/mL of kanamycin; as these plasmids possess the kanMX cassette. 
Cultures were incubated overnight at 37ᵒC. After 18 hours of growth one colony per plate 
was selected and inoculated into a 3ml aliquot of LB broth containing the antibiotics that 
corresponds with the plasmids selectable marker. The 3ml cultures were incubated at 37ᵒC 
in a shaking incubator for 8 hours, following which the 3ml cultures were inoculated into 
antibiotic containing 100mL of LB broth and returned to the shaking incubator at 37ᵒC for 18 
hours.  
DOCK9 point mutation plasmids were extracted and purified using PureLink® HiPure 
Plasmid Midiprep Kit (Invitrogen) according to manufacturer’s protocol. Plasmid 
concentrations were determined using Nanodrop spectrophotometry.  
2.8 Production of pOPINF-DOCK4 SH3, DOCK9 PH-PCIP, DOCK9 PCIP-DHR1, and 
pOPIN3SC-DOCK9 plasmids in E.coli. 
E.coli strain DH5α were transformed, as previously described, using 500pg of the 
described plasmid constructs pOPINF-DOCK4 SH3, DOCK9 PH-PCIP, DOCK9 PCIP-DHR1, and 
pOPIN3SC-DOCK9. Cultures were streaked onto ampicillin agar plates and grown over 72 
hours at 16oC. Colonies were selected using blue white screening and inoculated into 10ml 
of LB broth containing ampicillin and incubated overnight at 37ᵒC. Plasmids were extracted 
from DH5α cells using the Wizard MagneSil plasmid purification system.  
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All constructs were sequenced using Sanger sequencing, incorporating multiple 
primers designed to complement the DNA sequence in 700 base pair increments. Sequencing 
was carried out by ThermoFisher. 
2.9 Production and purification of Plasmids for mammalian cell expression 
Plasmids pEF4 Myc EV Flag, pEF4 Myc-Flag–DOCK9, and pEF4 Myc-Flag–DOCK9 PRR 
mut2, pEF4 Myc-Flag–DOCK9 PRR mut3, pEF4 Myc-Flag–DOCK9 PRR mut4, pEF4 Myc-Flag–
DOCK9 PRR mut5, pEF4 Myc-Flag–DOCK9 PRR mut9 were cultured from glycerol stocks and 
inoculated in BL21 (DES) competent cells (Invitrogen™, Carlsbad, California USA), in 
accordance with manufacturers protocol.  
Transformed competent cells were cultured on agar plates in the presence of either 
ampicillin (pEF4 Myc EV Flag, pEF4 Myc-Flag–DOCK9, and pEF4 Myc-Flag–DOCK9 PRR mut2, 
pEF4 Myc-Flag–DOCK9 PRR mut3, pEF4 Myc-Flag–DOCK9 PRR mut4, pEF4 Myc-Flag–DOCK9 
PRR mut5, pEF4 Myc-Flag–DOCK9 PRR mut9) or kanamycin (pC3 EGFP-DOCK4 and pC3 EGFP-
EV) and cultured over night at 37oC. Individual colonies was inoculated into 15ml of LB, 
supplemented with the appropriate antibiotics, cultures for 6 hours in a shaking incubator at 
37ᵒC. 15ml start-up cultures were then inoculated into 50ml of LB supplemented with 
antibiotics and placed in a shaking incubator at 37ᵒC overnight. Bacterial cultures were 
centrifuged at 5,000g for 15 minutes. Supernatant was discarded and pellet retained. 
Plasmids were extracted from bacterial pellets using a PureLink HiPure Plasmid Midiprep kit 
(Invitrogen™, Carlsbad, California USA), in accordance with manufacturers protocol. 
2.10 Restriction Enzyme Digestion  
Plasmids pEF-EV Flag pEF4 Myc EV Flag, pEF4 Myc-Flag–DOCK9, and pEF4 Myc-Flag–
DOCK9 PRR mut2, pEF4 Myc-Flag–DOCK9 PRR mut3, pEF4 Myc-Flag–DOCK9 PRR mut4, pEF4 
Myc-Flag–DOCK9 PRR mut5, pEF4 Myc-Flag–DOCK9 PRR mut9 were digested with NotI and 
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KpnI in NEB buffer 2.1 (New England Biosciences) according to the manufacturer’s protocol. 
Plasmids pC3 EGFP-DOCK4 and pC3-EGFP were digested with BamHI in NEB buffer 3.1 in 
accordance with the manufacture’s protocol. Digested plasmids were resolved on a 0.7% 
agarose gel using agarose gel electrophoresis.  
2.11 Transformation of competent cells for protein expression  
Optimal competent cells were selected through screening of a panel of competent 
cells (BL21 (DES), BL21 pLYsS (DES), BL21 (DES) RP, BL21 (DES) RIL, NiCo21), all competent 
cells produced in-house at the Protein Production Facility (Faculty of Biological Science, 
University of Leeds). Transformations of pOPINF and pOPIN3SC constructs were carried out 
as previously described. Transformed competent cells were streaked onto lysogeny broth 
(LB) agar plates prepared with selectable antibiotic markers (ampicillin 100μg/ml: BL21, 
NiCo21. Ampicillin plus chloramphenicol 34μg/ml: BL21 pLYsS (DES), BL21 (DES) RP, BL21 
(DES) RIL). Cultures were incubated overnight at 37ᵒC. Individual colonies were selected and 
inoculated into 1ml of LB supplemented with antibiotics and incubated overnight at 37ᵒC. 
20μl of overnight culture was inoculated into 2ml of LB plus antibiotic. Cultures were 
incubated in a shaking incubator at 37ᵒC until reaching an optical density (OD) 600 of 0.6nm 
(measured using spectrophotometer). Once cultures reach 0.6nm cultures were treated with 
0.2mM of Isopropyl β- d-1-thiogalactopyranoside (IPTG). Cultures were grown overnight at 
18ᵒC.  
For large scale cultures 1 colony was selected per agar plate. Each colony was 
inoculated into 100ml of LB supplemented with antibiotics, cultures were grown overnight 
at 37ᵒC. 100ml start-up culture was inoculated into 900ml of LB supplemented with 
antibiotics and placed in a shaking incubator at 37ᵒC until reaching an optical density at 
600nm (OD600) of 0.6 (measured using spectrophotometry). Once cultures reached OD600 
0.6 cultures were treated with 0.2mM of IPTG. Cultures grown overnight at 18ᵒC.  
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2.12 Bacterial culture lysis 
Bacterial cultures treated with IPTG were centrifuged at 5,000g for 15 minutes. 
Supernatant was discarded and pellet retained and re-suspended in a His wash buffer (20mM 
Imidazole, 150mM NaCl, 20mM Tris ph7.6). Cultures were lysed by sonication with 10x 10 
second sonication pulses with 30 second pauses in-between the pulses. All cultures were 
kept on ice during lysis protocols. Lysed cell cultures were then centrifuged at 17,000g for 35 
minutes. Supernatants were retained and pellets discarded. 
2.13 Transfection of plasmid DNA  
Plasmid DNA was transfected into HEK 293T cells using Lipofectamine 2000 
(Invitrogen) in accordance with manufacturer’s protocol. 3x106 HEK 293T cells were plated 
onto fibronectin coated 100mm plates in 10ml of DMEM supplemented with 10% v/v FBS, L-
Glutamine, and antibiotics. Cells were cultured overnight at 37ᵒC after which time the DMEM 
medium was removed and cells were washed 4x with antibiotic-free DMEM with 10% v/v 
FBS and L-Glutamine and 10ml antibiotic-free medium was left on each plate.  
For each 100mm plate 20μL of Lipofectamine 2000 was added to 480μL of reduced 
serum OptiMEM medium. 5μg of plasmid was suspended in reduced serum OptiMEM 
medium to a total volume of 500μL. Plasmid and Lipofectamine 2000 containing aliquots 
were combined, vortexed for 15 seconds, then incubated at room temperature for 30 
minutes. The combined solution was then added dropwise onto the cells. Transfected cells 
were incubated at 37ᵒC + 5% CO2 for 48 hours without medium change.  
2.14 Affinity chromatography 
His-tagged proteins were purified from bacterial lysates using a nickel column on an 
ÄKTA pure system (GE healthcare). The His-column was washed with 70% v/v ethanol then 
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equilibrated with a His wash buffer (20mM Imidazole, 150mM NaCl, 20mM Tris ph7.6). The 
sample was loaded onto the column at a rate of 1ml/min. The protein loaded column was 
then washed with His wash. Sample was eluted from the column through application of an 
elution buffer (50mM Tris pH 7.6, 300mM NaCl, 300mM imidazole, 5% v/v glycerol, 0.075% 
v/v β-mercaptoethanol) that was diluted with His wash buffer at increasing concentrations 
until reaching 100% elution buffer. DOCK4-SH3 domain and DOCK9 PCIP-DHR1 proteins 
purified through using affinity chromatography were stored in 20mM Tris pH7.6, 150mM 
NaCl, and 1mM DTT. 
2.15 Size exclusion chromatography 
Affinity chromatography of purified peptides DOCK4-SH3 domain and DOCK9 PCIP-
DHR1 were concentrated using a 3K MWCO Pierce™ Protein Concentrators PES for 
concentrating DOCK4-SH3 and 10K MWCO Pierce™ Protein Concentrators PES for 
concentrating DOCK9 PCIP-DHR1, prior to size exclusion chromatography (SEC). 
Protein samples were purified according to size using a Superdex® 75 Gel filtration 
column (GE Healthcare). In order to test DOCK4-SH3 and DOCK9 PCIP-DHR1 domain 
interaction, approximately 1ml of 1mg/ml DOCK4-SH3 was loaded onto the Superdex® 75 
Gel filtration column using a 2.5ml loop. Immediately afterwards, approximately 1ml of 
1mg/ml DOCK4-SH3 was loaded onto the Superdex® 75 Gel filtration column using a 2.5ml 
loop. Equal concentrations of DOCK4-SH3 and DOCK9 PCIP-DHR1 were combined then 
loaded onto the Superdex® 75 Gel filtration column using a 2.5ml loop. All samples were 
collected and analysed using SDS PAGE gel separation and Coomassie staining. 
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2.16 Lentiviral shRNA particle generation 
In order to knock down DOCK4 protein in HUVEC, two different DOCK4 shRNA and a 
non-silencing pGIPZ construct (Thermo Scientific, Open Biosystems) were used: 
DOCK4 shRNA 3 mature antisense - CTCAGTATTTGCAGATATA  
DOCK4 shRNA 4 mature antisense - CGCAAGGTCTCTCAGTTAT 
Non-silencing pGIPZ - ATCTCGCTTGGGCGAGAGTAAG 
HEK 293T cells were seeded onto poly-L-lysine coated 100mm dishes at a density of 
3x106. Cells were washed with 5ml of Opti-MEM and maintained in 7ml of Opti-MEM per 
plate prior to transfection. Cells were transfected with lentiviral packaging plasmids pMD2.G 
(3 µg) and psPAX2 (7 µg), and DOCK4 shRNA (10 µg) with 40μl of transfection reagent 
Lipofectamine 2000 per tissue culture plate. DNA and Lipofectamine were prepared 
separately in 500μl of Opti-MEM then combined, vortexed, and added dropwise to confluent 
HEK 293T cells. Cells were incubated at 37ᵒC with 5% CO2 for 4 hours after which Opti-MEM 
media was replaced with high glucose DMEM containing 10% v/v FBS, supplemented with 
1% v/v L- Glutamine. Cells were maintained at 37ᵒC with 5% CO2. 
Media was removed and replaced with fresh DMEM 24 hours post transfection and 
returned to the incubation cabinet at 37ᵒC with 5% CO2. 
Viral rich medium was removed and replaced with fresh media after 48 hours. The 
collected supernatant was centrifuged at 3000 x g for 20 mins then filtered through a 0.45 
µM syringe filter and stored at 4ᵒC for use within 7 days following particle production. 
All cell culture work was carried out using aseptic techniques within a sterile HEPA 
filtration NuAire CellGuard class II biological safety cabinet and all cells were grown a 
humidified chamber at 37ᵒC with 5% CO2.  
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2.17 Lentiviral transduction  
HUVEC were seeded onto 6 well flat bottom plastic culture plates at a density of 
1.5x105 cells per well, using cell culture conditions described in section 1.3. Approximately 
24 hours post seeding cells were treated with shRNA viral supernatant diluted in large vessel 
media in a 2:3 ratio.  
2.18 Cell lysis for Co-immunoprecipitation (Co-IP) 
Cells growing in 6 well plates or 100mm plates were washed with PBS and then lysed 
in 50μl or 400μl cold RAC lysis buffer (50mM TRIS pH 7.4, 10% v/v Glycerol, 1% v/v NP40, 
5mM MgCl2, 100mM NaCl, 5X Complete Protease Inhibitor EDTA free (Roche Applied 
Science), 1mM dithiothreitol (DTT)) respectively. Lysates were cleared by centrifugation at 
13,000g on a bench-top centrifuge for 30 minutes.  
2.19 Co-immunoprecipitation assay   
GFP-DOCK4 protein was extracted from total cell lysate through 
immunoprecipitation using GFP-trap (Chromotek) beads. GFP-trap beads were prepared 
according to manufacturer’s protocol. Cell lysates were added to 20μL of washed GFP-trap 
slurry and incubated with rotation at 4ᵒC for 1 hour.  
Samples were then centrifuged for 2 minutes at 12,000 g, the supernatants were 
removed and the beads were resuspended in RAC wash buffer (TBS, 10mM MgCl2, 5x EDTA 
free Complete Protease Inhibitor, 1mM DTT) and washed twice. After the final wash the 
pelleted beads with bound protein were resuspended in 40μl 4x Sodium dodecyl sulfate 
(SDS) sample buffer (Invitrogen) and 1.5μL of 1M DTT. The samples were then denatured at 
95ᵒC for 10 minutes.  
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2.20 SDS polyacrylamide gel electrophoresis  
3-8% v/v 12 well Tris-Acetate NuPAGE Novex® Pre-Cast Gel (Invitrogen) was used for 
the electrophoretic separation of proteins in an XCell4 SureLockTM Midi-Cell electrophoresis 
tank (Invitrogen). 1 litre of 1x NuPAGE® MES SDS running buffer (Invitrogen) was used to fill 
the tank, along with 465μl of NuPAGE® antioxidant (Invitrogen). 40μL of prepared protein 
sample was used per well and 5μL of Precision Plus ProteinTM All dual colour Standards (Bio-
Rad) was dispensed into the 10μL wells provided on either ends of the gel. Electrophoretic 
separation of proteins was carried out at 150V for 120 minutes.  
2.21 Western blotting  
Proteins were transferred onto an Immobilon® polyvinylidine difluoride membrane 
(PVDF) (Sigma-Aldrich) in a TE42 Standard Transfer Tank (Hoefer) submerged in 6L of 1x 
Towbin buffer (25nM Tris, 193mM Glycine, pH 8.3, 20% v/v methanol). The tank was 
positioned in a 4ᵒC cold-room and protein transfer was performed for 2 hours at 1A.  
Target proteins were probed using HRP labelled antibodies (see figure 2.3) diluted in 
TBS+0.1% (v/v) Tween-20 (TBST) in accordance with manufacturers recommendations. An 
ECL detection kit (Amersham) was used to visualise target proteins.  
2.22 Colorimetric quantification of Co-IP proteins 
Western blots analysis of the GFP-trap Co-IP of EGFP-DOCK4 and Flag-DOCK9 
proteins (WT; Proline rich regions 2, 3, 4, 5, and 9) were quantified using ImageJ colorimetric 
analysis software. GFP-tagged protein levels were detected through anti-GFP primary 
antibody and an appropriate HRP-labelled secondary antibody probing of the Western blots, 
followed by ECL detection, blot exposure and imaging. The concentration of GFP-tagged 
proteins was determined by the ratio of signal through ImageJ colorimetric analysis. 
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Quantification of GFP-DOCK4 was used as a control to depict the level of IP protein 
concentration. Quantification of Flag-tagged proteins was determined through anti-Flag 
primary antibody and an appropriate HRP-labelled secondary antibody probing of the 
Western blots, followed by ECL detection and blot exposure and imaging. The concentration 
of GFP-tagged proteins was determined through ImageJ colorimetric analysis and then 
normalised to the GFP-tagged DOCK4 concentration. Ratio of signal analyses was performed 
using GraphPad Prism 7.0a. 
2.23 Stripping and blocking  
PVDF membranes were washed with dH2O for 10 minutes on a rocker at RT. 
Membranes were then submerged in 50ml of 0.5M NaOH and returned to the rocker for 10 
minutes at RT. The washing step in dH2O was then repeated. PVDF membranes were then 














No. Primary antibody Dilution Reactivity Cat No./ Source 
1 Rabbit anti-CD31  1:30 Mouse, 
Human, Pig 
Ab28364/ ABCAM 
2 Mouse anti-CD31  1:20 Human M0823/ DAKO  
3 Mouse anti-CD31  1:400 Human KC1004/ Caltag medical systems 
4 Rabbit anti-DOCK4 1:100 Human, 
Mouse 
A302-263A/  Bethyl 
Laboratories 
5 Rabbit  anti-DOCK9  1:1000  Human A300-530A/ Bethyl Laboratories 
6 Mouse  anti Flag-M2  1:1000   Human F1804/ Sigma Aldrich 
7 Rabbit  anti-GFP  1:1000  Human sc-8334/ Santa Cruz  
8 Mouse anti-RFP Ab 1:1000 Mouse GTX82561/ GeneTex 
No. Secondary antibody Dilution Reactivity Cat No./ Source 
1 ImmPRESS™ HRP 
Anti-Rabbit IgG  
1:1000 Rabbit MP-7401/ Vector lab 
2 ImmPRESS™ HRP 
Anti-mouse IgG  
1:1000 Mouse MP-7402/ Vector lab 
3 Alkaline phosphatase 
conjugated anti-
mouse IgG1  
1:500 Goat KC1005 Caltag medical systems 
Table 2-3 List of primary and secondary antibodies. 
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2.24 Organotypic angiogenesis assay  
Human dermal fibroblasts (Caltag Medsystem) were seeded onto 24 well plastic 
tissue culture plates at a density of 2x104 cells per well. Fibroblasts cells were maintained in 
DMEM, as described in section 2.3. Fibroblasts were incubated at 37ᵒC +5% CO2 for 7 days. 
After 7 days of fibroblasts growth the medium was removed. 1x104 HUVEC were seeded on 
top of confluent fibroblasts per well. Where required, cells were stimulated with either 
10ng/mL FGF2 (Peprotech) or 25ng/mL of recombinant human VEGFA (Sigma-Aldrich) on 
days 4 and 6 post HUVEC seeding. On day 7, all media was removed from cultures and cells 
were fixed in 70 % ice cold ethanol for later analysis.  
2.25 Angiogenesis co-culture treatment with small molecule QL-47 
QL-47 inhibitor reconstituted in DMSO, to a concentration of 10mM, was gifted from 
the Nathanael Gray Lab (Dana Farber Institute, USA). QL-47 was used to treat HUVEC within 
an organotypic angiogenesis assay. HUVEC and HDF co-cultures were treated with QL-47 at 
a concentration of 5μM, or with DMSO at a 1-1000 dilution on days 4 and 6. Co-cultures were 
also treated with 10ng/ml FGF2, 25ng/mL of recombinant human VEGFA, or cultured without 
supplementation of addition GFs. On day 7 media was removed from cultures and cells fixed 
for later analysis.  
2.26 Hypoxic angiogenesis co-culture assay  
Hypoxic angiogenesis co-culture assays were carried out in accordance with the 
organotypic co-culture assay previously described, with modification to the GF treatment 
protocol. Co-cultures were supplemented with 10ng/ml FGF2 4 days following HUVEC 
seeding and immediately placed into a hypoxic incubator at 1% O2 and 5% CO2. Cultures were 
removed from the hypoxic incubator on day 6 and supplemented with 10ng/mL FGF2. 
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Cultures were returned back to the hypoxic incubator for a further 24 hours. After the 
remaining 24 hours, cultures were removed from the incubator and immediately fixed in 
70% ice cold ethanol for 30 minutes at RT. 
2.27 Angiogenesis co-culture fixation and immuno-histochemical staining  
 24 well plated fibroblasts and HUVEC co-cultures were washed once using PBS then 
fixed in 70% ice cold ethanol for 30 minutes at RT. Cells were stained using a commercially 
available CD31 tubule staining kit supplied by TCS cell works (Caltag Med systems). Tubules 
were permanently stained through binding of anti-CD31 primary antibody coupled to an 
alkaline phosphatase conjugated secondary anti-IgG antibody. Insoluble chromogenic 
substrates nitro-blue tetrazolium (NBT) and 5- bromo-4-chloro-3'-indolyphosphate (BCIP) 
were used for colourmetric detection of CD31 expressing ECs.  
2.28  In vivo mouse models 
All In vivo experiments were conducted in accordance with the Animal (Scientific 
Procedures) Act 1986 Amended Regulations 2012 (ASPA 2012) and NCRI Guidelines 
approved by the University of Leeds Animal Welfare and Ethical Review Committee. The 
Dock4 conditional knockout line was generated and verified by Ozgene, Australia and the 
iVEC-Cre; Rosa26tdTomato line was kindly provided by Dr Karen Blyth, Beatson Institute, 
Glasgow. The two lines were maintained and intercrossed under Project license 
(PFE6DC80B) at the St James’s Biological Services (SBS) animal facility unit. 
The project and personal licenses used to carry out all animal research described 
within this thesis are as follows: 
Project License: Stephen Wheatcroft P144DD0D6 
Personal License: Leander Stewart I91EAEBOC 
Personal License: Nadira Yuldasheva ICB059380 
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2.29 Mouse line breeding  
For global heterozygous Dock4 deletion, heterozygous Dock4 mice (Abraham et al 
2015) lacking exons 3, 4 and 5 were used (C57BL/6J background) as homozygous deletion is 
embryonic lethal (Abraham et al 2015). The line was maintained and experimental cohorts 
were generated through intercrossing with C57BL/6J mice (Appendix 3, Figure 7.13).  
For conditional Dock4 deletion, the mouse line Dock4f/f (Dock4 exon 6 flanked by 
LoxP sites for recognition by Cre recombinase, depicted in Appendix 3, Figure 7.14) was 
intercrossed with the mouse line iVEC-Cre; mice. Rosa26tdTomato double transgenic line for 
Cre recombinase expressed under the control of the endothelial specific VE-cadherin 
promoter (Wang et al., 2010), for tamoxifen inducible Cre expression and Cre deletion of the 
loxP site flanked exon, and the tdTomato Cre reporter protein designed to have a loxP-
flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent 
protein (RFP) variant (tdTomato), all inserted into the Gt(ROSA)26Sor locus (originally from 
The Jackson Laboratory). The LoxP sites flank exon 6 of the Dock4 gene (Appendix 3, Figure 
7.15), activation of Cre expression results in expression of an unstable truncated Dock4 
peptide. Dock4 and tdTomato immunofluorescent staining of the hind limb tissues was used 
to confirm knockdown of Dock4 expression (Figure 5.10). Knockout of the Dock4 gene 
expression was further confirmed through tdTomato immunofluorescent staining of brain 
sections of iVEC-Cre; Rosa26tdTomato mice (Teklu Egnuni, Thesis 2018). 
All pups produced for each mouse line were ear biopsied at 3 weeks old and 
genotyping was carried out by Transnetyx (TN, USA). Wild type littermates were used as an 
experimental control model. Both male and female mice were used during all experiments, 
as no difference in result was detected between the two genders. All mice were 21 weeks of 
age at the point of femoral artery ligation.  
Primers used for conditional mouse model genotyping by Transnetyx (TN, USA): 
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2.30 In vivo ischemia model 
Surgical procedures were carried out by Dr Nadira Yuldasheva. 24 hours prior to 
surgery the lower abdomen, groin, and legs of each mouse were depilated with hair removal 
cream (Veet, Reckitt Benckister UK). Mice were anaesthetised by inhalation of isoflurane-vet 
(Merial Animal Health Ltd, Essex, UK); initially isoflurane gas was delivered within a Perspex 
containment unit, then maintained via a nose cone mask. Each mouse was placed on a 
heating plane (Vettech, UK) in the supine position with the upper paws fixed on the mask 
and lower extremities abducted and extended. The surface area on and around the hind 
limbs were cleaned with providone-iodine 0.75% w/w (Vetasept animal care, York, UK).  
The left femoral artery extending from the region under the inguinal ligament to the 
saphenous artery was exposed and the adipose pad with epigastric artery was cauterised. 
The iliac artery was encircled with 8.0 Vicryl suture (Ethicon, Belgium) then dissected. The 
femoral artery, proximally at the inguinal ligament and distally at the bifurcation to 
saphenous and popliteal vessels, was separated from the vein, encirculated with 8.0 Vicryl 
sutures, and the intervening arterial segment was excised. 
Following surgery the mice were maintained at 38ᵒC within a warm chamber 
(Thermal cage; Vettck, UK) until regaining consciousness and motility. The operation was 
performed with the assistance of the surgical microscope (Ziess, OPMI 1-FC) under the 
appropriate magnification (x7.2-x30). 
2.31 Tamoxifen treatment 
iVEC-cre+ve; Rosa26-lsl-tdTomato; Dock4 f/f mice (n=9) and iVEC-cre-ve; Rosa26-lsl-
tdTomato; Dock4 f/f mice (n=8) underwent daily intraperitoneal injections of a 2mg dose of 
tamoxifen for 5 consecutive days. Seven days following the final tamoxifen dose all mice 
underwent a HLI operation to surgically ligate and transect the left femoral artery. 
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2.32 Laser Doppler Imaging techniques 
Approximately one hour following surgery, superficial blood flow within the hind 
limbs was analysed using a moorLDI2-HIR Laser Doppler imager (Moor Instruments LTD). 
Mice were anaesthetised by inhalation of isoflurane-vet (Merial Animal Health Ltd); 
delivered within a Perspex containment unit. The anaesthetic was then maintained via a 
mask. Data readings of vascular perfusion were obtained via dynamic light scattering analysis 
of which is converted to a signal proportional to the tissue perfusion. From this data a color-
coded perfusion image is generated by the moorLDI V6 PC Software (Moor Instruments LTD) 
which then generates a numerical value to represent the level of tissue perfusion of both 
hind legs. The region of hindlimb from the ankle to the foot was selected for comparative 
analysis, as this region of limb is the area most affected by the femoral artery ligation 
(Hellingman et al., 2010). The ratio of perfusion in the ischemic to non-ischemic limb was 
calculated to normalise the blood flow of the ischemic limb to that of the non-ischemic limb. 
Laser Doppler imaging (LDI) readings were taken 7, 14, and 21 days after surgical femoral 
artery ligation. 
2.33 Muscle harvest and fixation  
Approximately 2 hours after generating the final LDI reading mice were 
anaesthetised by inhalation of isoflurane-vet (Merial Animal Health Ltd); delivered within a 
Perspex containment unit. Mice were placed on a surgical table in a supine position on a 
heating plane (Vettech) with the upper paws fixed on the mask and lower extremities 
abducted and extended. Anaesthetic was then maintained via a nose mask.   
Each mouse was exsanguinated via caudal vena cava transection and whole body 
perfused. Abdominal cavity and pericardial cavity were exposed through a lower abdominal 
longitudinal incision, approximately 2 cm long, and a 3cm ventral midline incision. The Caudal 
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vena cava was dissected free of surrounding fascia and cut. Whole body vasculature was 
flushed through with injection of 10ml of 10% v/v PBS into the cardiac left ventricle. Muscle 
was fixed via injection of 10ml of 4% v/v paraformaldehyde into the cardiac left ventricle.  
All skin and fascia were removed from the lower extremities and the gastrocnemius 
and soleus muscles were surgically removed from both legs and placed together within a 
tissue storage cassette. All tissue samples were submerged in 4% v/v PFA for 24 hours then 
transferred to 70% v/v ethanol for approximately one week. Muscles were embedded in 
paraffin wax in a longitudinal orientation.  
2.34 Muscle sectioning 
Longitudinally orientated gastrocnemius and soleus embedded in paraffin wax were 
sectioned into 50x 5μm thick floating sections per block using a microtome (Leica Biosystem, 
Wetzlar, Germany). Initial 10 x 10μm sections of each muscles block were removed and 
discarded prior to selecting sections for mounting on non-frosted glass slides (Thermo 
Scientific).  
2.35 Immunohistochemistry 
 Dewaxing and rehydration 
Optimal slides were selected for immuno-histochemical (IHC) staining, with one slide 
selected after approximately every 10th slide. Slides were placed on a hotplate at 70ᵒC for 
20 minutes then transferred to 24-slide baskets. Slides were dewaxed in four separate 
consecutive Xylene containers for 5 minutes increments. Slides were then rehydrated in 
consecutive separate containers: absolute ethanol for 2x2 minutes, 90% v/v ethanol for 2 
minutes, and 70% v/v for 2minutes. Slides were then thoroughly rinsed in running tap water 
for 1 minute. 
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 Antigen retrieval and IHC staining 
Slides were submerged and incubated in Antigen Unmasking Solution, Tris-Based 
(Vector Laboratory) within a pressure cooker reaching 125ᵒC, then removed from Antigen 
Unmasking Solution and submerged in running water for 1 minute. Tissue section region was 
encircled using an ImmEdge™ Pen (H-4000) hydrophobic pen (Vector Laboratory). Slides 
were submerged in Tris buffered saline for 1 minute. Endogenous antibodies of tissue 
sections were incubated in BLOXALL Endogenous Peroxidase and Alkaline Phosphatase 
Blocking (Vector Laboratory) for 15 minutes followed by a 5 minute incubation in TBS-Tween. 
Tissue proteins were then blocked in 1/10 Casein Solution (Vector Laboratory) for 20 
minutes. Antibodies prepared in Antibody Diluent (ThermoFisher) to their optimised 
concentration (see table 2.3) then dispensed onto slides and incubated at ambient 
temperature for 1 hour followed by 2x 5 minute washes in TBS-Tween. Slides were incubated 
in the appropriate secondary antibody (see table 2.3) for 30 minutes, then washed for 2x 5 
minute washed in TBS. Slides were stained in ImmPACT DAB Peroxidase (HRP) (Vector 
Laboratory) prepared in ImmPACT DAB solution (Vector Laboratory).  
Cell nuclei were counterstained with Mayer’s haemotoxylin for 30 seconds, followed 
by a wash under running water and 1 minute immersion in Scott’s Tap water. Slides were 
placed in lithium carbonate for 2 minutes then rinsed in running water then placed in Xylene. 
 Dehydration, clearing and mounting 
IHC stained slides were dehydrated and cleared through submersion in 3 consecutive 
20 second absolute ethanol washes. Slides were air dried for 5 minutes and cleared in 4 
consecutive changes of Xylene. Glass slides were mounted onto slides with DEPEX (Sigma).  
 IHC quantitative image analysis 
CD31 IHC stained tissue sections were scanned using Apeiro AT Virtual Slide scanner 
(Leica Biosystems, Wetzlar Germay) and area for analysis selected using Apeiro ImageScope 
software (Leica Biosystems, Wetzlar Germay). Eight randomly selected 500μm x 500μm 
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boxes were placed over each section image. ImageJ software (National Institutes of Health) 
was utilised for quantification of all visible CD31 stained vasculature within the 500μm x 
500μm boxes. TVL and branch points within the defined areas were quantified within each 
box. RFP and DOCK4 IHC stained tissue sections were imaged at 20x using a Nikon light 
microscope (Nikon Instruments Inc, Edgewood NY). 
2.36 Statistical analysis  
All data within this thesis was collected and analysed by Leander Stewart. Data 
acquisition and analysis of organotypic co-cultures was blinded throughout. The genotypes 
of all mice to undergo HLI surgery were blinded from the outset and throughout the surgical 
procedure. However, genotypes of the mice utilised for the HLI was known during LDI data 
acquisition, and data analysis. 
 Organotypic angiogenesis assays 
Organotypic angiogenesis assay cultures were imaged using an Olympus CKX41 light 
microscope with 9 images taken per well. Images were analysed manually using ImageJ 
software, generating a measurement of total vessel length (TVL), average vessel length, and 
branch point index (BPI) for each image.  
Quantification of angiogenesis parameters (number of branches, tubules and tubule 
length) were performed as previously described (Hetheridge et al., 2011). The mean average 
of each data output was generated per experiment for each of the organotypic co-culture 
conditions. Gaussian distribution of calculated mean ± SD values of QL-47 treated 
organotypic co-cultures and DOCK4 shRNA knockout cultures were verified using Levene's 
and Bartlett's test and a Kruskal–Wallis one-way analysis of variance or One-way ANOVA 
analysis of variance were performed were appropriate using Origin 2015 software (OriginLab 
Corp., Northampton, MA) to assess significance. 
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 Laser Doppler Imaging 
Numerical values representing blood flow of tissues imaged by the Laser Doppler 
Imager Data were calculated as mean ± standard deviation. When comparing the ischemic 
limbs between experimental groups, the ratio of blood flow between the ischemic limb and 
non-ischemic limb was calculated, then the mean ± standard deviation ratio of blood flow of 
each experimental group was generated to compare hind limb perfusion between the 
different experimental groups using a One-way ANOVA with Tukey’s multiple comparisons. 
For analysis of non-ischemic limb, mean ± standard deviation of the absolute value of the 
non-injured limbs were calculated and compared using One-way ANOVA with Tukey’s 
multiple comparisons. Statistical analysis was performed with GraphPad Prism 7.0a. 
Area under the curve was also measured using GraphPad Prism 7.0a, the software 
uses the trapezoidal rule algorithm for area under the curve calculations, values were 
compared between experimental groups using one-way ANOVAs, with LSD post-hoc analyses 
where appropriate.  Statistical analysis was performed with GraphPad Prism 7.0a.  
Linear regression and slope intersects of the blood flow recovery over time of each 
experimental group were also analysed using GraphPad Prism 7.0a. Statistical analysis 
comparing linear regression and slope intersects were performed using GraphPad Prism 
7.0a. 
 Histological analysis 
TVL of all CD31 stained vasculature within the defined areas were quantified and 
used to generate a mean value of TVL for each section. All branch points of all CD31 stained 
vasculature within the defined areas were quantified and used to generate a BPI (defined as 
total branch points/TVL). The mean value of total BPI of each box was used to calculate a 
mean BPI for each muscle section. Gaussian distribution of calculated mean ± SD values were 
verified using Levene's and Bartlett's test and a One-way ANOVA analysis of variance was 
performed using GraphPad Prism 5 to assess significance. 
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Sr.No. Solution   Recipes or Cat. No 
1 PBS 500ml dH20 + 2 PBS tablets (Cat.No. P4117, Sigma) + 1 PBS 
tablet (Ca.No. BR0014G, OXOID) 
2 Lysis Buffer 
(PCR) 
100 mM Tris (pH 8.5), 5 mM EDTA, 0.2% v/v SDS, 200 mM 
NaCl 
3 Lysis buffer 
(WB) 
50mM TRIS pH7.4, 10% v/v Glycerol, 1% v/v NP40, 5mM MgCl2 
100mM NaCl  
4 RAC Lysis 
buffer 
50mM TRIS pH 7.4, 10% v/v Glycerol, 1% v/v NP40, 5mM 
MgCl2, 100mM NaCl, 25x Complete Inhibitor (no EDTA) and 
1mM DTT 
5 10xTBS 100ml 1M Tris-Base pH 7.5 + 200ml 5M NaCl  
(900ml dH20 + 24 gm Tris Base + 88 gm NaCl) 
6 1xTBS 900ml dH20 + 100ml 10xTBS  
7 TBST 1xTBS + 0.1% v/v Tween-20  
(900 ml dH20 + 200ml 10TBS + 1ml Tween-20) 
8 Running 
Buffer 
50ml 20xT.A + 950 ml dH20 
9 Transfer 
Buffer 
70% dH20, 20% v/v methanol and 10% v/v of 10XTBS  
10 4% PFA 500 ml PBS + 20 g PFA powder + 200 ul 1M NaOH 




20g LB powder in 1 litre dH20  
13 LB agar  15g agarose powder in 1 litre LB medium 
14 Tris-EDTA (TE) 
buffer (PCR) 
5ml 1M Tris (pH8), 1ml 0.5M Na2EDTA 
15  Access 
Revelation 
(10x) 
Antigen Retrieval (Cat.No. MP-607-X500, MenaPath) 
16 TBS (20x) Washing buffer (Cat. No. MP-945-X500, MenaPath) 
Table 2-4 Common laboratory standard solutions. 
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3 Results chapter I: In vitro investigation of DOCK4 signalling 
during sprouting angiogenesis 
3.1 Introduction 
Healthy vascular growth capable of adequately providing the precise blood flow to 
the organs and tissues depends strongly upon the correct vascular patterning. Developing 
vasculature with adequate, but not excessive branching, along with the correct level of 
tubule elongation is imperative for healthy physiological function of the body’s organs and 
tissues (Eilken and Adams, 2010). 
The precise cellular mechanisms which underlie the coherent processes of vascular 
pattering during sprouting angiogenesis rely strongly upon an intricate repertoire of 
interplaying GFs. Stimulation of ECs by each GF potentially prompts differing intracellular 
events which induce different cellular responses. The GEF, DOCK4, has been described as 
required for the signalling events downstream of VEGFA driven angiogenesis, with depletion 
of DOCK4 leading to a loss in lateral filopodia and vascular branching; inducing growth of 
long thin but unbranched tubules (Abraham et al., 2015). As much of post developmental 
angiogenesis occurs in response to oxygen deprivation, it is important to consider this 
signalling mechanism within the context of hypoxia, while also considering the potential 
interplay of DOCK4 in the cellular response to grow factors other than VEGF. To further 
understand the functionality of DOCK4 within the signalling pathways which drive 
angiogenesis, in vitro techniques were conducted with inhibition of DOCK4, and the DOCK4 
interaction partner DOCK9, through shRNA induced inhibition and small molecule inhibition, 
respectively; with consideration of hypoxic conditions. As FGF2 has previously been 
described as the predominant regulator of peripheral sprouting angiogenesis in response to 
ischemia (Ferraro et al., 2010), in vitro assays were carried out under VEGFA or FGF2 
stimulation.  
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In order to study these signalling mechanisms in vitro, an organotypic co-culture 
model was employed (figure 3.1). The co-culture model creates a 3D culture environment 
with HDF grown to produce an extracellular matrix, through which the ECs may form dynamic 
cords; which more closely resemble physiological vasculature than other 3D angiogenesis 
models (Hetheridge et al., 2011). 
QL-47, a DOCK9 binding small molecule inhibitor, was utilised as a tool for expanding 
upon the understanding of the DOCK4-DOCK9 signalling mechanism within angiogenesis. QL-
47 is capable of covalently binding to p.C628 within the DHR1 domain of the DOCK9 protein 
(unpublished data Gray, N. Appendix 2); a cysteine residue which lies within a proline-rich 
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Figure 3-1 Schematic diagram of organotypic angiogenesis co-culture assay 
An organotypic co-culture model was used to investigate sprouting angiogenesis within 
a 3D in vitro model. HDF cells were grown to form a confluent monolayer, forming a matrix 
through which ECs can sprout and develop into vascular structures. HUVEC were seeded on top 
of HDF, 7 days post HDF seeding. Where it was required, cells were stimulated with either 
10ng/mL FGF2 or 25ng/mL of recombinant human VEGFA on days 4 and 6 post HUVEC seeding. 
The time point of co-culture fixation is adaptable according to the phenotypical readout of 
results required. Co-cultures described within this thesis were cultured until day 7, post HUVEC 
seeding, allowing for dynamic remodelled of cords of EC to form into more established tubules. 
CFs=Confluent fibroblasts. 




 Effect of FGF2 stimulation on EC sprouting and elongation during tubule formation in 
the co-culture assay  
The organotypic angiogenesis co-cultures were carried out to investigate the 
phenotypical difference in sprouting angiogenesis stimulated by the GF VEGFA when 
compared to the GF FGF2 (figure 3.2). Co-culture assays were supplemented with VEGFA, 
FGF2, or no GF on days 4 and 6 following HUVEC seeding onto a HDF monolayer. Following 
7 days of endothelial growth within the co-culture model, cultures were fixed in ice cold 70% 
ethanol and IHC stained using an anti-CD31 antibody. Each co-culture condition was grown 
in duplicate (with two wells per condition) and each organotypic assay was repeated three 
times, as such n=6 per co-culture condition. Nine images per co-culture well, at random 
locations, were obtained using an inverted light microscope (example images given in figure 
3.2). Of the nine images, five were randomly selected. All visible tubules within the field of 
view were quantified, with tubules measuring below 20μm being excluded. ImageJ software 
was employed to analyse a number of quantifiable characteristics of the formed tubules, 
indicative of the total amount of tubule formation, tubule elongation and branching: number 
of tubules, total tubule length, mean tubule length, longest tubule length, branch points, and 
BPI. Quantified data sets were analysed comparing data of each culture condition using a 






(C) FGF2 (B) VEGFA (A) No GF 
Figure 3-2 Growth factor stimulation of blood tubule growth within an organotypic angiogenesis 
co-culture assay 
HUVECs were seeded onto a confluent monolayer of HDFs. Co-cultures were either (A) not 
treated with GF, (B) stimulated with VEGFA (25ng/ml) or (C) FGF2 (10ng/ml) on days 4 and 6 post 
HUVEC seeding. Co-cultures were fixed on day 7 with 70% ethanol and stained by IHC with an 
antibody against CD31. Images were taken under a light microscope (4x objective).  
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3.2.1.1 Mean tubule length 
Mean tubule length values represents the average length of all tubules measured 
within each individual image, representative images given in figure 3.2. Mean value from 
each image were combined to generate the mean values for each condition (figure 3.3). 
Analysis of the mean tubule length demonstrated that addition of VEGFA or FGF2 to culture 
media led to an increase in mean tubule length, when compared to the control (non-GF 
supplemented). The mean tubule length of VEGFA supplemented cultures increased from 
118μm, the mean measurement of the control cultures, to 142μm, this difference was not 
found to be statistically significant. Cultures supplemented with FGF2 developed an even 
larger increase in mean tubule length, to 193.1μm, with a significant difference 0.00005 
when compared to the control. 
3.2.1.2 Total tubule length 
Total tubule length readings depict the overall growth of endothelial tubules, 
without consideration of the number of tubules or individual tubule length (figure 3.3). 
Representative images given in figure 3.2. 
In cultures supplemented with VEGFA, total tubule length (10291μm) was increased, 
but the increase was not found to be statistically significant when compared to cultures 
without additional GF supplement (6863μm; figure 3.3). FGF2 supplemented cultures also 
developed a greater total tubule length (8985μm) when compared to control, however, this 
was also not found to be statistically significant. 
3.2.1.3  Number of tubules 
The number of tubules reading depicts how many tubules (defined as an elongated 
cord of CD31 positive cells) were detected within each co-culture image, with mean values 
for each condition used for statistical comparison (figure 3.3). Representative images given 
in figure 3.2. 
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The number of tubules detected in the VEGFA supplemented culture (75.25) 
increased when compared to the control (59.62), this increase was not statistically 
significant. FGF2 supplemented cultures had a slight reduction in the number of detected 
tubules, although this difference was not significant when compared to the control. 
However, statistical comparison between the number of tubules in VEGFA treated co-
cultures to FGF2 treated cultures found that VEGFA treated cultures had develop a 
statistically significant increase in the number of detected tubules (p=0.01004).  
3.2.1.4 Longest tubule length 
As FGF2 stimulation of co-cultures led to an observed increase in tubule lengths, the 
longest detected tubule from each co-culture image were used to generate a mean value of 
longest tubule length for each co-culture condition (figure 3.3). Representative images given 
in figure 3.2.  
The measure of the longest detected tubules (average of 6 wells, with 5 images per 
well) of FGF2 supplemented cultures (548.8μm) was significantly higher compared to control 
cultures (219.4μm), with a p value greater than 0.0001. FGF2 supplemented cultures showed 
a significant increase in the longest detected tubules (548.8μm) when compared to VEGFA 
supplemented cultures (436.8μm) in respect to control (219.4μm) with a p value of 0.018. 
VEGFA supplemented cultures also developed an increase in length of the longest detected 
tubule with a p value of 0.0013 when compared to the control cultures. 
3.2.1.5 Branch points 
Branch points were counted within each co-culture image and a mean per well was 
generated. Mean values were then compared between the three GF conditions, to 
demonstrate how branched endothelial tubules were within the co-cultures (figure 3.3). 
Representative images given in figure 3.2.  
Supplementation of culture media with VEGFA led to a significant increase in the 
number of detected branch points (51.86) when compared to the control (31.93) but not 
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FGF2 supplemented cells (33.38). FGF2 supplemented cultures had a level of branching 
similar to the control cultures (figure 3.3). 
3.2.1.6 Branch point index 
Calculation of the BPI (number of branch points/total tubule length) for each co-
culture image depicts the ratio of branch points to TVL (figure 3.3). With representative 
images of co-culture given in figure 3.2. Comparative analysis of the BPI of co-cultures under 
no-GF, VEGFA, or FGF2 treatment demonstrates how branched tubules are between the 
different co-culture conditions (no-GF=0.0045; VEGFA=0.0057; FGF2=0.00369). 
Supplementing culture media with FGF2 led to a decrease in BPI , while this was not found 
to be significantly different between the co-culture conditions, the trend of reduced BPI of 
FGF2 supplemented cultures indicates a reduction in the number of branches of FGF2 
supplemented cultures in comparison to the outgrowth of tubules; a measurement which 
reflects the observed phenotype of FGF2 supplemented cultures as longer and less branched 
in comparison to the control and VEGFA supplemented cultures.  
To summarise the data accumulated through comparison of FGF2 to VEGFA 
stimulation, sprouting angiogenesis within the organotypic co-culture model shows a 
different phenotype dependent on the angiogenic GF used to supplement the growth 
medium. FGF2 stimulation induces an increase in endothelial cord elongation with less 
branching and a trend for reduced number of tubules when compared to VEGFA 





HUVEC were seeded onto confluent monolayer of HDFs. Co-cultures were grown 
within a humidified chamber at 37 ̊C with 5% CO2. On days 4 and 6 post HUVEC seeding, 
Figure 3-3 Comparative quantification of VEGFA vs FGF2 stimulated endothelial tubule 
growth within an organotypic angiogenesis co-culture assay 


















































































































































































cultures were stimulated with VEGFA (25ng/ml), FGF2 (10ng/ml), or no GF. On day 7 cultures 
were fixed with 70% ethanol and stained using IHC with an antibody against CD31. N= 
number of wells analysed. Five images were taken per well under a light microscope, with 3 
independent experiments and 2 wells per condition, per experiment (n=6). Total tubule 
length, mean tubule length, number of tubules, and number of branch points, were 
measured manually per image using ImageJ software. Calculated values of each image were 
used to generate mean values and standard deviation per co-culture with readouts for: mean 
tubule length; total tubule length; longest detected continuous tubule; number of branch 
points; and BPI (branch points/TVL). Mean values of each co-culture well were analysed using 
a one-way analysis of variance (ANOVA) through Origin 2015 Software (OriginLab). Error bars 
signify standard deviation. Significant differences indicated by asterisks: *=P value equal to 
or lower than 0.05; **=P value equal to or lower than 0.01; ***=P value equal to or lower 
















 The impact of FGF2 stimulation on tubules with shRNA mediated DOCK4 depletion 
within an organotypic angiogenesis co-culture assay  
A DOCK4 Kd organotypic co-culture assay was utilised to investigate whether DOCK4 
expression is required during FGF2 stimulated angiogenesis, in normoxia and hypoxia 
(representative images in figure 3.4 and data analysis in figure 3.5).  
DOCK4 expression was attenuated in HUVEC by a method previously validated in Dr 
Mavria’s laboratory via transduction of a lentivirus harbouring a shRNA oligonucleotide 
targeting DOCK4 (figure 3.4A). Two DOCK4 shRNA lenti-viruses were selected to induce 
DOCK4 Kd in HUVEC, the two shRNAs were selected on the basis of previous optimisation 
(Gary Grant, Thesis 2016). Successful shRNA Kd of DOCK4 within HUVECs was determined 
through western blot (figure 3.4 A). The DOCK4 specific shRNA labelled shRNA 4 was found 
to proficiently deplete DOCK4 expression, the shRNA labelled shRNA 3 was not found to 
successfully deplete DOCK4 expression. Therefore cells transduced with the DOCK4 shRNA 4 
were used for the DOCK knockdown co-culture assays.  
HUVEC transduced with the DOCK4 shRNA and control non silencing (NS) shRNA 
lentiviruses were seeded on a monolayer of HDF and co-cultured for a duration of 4 days at 
20% O2 with GF supplementation of either FGF2 (10ng/ml), or in the absence of additional 
GF, after which time cultures were placed in a hypoxic incubator in 1% O2. On day 6 post 
HUVEC seeding, cultures were briefly removed from the hypoxic incubator and the media 
and FGF2 supplement were changed before being returned to the hypoxic incubator for a 
further 24 hours. Co-cultures were fixed and stained for CD31. For each well, 5 selected 
regions were imaged using brightfield microscopy, for each of the following conditions: 
HUVEC with DOCK4 shRNA, or control NS shRNA, supplemented with 10ng/ml FGF2 and 
cultured in hypoxic conditions; HUVEC with DOCK4 shRNA, or control NS shRNA, without 
FGF2 supplement and cultured in hypoxic conditions; HUVEC with DOCK4 shRNA, or control 
NS shRNA, supplemented with 10ng/ml FGF2 and cultured in normoxic conditions; HUVEC 
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with DOCK4 shRNA, or control NS shRNA, without additional FGF2 supplement and cultured 
within normoxic conditions. The impact of FGF2 stimulation of shRNA mediated DOCK4 
knockdown on angiogenesis, in the organotypic co-culture assay, was assessed under 
hypoxic conditions and compared to normoxic conditions. As this co-culture assay contains 
only 2 wells for each condition from a single experiment, statistical analysis could not be 
performed. However trends detected in this assay gave preliminary data which indicate a 
potential role for DOCK4 function during angiogenesis within a hypoxic environment. Light 
microscope images of the CD31 stained co-cultures (5 images X 2 wells per condition) were 
analysed using ImageJ software to characterise a number of quantifiable read outs: mean 
tubule length; total tubule length; number of tubules; longest tubule length; branch points; 




(A) Anti-DOCK4 Western blot analysis of HUVECs transduced with  either a (i) NS  
shRNA expressing lentivirus, or (ii) DOCK4 targeting shRNA lentivirus 3, or (iii) or DOCK4 
targeting shRNA lentivirus 4. Successful DOCK4 shRNA driven DOCK4 knockdown was 
determined through absence of a detectable band at 250kDa. (B) DOCK4 shRNA 4 depleted 
HUVEC and Non-silencing shRNA HUVEC, each co-cultured with HDF, were grown in a 
humidified chamber at 37oC with 20% O2 and 5% CO2. On days 4 and 6 post HUVEC seeding 
cultures were stimulated with FGF2 (10ng/ml), or no GF. Immediately following FGF2 
supplementation, the cell-culture plate with both FGF2 treated co-cultures and non-GF 
treated cells was placed back into the humidified chamber at 37oC with 20% O2 and 5% CO2. 
On day 7 cultures were fixed with 70% ethanol and stained by IHC with an antibody against 
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Figure 3-5 FGF2 stimulation of DOCK4 depleted ECs under hypoxia within an organotypic 
angiogenesis co-culture assay 
DOCK4 shRNA 4 depleted HUVEC were seeded onto confluent monolayer of HDF. 
Non-targeting shRNA HUVEC were also seeded onto a confluent monolayer of HDF to 
produce control co-cultures as a point of comparison. Co-cultures were initially grown in a 
humidified chamber at 37oC with 20% O2 and 5% CO2. On days 4 and 6, post HUVEC seeding, 
cultures were stimulated with FGF2 (10ng/ml), or no growth factor. Immediately following 
FGF2 supplementation one cell culture plate with both FGF2 treated co-cultures and non-
growth factor treated cells was placed within a hypoxic humidified chamber at 37oC with1% 
O2 and 5% CO2. On day 7 cultures were fixed with 70% ethanol and stained by IHC with an 
antibody against CD31. Five images per well were taken under a light microscope. 
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3.2.2.1 Mean tubule length 
The mean tubule length analysis demonstrated that the average length of measured 
tubules within NS co-cultures, under all 4 condition, were similar in measurements NS non-
hypoxic no GF=134.70μm; NS non-hypoxic FGF2=129.50μm; NS hypoxic no GF=128.50μm; 
NS hypoxic FGF2=153.95μm; figure 3.4, 3.5 and 3.6), with FGF2 treatment of cultures grown 
in hypoxia leading to an increase in average tube length.  
DOCK4 depleted co-cultures demonstrated a reduction in mean tubule length 
(DOCK4 non-hypoxic no GF=122.35μm; DOCK4 non-hypoxic FGF2=160.23μm; DOCK4 
hypoxic no GF=74.17μm; DOCK4 hypoxic FGF2=133.87μm). The reduction in mean tubule 
length of DOCK4 depleted tubules, when compared to NS tubules, was most pronounced in 
hypoxic conditions without FGF2 treatment. Within non-hypoxic conditions, FGF2 treatment 
lead to a strong increase in average tubule length. While FGF-treatment of hypoxic DOCK4 
depleted co-cultures grew tubules of a similar average length as NS co-cultures without GF 
treatment in hypoxia, and with FGF2 treatment of normoxic cultures. 
To summarise, FGF2 treatment appears to lead to an increase in average tubule 
length in hypoxia. DOCK4 depletion in ECs leads to a slight reduction in mean tubule length 
that becomes more pronounced under hypoxia. FGF2 treatment overcame this reduction of 
mean tubule length of DOCK4 deficient tubules, in both normoxia and hypoxia, with FGF2 
treatment of DOCK4 depleted cultures in normoxia leading to a strong increase in average 
tube length.  
3.2.2.2 Total tubule length 
The total tubule length of NS co-cultures were found to develop a similar level of 
overall tubule growth within non-GF treated cultures, grown in both hypoxia and normoxia, 
as well as FGF-supplemented co-cultures grown in hypoxia. However, NS co-cultures treated 
with FGF, but grown in normoxia, had a near 2-fold increase in total tubule length (NS non-
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hypoxic no GF=3991.42μm; NS non-hypoxic FGF2=6621.10μm; NS hypoxic no 
GF=3025.51μm; NS hypoxic FGF2=3643.37μm; figure 3.4, 3.5 and 3.6).  
In contrast, DOCK4 depleted cultures had an overall decrease in total tubule length 
across all conditions (DOCK4 non-hypoxic no GF=1286.12μm; DOCK4 non-hypoxic 
FGF2=5723.86μm; DOCK4 hypoxic no GF=1651.09μm; DOCK4 hypoxic FGF2=300.2224μm). 
FGF2 treatment of DOCK4 depleted co-cultures, grown in hypoxia, had a strong decrease in 
total tubule length.   
To summarise, FGF2 treatment greatly increase overall tubule length in normoxic 
conditions but does not impact on total tubule length under oxygen deprivation. DOCK4 
depletion leads to a reduction in total tubule length. This reduction in total tubule length is 
over-come by treatment with FGF2, within normoxic conditions. The FGF2 driven increase in 
total tubule length is strongly diminished in DOCK4 depleted cultures grown in hypoxic 
conditions. This result suggests DOCK4 signalling within FGF2 driven angiogenesis differs 
depending on oxygen availability. The total tubule length analysis demonstrated high 
variation in the overall growth of sprouting HUVEC when comparing the 8 different culture 
conditions (figure 3.5 and 3.6). 
3.2.2.3 Mean number of tubules 
Analysis of the number of detected tubules within NS co-cultures found a slight 
decrease in number of tubules under FGF2 stimulation (NS non-hypoxic no GF=30.2; NS non-
hypoxic FGF2=23.4; NS hypoxic no GF=30.2; NS hypoxic FGF2=23.2; figure 3.4, 3.5 and 3.6), 
normoxic and hypoxic NS co-culture were found to have a similar number of tubules.  
In DOCK4 depleted co-cultures, non-GF treatment led to a 3-fold decrease in the 
number of tubules of cultures grown in normoxia, and an almost 10-fold decrease in the 
number of detected tubules in cultures grown under hypoxia. Within FGF2 supplemented 
cultures, the number of tubules increased when compared to the NS cultures. This increase 
in tubule numbers was strongly decreased under hypoxia, with almost half the average 
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number of tubules detected in the FGF2 treated DOCK4 deficient co-cultures grown within 
hypoxia (DOCK4 non-hypoxic no GF=10.5μm; DOCK4 non-hypoxic FGF2=35.7; DOCK4 
hypoxic no GF=3.9; DOCK4 hypoxic FGF2=12.5μm).  
To summarise, FGF2 treatment appeared to have little impact on the number of 
tubules which develop during sprouting angiogenesis. In the absence of DOCK4, the number 
of tubules were greatly decreased, a phenotype that was rescued by FGF2 treatment. Under 
hypoxic conditions FGF2 treatment was seen to be less effective in prompting the growth of 
new sprouts. 
3.2.2.4 Longest tubule length  
Longest tubule length measurements were used to detect the difference in tubule 
lengths between GF treatment conditions (figure 3.4, 3.5 and 3.6) as FGF2 treated cultures 
were observed to have obviously longer tubules than the non-GF treated cultures. All tubules 
were measured and the longest tubule per image was selected, the longest tubule lengths 
from each image were averaged per well. The numbers given are the mean average longest 
tubule length per well.   
Analysis of the longest tubule length of NS co-cultures demonstrated that tubule 
length was increased in the presence of FGF2, and was further increased within hypoxic 
conditions (NS non-hypoxic no GF=364.88μm; NS non-hypoxic FGF2=401,36μm; NS hypoxic 
no GF=336.32μm; NS hypoxic FGF2=603.48μm; figure 3.5 and 3.6). 
DOCK4 Kd led to a slight reduction in the longest tubule length of non-GF treated co-
cultures under normoxia. This decrease was overcome with FGF2 treatment of DOCK4 
depleted cultures, resulting in an increase in the average lengths of longest tubules 
compared to the NS co-cultures. DOCK4 depleted co-cultures grown with hypoxia developed 
shorter vessels, with FGF2 treated DOCK4 Kd cultures developing the tubules with a similar 
length to the non-GF treated NS cultures from in hypoxia (DOCK4 non-hypoxic no 
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GF=247.44μm; DOCK4 non-hypoxic FGF2=519.91μm; DOCK4 hypoxic no GF= 101.10μm; 
DOCK4 hypoxic FGF2=339.10μm).  
To summarise, FGF2 treatment appeared to have little impact on the number of 
tubules which develop during sprouting angiogenesis. In the absence of DOCK4, the number 
of tubules were decreased, a phenotype that was reversed by FGF2 treatment. Under 
hypoxic conditions FGF2 treatment was seen to be less effective in prompting the growth of 
new sprouts. 
3.2.2.5 Branch points 
Mean values of all branch points within each co-culture image (figure 3.5 and 3.6) 
determined that FGF2 treatment of co-cultures prompted a strong increase in branching. 
This increase was greatly reduced under the conditions of hypoxia, with non-growth factor 
treated co-cultures developing slightly less branch points, and FGF2 treated co-cultures 
developing a 3-fold decrease in the number of branch points (NS non-hypoxic no GF=9.7; NS 
non-hypoxic FGF2=33.9; NS hypoxic no GF=7.2; NS hypoxic FGF2=9.1; figure 3.5 and 3.6).  
DOCK4 depletion led to a decrease in overall branching detected in non-growth 
factor supplemented and FGF2 supplemented co-cultures grown in normoxia; with non-
growth factor supplemented co-cultures showing a much higher reduction in branching. The 
growth of DOCK4 depleted co-cultures supplemented with FGF2 under hypoxic conditions 
led to a decrease in detected branch points similar to that of the DOCK4 depleted non-FGF2 
supplemented co-cultures, grown in both normoxia and hypoxia (DOCK4 non-hypoxic no 
GF=1.5; DOCK4 non-hypoxic FGF2=13.7; DOCK4 hypoxic no GF=0.3; DOCK4 hypoxic 
FGF2=2.5). DOCK4 depleted co-cultures supplemented with FGF2 and grown within 
normoxia develop a level of branch points similar to the number of branch points seen in in 
NS FGF2 supplemented and non-growth factor supplemented co-cultures grown in hypoxia, 
and non-growth factor supplemented NS co-cultures grown in normoxia.  
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To summarise, FGF2 treatment induces a higher number of branch points. This 
increase in branch point numbers greatly reduced by DOCK4 depletion and is almost 
diminished by culture of DOCK4 depleted cells in hypoxia. 
3.2.2.6 Branch point index  
Calculation of the BPI for each co-culture image (figure 3.5 and 3.6) demonstrated 
that supplementing culture media with FGF2 in normoxic conditions led to an increase in BPI 
when compared to the no GF, thus reflecting the increase in the number of branches in 
comparison to total tubule length of FGF2 supplemented co-cultures; a result in 
contradiction with the previous findings within this chapter (3.2.1.6). All other NS co-culture 
conditions were found to have very similar BPI, indicating no difference in the number of 
branch points per vessel length under hypoxia when compared to normoxia (NS non-hypoxic 
no GF=0.0024; NS non-hypoxic FGF2=0.005; NS hypoxic no GF=0.0021; NS hypoxic 
FGF2=0.0025; figure 3.5 and 3.6).  
The BPI was slightly reduced in DOCK4 depleted, no GF treated, non-hypoxic co-
cultures. However, the BPI was unaffected in the hypoxic equivalent; suggesting a lower level 
of branching in the cells grown in normoxia. Within hypoxia this result was reversed, with no 
GF treated co-cultures having the same ratio of branch points to tubule length as the NS co-
culture. However, DOCK depleted hypoxic co-cultured treated with FGF2 had a marked 
decrease in BPI, indicating much fewer branches per vessel length (DOCK4 non-hypoxic no 
GF=0.0012; DOCK4 non-hypoxic FGF2=0.002; DOCK4 hypoxic no GF=0.0023; DOCK4 hypoxic 
FGF2=0.0005). 
In summary, the comparison of FGF2 stimulation in normoxic and hypoxic conditions 
showed that under normoxic conditions within this assay, sprouting angiogenesis was 
enhanced with FGF2 stimulation leading to an increase in the overall length of tubules and 
number of branch points. However, culture under hypoxic conditions abolished this FGF2 
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driven stimulation, with the exception of average tubule length which was higher in the 
presence of FGF2 in hypoxic conditions.  
DOCK4 depletion had little impact on FGF2 stimulated cultures when grown under 
normoxia, leading to an increase in the length of the longest detected tubules while reducing 
the number of branch points; suggesting DOCK4 depletion had induced the phenotype 
described by Abraham et al. (2015) whereby DOCK4 depletion drove growth of endothelial 
cords that were elongating yet less branched.  
FGF2 stimulated DOCK4 depleted ECs grown under hypoxic conditions showed 
impairment in both tubule elongation and branching, with profoundly fewer tubules, total 
tubule length, and number of branch points.  
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DOCK4 Kd or DOCK4 NS HUVECs were seeded onto confluent monolayer of HDFs. 








































































































































































Figure 3-6 Comparative analysis of DOCK4 depleted HUVEC within a hypoxic organotypic 
angiogenesis co-culture assay 
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CO2. On days 4 and 6 post HUVEC seeded cultures were stimulated with FGF2 (10ng/ml), or 
no GF. Immediately following FGF2 supplementation one cell culture plate with both FGF2 
treated co-cultures and non-GF treated cells placed within a hypoxic humidified chamber at 
37oC with 1% O2 and 5% CO2, a second co-culture plate also possessing FGF2 treated co-
cultures and non-GF treated co-cultures were placed within a humidified chamber at 37oC 
with 20% O2 and 5% CO2. On day 7 cultures were fixed with 70% ethanol and stained by IHC 
with a CD31 targeting antibody. N= number of wells analysed. Five images per well were 
taken under a light microscope, with 2 co-cultures per condition (n=2). Total tubule length, 
mean tubule length, number of tubules, and number of branch points, were measured 
manually per image using ImageJ software. Calculated values of each image were used to 
generate mean values and standard deviation per co-culture with readouts for: mean tubule 
length; total tubule length, longest detected continues tubule; number of branch points; and 
BPI (branch points/TVL). Graphs representing the mean values of each co-culture were 




 The effect of QL-47 treatment on blood vessel tubule growth in an organotypic 
angiogenesis co-culture assay  
QL-47 is a small molecule inhibitor which has been demonstrated to inhibit Cd42 
activation (Appendix 2). QL-47 binds DOCK9 at p.C628, a cysteine residue of DOCK9. In-order 
to test whether QL-47 has anti-angiogenic potential, an organotypic angiogenesis co-culture 
assay was carried as previously described with incorporation of QL-47 treatment at a 5μM 
concentration, or DMSO as a treatment control, on days 4, and 6 post seeding, control co-
cultures were treat with DMSO in place of QL-47. Working concentrations of QL-47 used 
within this study were based on previously determined concentrations (Wu et al., 2014). It 
must be noted that QL-47 was found to aggregate once added to media and cell culture. This 
became apparent through observation of QL-47 treated cell cultures using light microscopy; 
where QL-47 was easily observed within cell culture plates. In order to properly dissolve the 
compound, QL-47 was diluted in warm media and vortexed for approx. 5 mins. Successful 
solubilisation of the compound was confirmed through loss of visible aggregates on cells 
within tissue culture. On day 7 post seeding co-cultures were fixed in 70% ethanol and 
staining using CD31 tubule staining kit. Cultures were imaged using light microscopy. 
In co-cultures treated with a combination 5μM QL-47 and VEGFA, endothelial growth 
was ablated (figure 3.7). The ablation of ECs was not observed within co-cultures treated 
with 5μM QL-47 in the absence of additional GF supplementation, or in cultures treated with 
5μM QL-47 and supplemented with FGF2 (figure 3.8). Treatment of co-culture with 5μM of 
QL-47 led to a reduction in overall sprouting angiogenesis. In co-cultures without additional 
GF or FGF2 stimulation, QL-47 treatment also inducing a slight tortuous phenotype of the 
observed vascular cords, with tubules displaying a more curved appearance (figure 3.8). 
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 The effect of QL-47 treatment on sprouting angiogenesis within an organotypic 
angiogenesis co-culture assay following VEGFA or FGF2 stimulation 
To further understand the effect of QL-47 on sprouting angiogenesis, the co-culture 
model was carried out in the presence of QL-47 with supplementation of either VEGFA or 
FGF2, to determine if the small molecule elicited a GF signalling specific effect. The 
organotypic angiogenesis co-cultures treated with either DMSO or QL-47 and supplemented 
with VEGFA, FGF2, or no GF were imaged using light microscopy. ImageJ software was 
employed to analyse a number of quantifiable characteristics which represent sprouting 
angiogenesis: mean tubule length; total tubule length; number of tubules; longest tubule 
length; branch points; and BPI. Quantified data were analysed using a one-way test of 

















VEGFA + DMSO No Growth factor + DMSO 
VEGFA + 5µM QL-47 No Growth factor + 5µM QL-47 
Figure 3-7 Comparative quantification of VEGFA vs no growth factor supplemented ECs 
treated with the small molecule QL-47 within an organotypic angiogenesis co-culture assay. 
HUVECs were seeded onto a confluent monolayer of HDFs. Co-cultures were 
stimulated with VEGFA (25ng/ml) on days 4, and 6 post HUVEC seeding. Cells were treated 
with QL-47 at concentrations of 5µM on days 4 and 6 post HUVEC seeding. Co-cultures were 
fixed on day 7 with 70% ethanol and stained by IHC with a CD31 targeting antibody. Images 




FGF2 + DMSO No Growth factor + DMSO 
FGF2 + 5µM QL-47 No Growth factor + 5µM QL-47 
Figure 3-8 The effect of QL-47 treatment on EC tubule growth in an organotypic angiogenesis co-
culture assay following FGF2 stimulation 
HUVECs were seeded onto confluent monolayer of HDFs. Co-cultures were stimulated with 
FGF2 (10ng/ml) on days 4 and 6 post HUVEC seeding. Cells were treated with QL-47 at concentration 
of 5µM on days 4 and 6 post HUVEC seeding. Co-cultures were fixed on day 7 with 70% ethanol and 
stained by IHC with a CD31 targeting antibody. Images were taken under a light microscope.  
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3.2.4.1 Mean tubule length 
Mean tubule length values represents the average length of all tubules measured 
within each individual image. Mean value from each image was then used to calculate mean 
values for each condition (figure 3.9).  
Analysis of the mean tubule length in untreated control co-cultures followed the 
trend seen in previously described co-cultures, with no significant increase in mean tubule 
length of VEGFA supplemented co-cultures (over all mean=149μm) when compared to non-
GF supplemented control cultures (over all mean=140.5μm). FGF2 supplemented untreated 
control co-cultures developed a statistically significant increase in mean tubule length 
(overall mean=196.9μm) when compared to both non-GF and VEGFA supplemented control 
co-cultures.  
Co-cultures treated with QL-47 saw an overall reduction in mean tubule length in all 
three GF conditions (No GF=133.7μm; VEGFA=17.47μm; FGF2=107.5μm), with VEGFA 
experience the most significant reduction in mean tubule length following QL-47 treatment 
due to ablation of the majority of ECs within the VEGFA and QL-47 treated co-cultures.   
3.2.4.2 Total tubule length 
Total tubule length readings depicted the overall growth of endothelial cords of cells, 
without consideration of the number of tubules or length of individual tubules (figure 3.9).  
In control cultures, non-QL-47 treated cultures supplemented with VEGFA total 
tubule length (12822μm) was significantly increased when compared to cultures without 
additional GF supplement (8529μm) with a p value of <0.001 (figure 3.9). In FGF2 
supplemented control cultures there was also a significant increase in total tubule length 
(10720μm; p<0.01). 
Treatment of cultures with the small molecule QL-47 lead to significant decrease in 
total tubule length within all three GF conditions (no-GF=3843μm; VEGFA=42.28μm; 
FGF2=1678μm), with the non-GF treated cultures total length being the least reduced of the 
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three conditions and VEGFA having the largest decrease in total tubule length; with a p value 
of <0.001 when compared to the non-GF supplemented QL-47 treated cultures. FGF2 
supplemented QL-47 treated cultures also had a significantly lower total tubule length when 
compared to the non-GF treated co-cultures (0.0025; p<0.01). 
3.2.4.3 Mean number of tubules 
Mean number of tubules lengths were measured within each individual image 
(figure 3.9). Mean value from each image was then used to calculate mean values for each 
condition.  
Within control co-cultures, VEGFA stimulation lead to a highly significant increase in 
the number of tubules (89.95), with a p value <0.01 when compared to the non-GF treated 
cultures (64.9), and a p value of <0.001 when compared to FGF2 treated cultures (56.06). QL-
47 treatment of co-cultures significantly reduced the number of tubules within all three GF 
conditions (no GF=26.68; VEGFA=0.625; FGF2=12.94). Cultures stimulated with VEGFA 
experienced a near total loss of sprouted ECs (figure 3.7 and figure 3.9). While both non-GF 
cultures and FGF2 supplemented cultures experienced a reduction in the number of tubules 
(figures 3.8 and 3.9), the trend between the two GF conditions reflected that of the control 
co-cultured cells (with p<0.01), with a slight decrease in the number of tubules grown when 
stimulated with FGF2. 
3.2.4.4 Longest tubule length measurements 
Longest tubule length measurements were used to detect the difference in tubule 
lengths between GF treatment conditions (figure 3.9). Mean value from each image were 
then used to calculate mean values for each condition.  
Co-culture experiments with culture media supplemented with either VEGFA or 
FGF2 demonstrated how the two GFs impact differently upon tubule length, with FGF2 
stimulation inducing growth of longer tubules with a p value of <0.0001 when compared to 
non-GF stimulated cultures, and p < 0.01 when compared to VEGFA stimulated cultures. 
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Treatment of co-cultures with QL-47 lead to a marked decrease in branch points 
within VEGFA supplemented cultures, primarily due to an almost complete loss of sprouting 
ECs. QL-47 treatment led to a significant decrease in branch points in non-GF treated 
compared to FGF2 treated cultures (p<0.01). 
3.2.4.5 Mean branch point number 
The mean branch point number were measured (figure 3.9) to reflect how branched 
and dynamic the co-culture endothelial tubules between GF treatment conditions. Mean 
value from each image was then used to calculate mean values for each condition. 
In control co-cultures, supplementation of culture media with VEGFA led to a 
significant increase in the number of branch points (VEGFA=55.15), when compared to the 
control non-GF co-culture (No GF=34.75; p<0.01; figure 3.9). This trend was not observed in 
FGF2 treated cells (FGF2=47.5), however FGF2 treated cultures did have a slight increase in 
the number of branch points when compared to the non-GF supplemented cultures. Within 
QL-47 treated co-cultures, the overall trend for a reduction in the number of observed 
branch points was seen across all three GF conditions (No GF=14.95; VEGFA=0.00 
FGF2=6.889). Non-GF supplemented cultures branch point numbers were the least affected 
by QL-47. The almost total ablation of ECs within the QL-47 treated VEGFA stimulated 
cultures led to no detectable branch points within any of the co-culture wells. FGF2 and QL-
47 treated cultures experienced a substantial reduction in the presence of branch points.  
3.2.4.6 Branch point index 
The BPI were measured to reflect how many branches tubules produce within the 
angiogenic co-cultures (figure 3.9) and thus how dynamic the co-culture endothelial tubules 
between GF treatment conditions. BPI defined as the number of branch points per co-culture 
image divided by the total tubule length per image. Mean value from each image was then 
used to calculate mean values for each condition. 
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Within the VEGFA supplemented control cultures total tubule length measurements 
and number of branch points were increased when compared to the non-GF stimulated 
control cultures, leading to an increase in the BPI of the VEGFA stimulated control cultures 
(BPI=0.007774; figure 3.9) when compared to the non-GF controls (BPI= 0.00391) with a p 
value of <0.01. FGF2 supplemented control cultures also saw a slight increase the BPI (BPI= 
0.005408) when compared to the non-treated cultures, however this was not statistically 
significant. 
Treatment of cultures with QL-47 saw a slight reduction in BPI detected within the 
non-GF supplemented culture images, with a mean of 0.00254. As VEGFA supplemented 
cultures grew little to no EC sprouts, the BPI of these cultures was 0, yielding a significant 
difference of <0.05 when compared to the non-GF treated cultures. The FGF2 supplemented 
QL-47 treated cultures had a reduction in BPI following QL-47 treatment (BPI=0.00254), 
however there was no significant difference in the mean BPI when compared to the non-GF 
supplemented cultures.   
To summarize the overall effect of QL-47 treatment on sprouting angiogenesis in 
vitro; the small molecule inhibitor led to an angiogenic impairment, reducing the number of 
endothelial cords formed, and the elongation of these endothelial cords, while driving a 
more tortuous phenotype. Reduction in tubule growth resulting in fewer sites of tubule 
branching, however, this reduction was relative to the reduction in the amount of overall 
tubule growth within non-GF stimulated cultures (figure 3.7 and figure 3.8). The anti-
angiogenic effect of QL-47 was greatly amplified in the presence of the angiogenic GF VEGF; 
leading to an almost complete ablation of ECs at a 5μM concentration of QL-47. Endothelial 
cultures supplemented with FGF2 were less affected by QL-47 treatment than VEGFA 
supplemented cultures. However, in comparison to the non-GF supplemented cultures the 
FGF2 supplemented cultures experienced a greater loss of endothelial cord elongation, a 
118 
reduction in average tubule length, and, unlike the non-GF supplemented cells, a reduction 
in the relative number of branch points in relation to the overall level of tubule growth.  
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HUVECS were seeded onto confluent monolayer of HDFs. Co-cultures were grown 

































































































































































































































































































































































































Figure 3-9 Comparative quantification of VEGFA vs FGF2 supplemented ECs treated with 
QL-47 within an organotypic angiogenesis co-culture assay. 
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GF supplemented or stimulated with FGF2 (10ng/ml) on days 4 and 6 post HUVEC seeding. 
Cells were treated with QL-47 at concentrations of 5µM on days 4 and 6 post HUVEC seeding. 
Co-cultures were fixed on day 7 with 70% ethanol and stained by IHC with a CD31 targeting 
antibody. N= number of wells analysed. 2 independent experiments were carried out, with 
3 wells per condition, 5 images per co-culture well were taken under a light microscope 
(n=6). Total tubule length, number of tubules, and number of branch points, were measured 
manually per image using ImageJ software. Calculated values of each image were used to 
generate mean values and standard deviation per co-culture, with readouts for: mean tubule 
length; total tubule length, longest detected continues tubule; number of branch points; and 
BPI (branch points/TVL). Mean values of each co-culture were analysed using a one-way 
analysis of variance (ANOVA) through Origin 2015 Software (OriginLab). Error bars signify 
standard deviation. Significant differences indicated by asterisks: *=P value equal to or lower 
than 0.05; **=P value equal to or lower than 0.01; ***=P value equal to or lower than 0.001; 



















To expand upon the understanding of DOCK4 function within sprouting angiogenesis 
DOCK4 signalling was investigated under FGF2 stimulation. In order to adequately establish 
the distinct characteristics between FGF2 driven angiogenesis compared to VEGFA driven 
angiogenesis, an organotypic angiogenesis co-culture model was employed and assays were 
set up with either FGF2 or VEGFA stimulation (figure 3.2). This investigation showed 
differences in sprouting angiogenesis phenotypes between the two GFs (figure 3.3) and 
served as a model for investigating any differences in DOCK4 signalling under the stimulation 
conditions. 
Lentiviral DOCK4 targeting shRNA transduced ECs were incorporated into the co-
culture assay under both normoxic and hypoxic conditions (figure 3.4-3.6). DOCK4 was found 
to not be required for sprouting angiogenesis under FGF2 stimulation in normoxia. However, 
the preliminary results indicated DOCK4 may be required for FGF2 driven angiogenesis 
within a hypoxic environment. 
 Comparison of VEGFA vs FGF2 stimulated sprouting angiogenesis in vitro 
To further understand the downstream mechanisms of FGF2 signalling within ECs, 
an organotypic co-culture assays was employed. The organotypic angiogenesis assay, 
adapted to incorporate FGF2 within the growth culture media, demonstrated how FGF2 
stimulation of sprouting angiogenesis induces growth of fewer number of tubules, however, 
the cords of ECs produced were more elongated and less branched than the VEGFA 
stimulated counterparts (figure 3.6). Thus implying that FGF2 signalling either directly, or 
indirectly, induces an intracellular response within the ECs which stimulates signalling to 
drive cord elongation, or cell proliferation of the forming cord.  
The accumulated data within this study was unable to distinguish whether 
elongation of the endothelial cords were due to elongation of the individual cells within the 
tubules or due to an increase in cell proliferation of growing tubules. Distinguishing between 
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the two potential characteristics would lead to insight into the EC response to FGF2 
stimulation. The potential of FGF2 signalling to impact on both cell proliferation and cell 
elongation has been demonstrated in previous studies (Ware and Simons, 1997; Ornitz and 
Itoh, 2001). It has been established that FGF2 promotes EC proliferation, migration and 
physical organisation of ECs into tube-like structures (Ware and Simons, 1997; Ornitz and 
Itoh, 2001). FGF2 stimulated endothelial activation of PI 3-kinase induces the reorganization 
of actin cytoskeleton to the cortex and stimulates changes in cell morphology to induce an 
elongated phenotype in a Rho GTPase dependent manner (Lee and Kay, 2006). Thus lending 
evidence to the concept that the observed FGF2 driven phenotype has potential to be driven 
by an increase in EC proliferation and recruitment to elongating vascular cords, as well as 
elongation of the individual cells within each cord of cells. This does not however explain the 
loss of branching observed within the FGF2 stimulated cultures (figure 3.6). Interestingly, it 
could suggest that FGF2 signalling acts to inhibit VEGF-driven branching. It would be 
interesting to test this hypothesis in future studies. It would also be interesting to analyse 
the number of nuclei, and individual cell length and orientation, of growing cords within the 
organotypic co-culture during FGF2 stimulation to determine whether the FGF driven 
phenotype is due to cell proliferation or elongation.  
It must also be noted that the DOCK4 Kd organtotypic angiogenesis assays found a 
slight increase in the branching of tubules under FGF2 stimulation, when compared to no GF, 
which directly contradicts the finding of the VEGFA vs FGF2 co-culture result (figure 3.2-3.3 
and 3.4-3.6). Further repeats of both assays would be required to determine if loss of 
branching is a true characteristic of FGF2 stimulated angiogenesis. 
While a difference in the characteristics of sprouting angiogenesis was observed 
when comparing FGF2 to VEGFA stimulated phenotype, the limitations of the experimental 
model need to be taken into consideration when attributing the observed results to 
physiological function. When comparing the two GF conditions it must be noted that 
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experiments were conducted in vitro, within an environment without the presence of the 
physiological variables found in vivo, such as: inflammatory factors, immune cell influence of 
angiogenesis, tissue specific signalling, the presence of pre-existing vasculature, and other 
signalling molecules within the tissue environment (Bishop et al., 1999; Stryker et al., 2019; 
Vailhé et al., 2001). Another limitation of the co-culture model lies within the lack of the GF 
gradient which would exist in vivo (Hetheridge et al., 2011). Growth factor gradients that 
induce angiogenesis drive polarisation of ECs, and guide directional growth of newly forming 
sprouts (Hetheridge et al., 2011). It must also be noted that all experiments were conducted 
using a single batch of commercially purchased angiogenesis tested HDF and a single batch 
of pooled HUVEC; in-order to reduce variability and maintain reproducibility. To confirm the 
robustness of the observed result, in demonstrating a physiological difference between 
angiogenesis stimulation between VEGFA and FGF2, these results should be replicated in 
HDF and HUVEC from other sources, to demonstrate that the observed results are not 
specific to the batch of cells (Abo et al., 1992). 
In order to fully evaluate the findings of this study, it is also necessary to consider 
potential elements of the culture conditions which may confound the results. A limitation of 
this assay is the presence of different angiogenic factors in the LVEM, which makes the 
delineation of GF specific effects challenging, as it is not possible to eliminate other GFs in 
the system as such factors are required for EC survival (Huttala et al., 2015). 
The growth serum present in the LVEM and additional FBS used to supplement the 
Dulbecco's Modified Eagle Medium, within all co-culture studies, possess a composition of 
proteins and hormones required for culture of both the HUVEC and HDF, respectively. The 
exact composition of proteins and hormones are unknown but have been equally maintained 
in all co-culture experiments in-order to establish a basal level of growth from which the 
growth characteristics, prompted by the two GFs, were investigated. It is however known 
that the media used contain a very small concentration of FGF2. Further to this, it must be 
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considered that VEGFA is produced by the HDFs in the assay, levels of which may not be 
equal across each experiment (Mavria et al., 2006). However, each assay was treated equally 
to reduce variability, and as such produced quantifiable results that served as a baseline from 
which an in-depth analysis was carried out.  
FGF2 has been demonstrated, in part, to act on EC-associated fibroblasts and prompt 
fibroblasts to secrete VEGF; which in turn stimulates an angiogenic response within ECs 
leading to an increase in angiogenesis. However the results of this study demonstrate 
stimulation of angiogenesis by the two GFs induce different growth characteristics of 
sprouting angiogenesis, thus suggesting a role for FGF2 signalling in angiogenesis which acts 
independently from VEGFA signalling in driving a unique phenotype. Further dissection of 
each growth factor pathways involved in angiogenesis will expand our understanding of the 
complex mechanisms which drive the growth of new vasculature and offer insight in to 
potential therapeutic targets for manipulating how the new vasculature grows and develops.  
 DOCK4 function within sprouting angiogenesis 
The small RhoGTPase RAC1 serves as an important component in the intracellular EC 
response to FGF2, inducing changes to the actin cytoskeleton required for the elongation of 
the individual cells. DOCK4 is a GEF involved in endothelial RAC1 activation downstream of 
VEGFA (Abraham et al., 2015) but has not yet been described as a component in the FGF2 
angiogenic response. DOCK4 depletion within an organotypic angiogenesis co-culture model 
indicated that loss of endothelial DOCK4 expression leads to a loss in lateral branch points 
and less branching, without impacting endothelial cord elongation (Abraham et al., 2015), a 
phenotype similar to that of the FGF2 stimulated sprouting. Thus is possible to hypothesis 
that DOCK4 may act in RAC1 activation within a FGF2 driven sprouting angiogenesis context.  
To investigate whether DOCK4 was involved in FGF2 stimulated sprouting 
angiogenesis, a preliminary co-culture was conducted incorporating lentiviral DOCK4 
targeting shRNA transduced HUVEC into the organotypic angiogenesis co-culture model, 
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with FGF2 stimulation, along with lentiviral NS shRNA transduced HUVEC to serve as a control 
(figures 3.4-3.6). The results of this single experiment indicated that DOCK4 depletion led to 
a reduction in overall tubule growth when growth medium had no additional GF supplement, 
resulting in loss in total tubule length, the number of tubule, and the number of branch 
points. Supplementing growth medium with FGF2 rescued the loss in total tubule length, 
increasing mean tubule length, and inducing growth of the number of tubules and BPI back 
to the level of non-GF stimulated control cultures (figure 3.5 and 3.6). This finding indicates 
that in the absence of DOCK4, FGF2 stimulation of sprouting angiogenesis may overcome 
growth deficiencies prompted by loss of DOCK4 expression. Thus indicating that DOCK4 may 
not be required for FGF2 driven sprouting angiogenesis.  
It must be noted, as previously mentioned, that within this experiment FGF2 
treatment led to an increase in BPI (figure 3.6), a result which contradicts previous 
experiments. Further repeats of the experiment would be required to determine if this 
finding was an anomaly of this singular experiment. It should be considered that the 
variables, introduced by the conditions involved in treating cells with the NS shRNA, may 
have impacted upon branching, and would require further investigation to confirm the NS 
shRNA control cultures reflect the growth of non-transduced co-cultures.  
Also, further investigation would be required to attribute the observed phenotype 
to loss of DOCK4 driven RAC1 activation, under FGF2 signalling. It would be necessary to 
measure changes in RAC1 activity within the cellular assay, to attribute the changes in 
phenotype to changes in RAC1 regulation. Measuring changes to RAC1 activation within the 
DOCK4 depleted co-cultures may prove challenging, as RAC1 may be involved in non-DOCK4 
related activity within the same ECs during FGF2 driven sprouting angiogenesis (Shin et al., 
2004). Investigating changes between DOCK4 depleted vs NS control ECs through observing 
any differences between the level of RAC1 activation, changes to RAC1 localisation within 
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the ECs, and changes to activation of RAC1 targets, may offer insight into DOCK4 involvement 
in RAC1 regulation during FGF2 vs VEGFA driven sprouting angiogenesis. 
 DOCK4 signalling in sprouting angiogenesis within hypoxia 
FGF2 has been strongly linked to the angiogenic response within ischemia (Unger et 
al., 2000; Laham et al., 1999; Comerota et al., 2002; Nikol et al., 2008). As gene expression 
and cellular response within a hypoxic environment can differ greatly to a normoxic 
environment, it was imperative to also investigate the effect of DOCK4 functionality within 
FGF2 signalling under hypoxic conditions. For this purpose, the previously described culture 
was also conducted with co-cultures incubated in a hypoxic incubator (1% 02) following GF 
stimulation 4 days following HUVEC seeding to the HDF monolayer.  
The culture of FGF2 stimulated NS HUVEC, within a hypoxic environment, led to a 
sprouting response similar to that of the non-GF supplemented cells grown in normoxia 
(figures 3.4-3.6), with only the FGF2 driven increase in mean length being maintained and 
longest tubule increasing. Thus indicating that FGF2 stimulation maintains the proliferative 
phenotype of ECs when experiencing oxygen deprivation. Conversely this phenotype was 
reversed when DOCK4 expression was depleted. Co-cultures of DOCK4 depleted HUVEC 
produced significantly fewer sprouts, resulting in loss in overall tubule length and fewer 
branch points than the NS FGF2 stimulated co-cultures also grown within hypoxia (figures 
3.4-3.6). This result indicates a potential requirement for DOCK4 expression within FGF2 
induced angiogenesis under oxygen deprivation.  
While this experiment demonstrates a distinct response, a number of elements need 
to be evaluated when interpreting the results, and for use in optimising future investigations. 
It must be noted that the hypoxic environment will have been disrupted during the opening 
and closing of the incubator, and during additional GF treatments. Thus leading to some 
intermittent hypoxia during the sprouting angiogenesis. Using a hypoxia chamber, such the 
Modular Incubator Chamber manufactured by Billups-Rothenberg, Inc. (San Diego, CA USA), 
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would reduce instances of intermittent oxygen exposure and potentially provide more 
reproducible experimental results. Also, further confirmation must be carried out to ensure 
no off-target effect have been introduced by the NS shRNA or conditions which occur during 
treatment of the HUVECs with the shRNA lentiviral particles.   
While this experiment was purely a preliminary test (with only 2 replicates within a 
single assay) to evaluate whether DOCK4 is relevant for FGF2 stimulation of sprouting 
angiogenesis, the outcome of the hypoxic DOCK4 depleted co-cultures indicates a potential 
role of DOCK4 within FGF2 driven sprouting angiogenesis within hypoxia. Implicating DOCK4 
is required for the proliferation and branching of tubules within these conditions.  
 QL-47 treatment of organotypic angiogenesis co-cultures 
It has been established that DOCK4 is required for development of functional 
vascular structures through sprouting angiogenesis. The interaction of DOCK4 with the 
CDC42 GEF DOCK9 has also been implicated in conferring the angiogenic response to VEGFA 
stimulation. To further understand the functionality of the SGEF-RhoG-DOCK4-RAC1-DOCK9-
CDC42 signalling module, the interaction between DOCK4 and DOCK9 was investigated. 
Previous evaluation by Abraham et al. (2015) confirmed that the SH3 domain of DOCK4 is 
required for interaction with DOCK9, implicating a PRR of DOCK9 as important for DOCK4-
DOCK9 interaction. Evaluation of the amino acid sequence of DOCK9 detected 11 potential 
PRRs of DOCK9, with 8 possessing the typical PxxP or PxxxP motif of a PRR. During the course 
of this study a DOCK9 binding small molecule inhibitor, QL-47, was gifted to the Mavria 
research group by Prof. Nathaniel Grey’s research group (Dana-Farber Cancer Institute, MA 
USA).  
QL-47 had been demonstrated to specifically bind to p.C628, a cysteine located 
within the 4th identified PRR of DOCK9. While the specific site of DOCK9 which binds DOCK4 
had not been established, QL-47 offered the opportunity to utilise the compound to 
investigate whether the PRR4 of DOCK9 was a DOCK4 binding site. Before utilising the 
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compound to investigate DOCK4-DOCK9 interaction it was imperative to establish whether 
QL-47 possessed the ability to impact on angiogenesis.  
3.3.4.1 The effect of QL-47 on sprouting angiogenesis 
The organotypic co-culture model was adapted to include the covalently binding 
small molecule QL-47. As it had been established that angiogenic response to VEGFA and 
FGF2 stimulation differed, and that DOCK4 function may differ between VEGFA and FGF2 
stimulated sprouting angiogenesis. For this reason co-cultures were carried out either in the 
absence of additional GF or under either VEGFA or FGF2 stimulation. This experiment 
strongly validated that QL-47 induced an anti-angiogenic effect under all three GF conditions, 
reducing both the number of endothelial cords formed and the elongation of these 
endothelial cords, while also driving a more tortuous phenotype (figures 3.7-3.9). Reduction 
in tubule growth resulted in fewer sites of tubule branching, however this reduction was 
relative to the reduction in the amount of overall tubule growth within non-GF stimulated 
cultures (figure 3.9). QL-47 induced a much more profound anti-angiogenic response when 
cultures were also supplemented with VEGFA; with an almost complete ablation of the ECs. 
Co-cultures grown without additional GF stimulation experienced a less profound anti-
angiogenic affect (figures 3.7 and 3.9). The small molecule inhibitor led to an angiogenic 
impairment in all GF culture conditions. 
Endothelial cultures supplemented with FGF2 were less affected by QL-47 treatment 
than VEGFA supplemented cultures, however, FGF2 supplemented cultures experienced a 
greater loss of endothelial cord elongation, a reduction in average tubule length, and, unlike 
the non-GF supplemented cells, a reduction in the relative number of branch points in 
relation to the overall level of tubule growth.  
Within non-GF supplemented cultures the mean tubule length was not impacted, 
but did result in a reduction in total tubule length and the number of tubules, potentially 
indicating that that the inhibitor does not affect the outgrowth of endothelial cords but 
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impacts the overall proliferation of ECs and number of cords developed (figure 3.9). Branch 
point index was also unaffected, indicating that, while there was no reduction in the number 
of branch points tubules developed in comparison to overall length of tubules (figure 3.9). 
The accumulated data investigating QL-47 indicate that the small molecule 
stimulates an apoptotic response under VEGFA signalling mechanisms, and also impairs 
correct FGF2 induced angiogenesis. While the DOCK9 binding molecule activity reflects the 
DOCK4 depleted cultures within VEGFA driven sprouting angiogenesis, and, to a lesser 
degree, DOCK4 within FGF2 driven sprouting angiogenesis, these results can only indicate a 
correlation but not causation. Investigation of the non-DOCK9 binding activity of QL-47 
within ECs would be required to validate the anti-angiogenic phenotype as being a DOCK9 
specific response. It would also be imperative to validate whether QL-47 disrupts DOCK4 
interaction with DOCK9, a subject which will be discussed in results chapter 2.  
QL-47 was originally developed as an inhibitor of the non-receptor tyrosine kinase 
BTK (Bruton's tyrosine kinase). BTK is not expressed within ECs, however, the BTK Family 
Tyrosine Kinase BMX (bone marrow tyrosine kinase gene on chromosome X) is expressed 
within endothelia and is targeted by QL-47; with QL-47 binding inducing a reduction in the 
tyrosine kinase activity of BMX (Wu et al., 2014). BMX is a cytoplasmic tyrosine kinase 
expressed within endocardium and in arterial endothelia and has been indicated as required 
for angiogenesis under inflammatory conditions not physiological angiogenesis (He et al., 
2006; Luo et al., 2010). BMX is not expressed within capillaries and in not required for 
angiogenesis during development; with BMX null mice developing normal health vasculature 
(He et al., 2006; Luo et al., 2010). As the organotypic angiogenesis co-culture model is not 
designed to reflect the conditions of pathological angiogenesis it is unlikely BMX would be 
expressed within the experimental ECs used within the organotypic angiogenesis co-culture 
system employed within this study.  
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However, expression of BMX should be determined within the organotypic co-
culture model, in-order to eliminate this protein as the QL-47 target driving the observed 
phenotype. Future experiments should also be carried out to confirm the observed 
phenotype is not due to BMX inhibition, through repeating QL-47 treatment of co-cultures 
with added BMX inhibition.   
The findings of these studies establish the phenotypical differences in sprouting 
angiogenesis between VEGFA and FGF2 driven angiogenesis in vitro. DOCK4 has been 
implicated as a potential component in FGF2 signalling under hypoxic conditions, and to a 
much lesser degree under normoxic conditions. The small molecule inhibitor QL-47 is a 
potent anti-angiogenic compound, with VEGFA stimulated ECs being particularly sensitized 
to QL-47, however it cannot be concluded that the anti-angiogenic effects are due to 















4 Results chapter II: Elucidating the site of DOCK4-specific 
binding to DOCK9  
4.1 Introduction 
The VEGFA-SGEF-RhoG-DOCK4-RAC1-DOCK9-CDC42 signalling module is required 
for correct vascular patterning and lumenisation during sprouting angiogenesis (Abraham et 
al., 2015). As part of this signalling module, DOCK4 has been demonstrated to 
heterodimerise with DOCK9, and is the first time a DOCKB subfamily protein has been seen 
to interact with a DOCKD subfamily protein (Abraham et al., 2015). Abraham et al. (2015) 
found the DOCK4 SH3 domain was the site of DOCK9 interaction. SH3 domains are short 
peptide sequences with aromatic residues that drive weak and transient interactions via 
their shallow groove, with PRR of interacting proteins to form left handed type II polyproline 
helices (Pollard et al., 2016). A PRR is a sequence of amino acids with multiple proline 
residues within close proximity of one another (Yu et al., 1994; Alexandropoulos et al., 1995). 
DOCK9 possesses 11 PRRs with 5 of them containing the typical PxxP or PxxxP motifs which 
form a continuous hydrophobic patch that preferentially binds to the amino acid sequence 
of SH3 domains.  
In order to examine further the site of interaction between DOCK4 and DOCK9, five 
DOCK9- N-terminal Flag-tagged mutants had been cloned previously in the lab by Ms. Anne 
Sanford, each with a single point mutation within one of the five typical PRR regions (figure 
4.1). DOCK9 mutant expression vectors were co-transfected together with an N-terminal 
GFP-tagged DOCK4 expression vector into HEK 293T cells and Co-IP assays were carried out 
analysing the DOCK4-DOCK9 interaction in the presence of the DOCK9 PRR mutations. A 
DOCK9 binding small molecule compound, QL-47, which binds within one of the PRR regions 
(figure 4.1), was used to determine whether it was capable of disrupting the DOCK4-DOCK9 
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interaction. SEC was also utilised to investigate the direct interaction between the DOCK4-




Figure 4-1 Identification of DOCK9 PRRs and site of QL-47 binding 
The GEF DOCK9 possess 11 PRR. Five PRR have the typical PxxP or PxxxP motif. The 







PRR region selected for 
further analysis  
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4.2 Results 
Figure 4-2 DNA plasmid preparation and restriction enzyme digestion. 
(A) DNA plasmid pEF4 Myc-Flag-DOCK9, non-digested (12.3kbp), and digested with 
restriction enzymes NotI and KpnI, cutting out the Flag-DOCK9 insert (6.4kbp) from the pEF4 
myc vector (5.9kbp). (B) DNA plasmids pC3 EGFP DOCK4 (12.4kbp) (C) and pC3 EGFP-EV (4.7kbp) 
were linearized using restriction enzyme BamHI. (D) Enzymes NotI and KpnI were used to 
separate Flag-DOCK9 insert (6.4kb) from the pEF4 vector (5.9kb) of the mutation variants of 
pEF4 Myc-Flag-DOCK9 (mutants 2, 3, 4, 5, and 9). Linearized plasmid fragments were resolved 








(A) pEF4 Myc-Flag-DOCK9 (B) pC3 EGFP DOCK4  (C) pC3 EGFP-EV 
(D) pEF4 Myc-Flag-DOCK9 PRR mutants 
         BamHI          BamHI  NotI + KpnI 
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 Plasmid preparation and verification of DOCK9 mutant plasmids 
DNA plasmids to be used for overexpression of EGFP-DOCK4 (pC3 EGFP-DOCK4), 
Flag-DOCK9 proteins (pEF4 Myc-Flag-DOCK9), EGFP-EV (pC3 EGFP), and five Flag-DOCK9 
constructs with mutated PRR 2, 3, 4, 5, and 9 (pEF4 Myc-Flag-DOCK9 PRR mut 2, pEF4 Myc-
Flag-DOCK9 PRR mut 3, pEF4 Myc-Flag-DOCK9 PRR mut 4, pEF4 Myc-Flag-DOCK9 PRR mut 5, 
pEF4 Myc-Flag-DOCK9 PRR mut 9), were purified from E. coli cultures (as described in 
methods 2.9). Confirmation of extraction of the correct plasmid was determined through 
restriction enzyme digestion.  
Each construct was confirmed based on kilobase pair size. Flag-DOCK9 plasmids 
(including all five Flag-DOCK9 mutants) were digested with restriction enzymes NotI and 
KpnI, cutting out the DOCK9-Flag insert (6.4kbp) from the pEF vector (5.9kbp). EGFP DOCK4 
(12.4kbp) and EGFP-EV (4.7kpb) were linearized using restriction enzyme BamHI. Linearised 
plasmid fragments were resolved on a 0.7% agarose gel containing ethidium bromide. 
Agarose gel electrophoresis demonstrated that digestion of the plasmids, with the 
appropriate enzymes, yielded the expected DNA fragment sizes (figure 4.2). Non-digested 
constructs were determined to be supercoiled and thus detected as having a lower molecular 










 Confirming the presence of a complex between the RAC GEF DOCK4 and CDC42 GEF 
DOCK9 in HEK 293T. 
The ability for DOCK4 and DOCK9 to interact and form a complex has previously been 
demonstrated (Abraham et al., 2015). This interaction was successfully reproduced through 
Co-IP of overexpressed DOCK4 and DOCK9 proteins, purified from HEK 293T cell lysates 
(figure 4.3). This condition formed the baseline for interaction between DOCK4 and DOCK9 
in-order to investigate the loss of interaction through point mutation of prolines within 
identified PRR of DOCK9. 
HEK 293T cells were transfected with EGFP-DOCK4 and Flag-DOCK9. Immunoblotting 
of total cell lysate was used for confirmation of successful expression of over-expressed 
proteins (figure 4.3). 48 hours after transfection, cells were lysed under mild conditions and 
GFP-DOCK4 and Flag-DOCK9 were precipitated in complex from TL using a GFP-trap 
(Chromotek). IP and Co-IP proteins were resolved by Western blot, and presence of Flag-
tagged and GFP-tagged proteins was determined using HRP-conjugated anti-EGFP and anti-














Figure 4-3 EGFP-DOCK4 overexpression and interaction with Flag-DOCK9 
EGFP-DOCK4, pEF4-DOCK9, and EGFP-EV expression vectors were co-transfected into 
confluent HEK 293T. 48 hrs post transfection cells were lysed under mild lysis conditions. GFP-
tagged proteins and interacting proteins were precipitated out of TL using a GFP-trap 
(Chromotek). TL and Co-IP products were resolved using Western blot and the ECL system. 
Representative Western blots depicts precipitated EGFP-DOCK4, Flag-DOCK9, EGFP-EV, and TL 
Flag-DOCK9 and EGFP-DOCK4  
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 Investigation of the DOCK4 interaction site of DOCK9 
Once the ability for DOCK4-DOCK9 to form a complex was established, the regions 
of DOCK9 required for the interaction were investigated. Previous work in the laboratory (by 
Ms. Anne Sanford, unpublished) had led to selection of 5 proline-rich regions of DOCK9 as 
potential candidates as the site of DOCK4 binding. Five pEF4 Myc-Flag-DOCK9 plasmids had 
then been generated using a Stratagene Quickchange II XL site-directed mutagenesis kit (by 
Ms. Anne Sanford), each with a mutation of proline to alanine within each of the five 
identified PRRs. Each of the DOCK9 mutants was co-expressed together with GFP-DOCK4 in 
HEK 293T (figure 4.4-4.6), and precipitated from whole cell lysates using a GFP Trap. 
Immunoblotting of Co-IP proteins was used to identify potential disruption of the 
DOCK4-DOCK9 complex, this was determined through the presence or absence of the DOCK9 
mutant protein, following anti-Flag probing.  
Co-IP of DOCK4 and DOCK9 mutant 2 consistently showed that a mutation within the 
2nd PRR had no obvious effect on the complex, as can be seen by the presence of a strong 
band in the representative blot imagine in figure 4.4 and colourimeteric analysis in figure 4.7. 
This results indicates that this point mutation does not disrupt binding between 
overexpressed DOCK4 and DOCK9. 
In initial experiments with samples derived from cells expressing DOCK9 mutant 3, 
anti-Flag probed Western blot bands yielded a much weaker, if not absent, signal than that 
of the positive control, suggesting this PRR may be necessary for DOCK4 binding. However, 
probing for GFP showed that this could be due to less IP of EGFP-DOCK4. Repeats of this 
experiment yielded conflicting results, with DOCK9 mutant 3 successfully precipitated with 
GFP-DOCK4, giving a signal equal to the positive control in Western blot analysis (figure 4.4) 
This variability has been demonstrated through combined colorimetric analysis (figure 4.7).  
Analysis of lysates derived from DOCK9 mutant 4 initially yielded a weaker Western 
blot signal, when compared to the positive control in two out of four repeat experiments, 
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with the latter two repeat experiments showing a DOCK4 interaction with DOCK9 mutant 4 
which was equivalent to that of the control (figure 4.4, 4.5, 4.7). DOCK9 mutant 4 consistently 
had a lower level of detectable protein within TL samples, something not seen with the other 
four DOCK9 mutant expression vectors, which further supported the conclusion that the 
reduction in the DOCK9 mutant 4 Co-IP product was likely due to a lower level of protein 
expression. Interaction of DOCK4 was also detected with DOCK9 mutant 5 (figure 4.5 and 
4.7).  
In initial experiments, DOCK9 mutant 5 also appeared to have less interaction with 
DOCK4, as the Western blot signal of Co-IP product were less pronounced than the positive 
control. However, this result was not reproducible in 3 out of 4 repeat experiments, which 
all yielded results which indicated that the interaction between DOCK4 and DOCK9 mutant 
5 was equal to that of DOCK4 with WT DOCK9 (figure 4.5 and 4.6), and thus an unlikely site 
of direct DOCK4-DOCK9 interaction.  
Co-IP product of DOCK9 mutant 9, with GFP-DOCK4, consistently yielded results 
equal to that of WT DOCK9 (figure 4.6 and 4.7). The results suggest that DOCK9 PRR 9 is 
unlikely to be involved in a direct interaction with DOCK4. 
DOCK9 mutant 2 (figure 4.4) and mutant 9 (figure 4.6) both consistently gave a 
strong signal, which was comparable to the positive control, indicating the interaction 
between DOCK4 and DOCK9 was maintained in the presence of mutation within these PPR 
regions. DOCK9 mutant 5 Co-IP results were less consistent, but as 3 out 4 Co-IP experiments 
led to a strong level of DOCK9 mutant 5 pull down, the DOCK9 PRR 5 may not be required 
for direct interaction. Thus, it could be hypothesised that the PRR regions mutated in these 
experiments are unlikely to be required for the direct interaction of DOCK4 with DOCK9.  
The Co-IP results obtained through analysis of DOCK4 interaction with DOCK9 PRRs 
3 and 4 were non-conclusive. While initial experiments indicate a potential loss of DOCK4 
interaction, the loss of these points of interaction between DOCK4 and DOCK9 PRR mutants 
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3 and 4 in these Co-IP experiments were not reproducible and thus a conclusion cannot be 
drawn from these experiments.  
The conflicting results obtained in these assays suggest that DOCK9 PRR 3 and 4 may 
be involved in interaction between DOCK4 and DOCK9, however, the Co-IP model used 
within this chapter may not be a proficient method to elucidate if the selected PRR are 




















Figure 4-4 Co-IP EGFP-DOCK4 and Flag-DOCK9 mutants 2 and 3 
Analysis of DOCK9 PRR through Co-IP of proteins overexpressed in HEK 293T 
cells. EGFP-DOCK4 was over expressed with one Flag-DOCK9 mutant 2 (green box) or 
mutant 3 (red box), mutant 4 also depicted. Flag-DOCK9 was also overexpressed with 
EGFP-EV. 48 hrs post transfection cells were lysed under mild lysis conditions. GFP-
tagged proteins were precipitated out of total cell lysates using a GFP-trap (Chromotek).  
Co-IP and TL were resolved through Western blot and presence of Flag-tagged and GFP-
tagged proteins were determined through targeted HRP conjugated antibody binding 
and ECL detection analysis. 
Ab=Antibody; MW=Molecular Weight; kDa= kilodalton; IP=Immunoprecipitation; TL= 







Figure 4-5 Co-IP of EGFP-DOCK4 and Flag-DOCK9 mutants 4 and 5  
Analysis of DOCK9 PRR through Co-IP of proteins overexpressed in HEK 293T cells.  
EGFP-DOCK4 was over expressed with one Flag-DOCK9 mutant 4 (green box) or mutant 5 
(red box). Flag-DOCK9 was also overexpressed with EGFP-EV. 48 hrs post transfection cells 
were lysed under mild lysis conditions. GFP-tagged proteins were precipitated out of total 
cell lysates using a GFP-trap (Chromotek).  Co-IP and TL were resolved through Western blot 
and presence of Flag-tagged and GFP-tagged proteins were determined through targeted 
HRP conjugated antibody binding and ECL detection analysis. 
Ab=Antibody; MW=Molecular Weight; kDa= kilodalton; IP=Immunoprecipitation; TL= Total 
lysate; D4=DOCK4; D9=DOCK9; EV=Empty vector. 
 
 






Figure 4-6 Co-IP EGFP-DOCK4 and Flag-DOCK9 mutant 9 
Analysis of DOCK9 PRR through Co-IP of proteins overexpressed in HEK 293T cells.  EGFP-
DOCK4 was over expressed with either Flag-DOCK9, or Flag-DOCK9 mutant 9. Flag-DOCK9 was 
also overexpressed with EGFP-EV. 48 hrs post transfection cells were lysed under mild lysis 
conditions. GFP-tagged proteins were precipitated out of TL using a GFP-trap (Chromotek).  Co-
IP and TL were resolved through Western blot and presence of Flag-tagged and GFP-tagged 
proteins were determined through targeted HRP conjugated antibody binding and ECL detection 
analysis. 
Ab=Antibody; MW=Molecular Weight; kDa= kilodalton; IP=Immunoprecipitation; TL= Total 





Figure 4-7 Quantitative colorimetric analysis of DOCK4 interaction with DOCK9 PRR mutant 
during Co-IP 
Western blots of GFP-trap Co-IP experiments following co-transfection of EGFP-
DOCK4 and Flag-DOCK9 proteins (WT or mutant PRRs 2, 3, 4, 5 and 9) were quantified from 
independent repeats of the experiments shown in figures 4.6 (n=3 for each PRR mutant co-
culture) using Image J software. The values of each column represents the mean+SD of the 
ratio of Western blot signal when compared to a positive WT-Flag-DOCK9 Western blot 
signal, which was given a value of 1. Western blot band signal representing a mutant PPR 
DOCK9 complex with GFP-DOCK4. Data graph generated using GraphPad Prism 7.0a 
software. WT=Flag-DOCK9 expressed with EGFP-DOCK4; Neg ct=EGFP-EV negative control 
expressed with Flag-DOCK4; mut2=Flag-DOCK9 mutant 2 expressed with EGFP-DOCK4; 
mut3=Flag-DOCK9 mutant 3 expressed with EGFP-DOCK4; mut4=Flag-DOCK9 mutant 4 
expressed with EGFP-DOCK4; mut5=Flag-DOCK9 mutant 5 expressed with EGFP-DOCK4; 












































 Effect of the DOCK9 binding small molecule inhibitor QL-47 on disruption of the DOCK4-
DOCK9 complex 
QL-47 is a small molecule inhibitor which has been demonstrated to inhibit Cd42 
activation and disrupt VEGFA driven angiogenesis (appendix 2, figure 7.10). QL-47 binds 
DOCK9 at p.C628, a cysteine residue which lies within PRR 3 (p.PCIP627-630) of DOCK9 
(figure 4.1). When considering DOCK4-DOCK9 PRR mutant 3 Co-IP experimental results, 
which indicated a potential role for PRR 3 in disrupting DOCK4-DOCK9 interaction, QL-47 
served as a potential tool for investigating whether this region serves as the site of DOCK4-
DOCK9 binding (figure 4.1).   
Immunoprecipitation experiments of over expressed GFP-DOCK4 and Flag-DOCK9 
from cell lysates of HEK 293T were carried out following treatment of 293T for 24 hours with 
5μM of QL-47; a previously determined concentration (Wu et al., 2014) that was found to 
also disrupt angiogenesis in an organotypic angiogenesis co-culture model (Chapter 3. 
figures 3.7-3.9). 
Western blot analysis of TLs of QL-47 treated cells showed an initial mild disruption 
of DOCK4-DOCK9 interaction (figure 4.8), however this could not be demonstrated through 
repeat experiments. Review of literature describing use of QL-47 in cell culture treatment 
(Wu et al., 2014) indicated QL-47 was unable to infiltrate cells to successfully bind the target 
protein (Wu et al., 2014). The lack of solubility of QL-47 had been apparent during use of the 
compound within the co-culture assays (Chapter 3, figures 3.7-3.9), this was overcome by 
adding QL-47 to warm media and vortexing for approx. 5 minutes. While this approach 
overcame the solubility issues within the co-culture, proper entry into the cell could not be 
determined within the transfected HEK 293T cells. Wu et al (2014) addressed this issue by 
treating cell lysates as opposed to cultured cells, therefore QL-47 treatment was carried out 
on TLs and cultured cells in order to overcome any issues of uptake by the cells. Western blot 
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analysis of Co-IP proteins treated with QL-47 established that QL-47 was unable to disrupt 




Figure 4-8 Co-IP of overexpressed EGFP-DOCK4 and Flag-DOCK9 following treatment of HEK 
293T cells with the compound QL-47 
Analysis of the effect of QL-47 treatment on the DOCK4-DOCK9 interaction through 
Co-IP of proteins overexpressed in HEK 293T cells. EGFP-EV and Flag-DOCK9, or EGFP-DOCK4 
and Flag-DOCK9, expression vectors were co-transfected into HEK 293T cells. 24 hours post 
transfection cells were treated with 5µM QL-47. Cells were lysed 24 hrs post QL-47 treatment. 
Co-IP of protein complexes from TL was performed using a GFP-trap (Chromotek). Precipitated 
proteins and proteins of TL were resolved through Western blot and presence of Flag-tagged 
and GFP-tagged proteins were determined through targeted HRP conjugated antibody binding 
and ECL detection analysis. 
Ab=Antibody; MW=Molecular Weight; kDa= kilodalton; IP=Immunoprecipitation; TL= Total 
lysate; D4=DOCK4; D9=DOCK9; EV=Empty vector. 
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 Size exclusion analysis of DOCK4 SH3 domain and DOCK9 PCIP-DHR1 domain 
interaction 
The SH3 domain of DOCK4 has already been established as the domain which drives 
DOCK4 interaction with DOCK9 (Abraham et al., 2015). Co-IP analysis of DOCK9 PRR mutants 
indicated PRR 3 (p.PCIP627-630), which lies just upstream of the DHR1 domain, and PRR 4, 
which lies within the DHR1 domain (figure 4.1) may be involved in the DOCK4-DOCK9 
binding. Hence, a DOCK9 construct was generated to include a nucleotide sequence which 
encompasses the p.PCIP627-630 residues and the DHR1 domain.  
Nucleotide sequences for DOCK4 SH3 domain and DOCK9 PCIP-DHR1 domain were 
cloned into pOPIN-F expression vectors with inclusion of a His-tag (figure 7.4; figure 7.5). 
DOCK4 SH3-His (figure 4.9) and DOCK9 PCIP-DHR1-His peptides (figure 4.10) were produced 
in BL21 (DE3) competent cells and purified using affinity chromatography, then both further 
purified using SEC (figure 4.11). All protein lysates were concentrated to approximately 
100μM/ml. Purified DOCK4 SH3 His-tagged peptides were diluted in a 1:1 ratio with elution 
buffer and aliquoted into 2ml fractions. Diluted peptides were further purified and separated 
according to size using SEC (figure 4.12).  
The concentration of peptide particles within each 1ml fractions were determined 
by UV light spectroscopy (mAU), generating a line graph which indicates concentration of 
each fraction, with peaks indicating the UV absorbance and therefore hydrodynamic volume 
of the molecules. Fractions represented by the large peak in figure 4.12 A.1 were then 
resolved using a SDS PAGE gel and confirmed as DOCK4 SH3 moieties through Coomassie 
blue staining of the gel based on the molecular weight of the detectable band by comparison 
to a Bio-Rad molecular weight ladder (Figure 4.12 B, well 1). Purified DOCK9 PCIP-DHR1 
peptides were then further purified and separated according to size using the same 
methodology as the DOCK4 SH3 domain peptides. Fractions represented by the large peak 
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in figure 4.12 A.2 were then resolved using a SDS PAGE gel and confirmed as DOCK9 PCIP-
DHR1 through Coomassie blue staining of the gel (Figure 4.12 B, well 2).
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POPINF DOCK4-SH3-HIS construct was cloned to express DOCK4-SH3 peptides. His-tagged 
DOCK4-SH3 peptides expressed in BL21 (DE3) competent cells were purified using affinity 
chromatography and a His Trap HP column, connected to an ÄKTA pure protein purification 
system (GE Lifesciences). (A) PCR agarose gel of DOCK4 SH3 gene fragment isolated from a 
pBabe puro DOCK4-Flag expression vector, and amplified through PCR amplification. DOCK4 
SH3 domain nucleotide sequence (216 bp,) confirmed through Sanger sequencing 
(ThermoFisher), was cloned into a pOPINF-HIS vector using cloning NEBuilder® HiFi DNA 
Assembly Cloning Kit. Correct gene insert was determined by agarose gel DNA separation. 
(B) Graph depicting an affinity chromatography elution profile of DOCK4 SH3 domain 
















1            2       
151 
peptides. DOCK4 SH3 domain peptide purification from a BL21 (DES) competent cell lysate. 
mAU= Milli absorbance units; ml=Millilitre of eluted sample, collected in 1ml aliquots on a 
96 well collection plate; UV1_280= UV absorbance at 280 nm and represents protein 
concentration within lysate samples as they are eluted from the His-column; Cond= 
Conductivity monitor used to follow column equilibration; Cond B= Conductivity monitor 
used to monitor salt gradient formation. (C) Coomassie stained SDS-Page gel of affinity 
chromatography purified DOCK9 PCIP-DHR1 domain peptide. pOPINF DOCK4-SH3-His 
plasmid was transformed into BL21 (DE3) competent cells, grown in 1l cultures, lysed, and 
purified using affinity chromatography. C.1= Whole bacterial culture sample. C.2= Bacterial 
pellet sample. C.3= Sample of initial elution of the His-column wash of DOCK4-SH3 domain 
peptide containing lysate, during affinity chromatography.  C.4= Second sample of elution of 
the His-column wash of DOCK4-SH3 domain peptide containing lysate, during affinity 
chromatography.  C.5-11=Samples of affinity chromatography eluents corresponding to the 
eluted purified proteins in ml samples 63-68ml of the given chromatography elution peak. 
(D) Anti-His Western blot of DOCK4 SH3 proteins purified through affinity chromatography. 
Western blot lane 1-3 correspond to lanes labelled 8 and 9 of the Coomassie stained SDS-








pOPINF DOCK9 PCIP-DHR1-His construct was cloned to express DOCK9 PCIP-DHR1 
peptides. His-tagged DOCK9 PCIP-DHR1 peptides expressed in BL21 (DE3) competent cells 
were purified using through affinity chromatography using a using a His Trap HP column 
connected to an ÄKTA pure protein purification system (GE Lifesciences). (A) PCR agarose gel 
of DOCK9 PCIP-DHR1 gene fragment (well 2; BP 663) was isolated from a Flag-DOCK9 
expression vector and amplified through PCR amplification. DOCK9 PCIP-DHR1 domain 
nucleotide sequence was cloned into a pOPINF-HIS vector using cloning NEBuilder® HiFi DNA 
Assembly Cloning Kit. Correct gene insert was determined by agarose gel DNA separation. 
(B) Affinity chromatography peak of DOCK9 PCIP-DHR1 domain peptide purification from a 
BL21 (DES) competent cell lysate. mAU= Milli absorbance unit; ml=Millilitre of eluted sample, 
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Figure 4-10 Expression vectors of DOCK9 truncated peptide regions of interest. 
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collected in 1ml aliquots on a 96 well collection plate; UV1_280= UV absorbance at 280 nm 
represents concentration of protein within lysate samples as they are eluted from the His-
column; Cond=Conductivity monitor used to follow column equilibration; Cond 
B=Conductivity monitor used to monitor salt gradient formation. (C) Coomassie stained SDS-
Page gel of affinity chromatography purified DOCK9 PCIP-DHR1 domain peptide. pOPINF 
DOCK9 PCIP-DHR1-His construct was transformed into BL21 (DE3) competent cells, grown in 
1l cultures, lysed, and purified using affinity chromatography. C.1=Sample of initial elution 
of the His-column wash of DOCK9 PCIP-DHR1 domain peptide containing lysate, during 
affinity chromatography. C.4=Bacterial pellet sample. C.6-10=Samples of affinity 
chromatography eluents corresponding to the ml of eluted purified proteins in samples 118-
122ml of the given chromatography elution peak. (D) Anti-His Western blot of DOCK9 PCIP-
DHR1 proteins purified through affinity chromatography. Western blot lanes 1-3 represent 
affinity chromatography elutions detected on the Coomassie stained SDS-Page gel (C) lanes 










His-tagged DOCK4-SH3 peptides and DOCK9 PCIP-DHR1 peptides expressed in BL21 
(DE3) competent cells were purified from bacterial lysates using affinity chromatography and 
further purified through SEC using a Superdex® 75 10/300 GL column connected to an ÄKTA 
pure protein purification system (GE Lifesciences). (A1) DOCK4-SH3 peptide SEC elution 
peaks and (B1) DOCK9 PCIP-DHR1 peptide SEC elution peaks. mAU= Milli absorbance unit; 
ml=Millilitre of eluted sample, collected in 1ml aliquots on a 96 well collection plate; 
UV1_280= UV absorbance at 280 nm represents concentration of protein within lysate 
samples as they are eluted from the His-column; Cond= Conductivity monitor used to follow 
column equilibration; Cond B= Conductivity monitor used to monitor salt gradient formation. 
(A2) Coomassie stained SDS-Page gel of affinity chromatography purified DOCK4-SH3 
domain peptide and (B2) DOCK9 PCIP-DHR1 domain peptide. (A2 and B2) Peptides purified 
using affinity chromatography were further purified using SEC (A2) SDS PAGE gel lanes 
correspond to specific 1ml DOCK4 SH3 SEC protein sample eluents as follows: A2 lanes 1-2 
correspond to sample collected from A1 SEC peak 1. A2 lanes 3-5 correspond to sample 
collected from A1 SEC peak 2. A2 lanes 6-8 correspond to sample collected from A1 SEC peak 
3.  (B2) SDS PAGE gel lanes correspond to specific 1ml SEC DOCK9 PCIP-DHR1 protein sample 
eluents as follows B2 lanes 1-6 correspond to sample collected from A1 SEC peak 1. B2 lanes 
7-9 correspond to sample collected from A1 SEC peak 2. B2 lane 10 corresponds to sample 
collected from A1 SEC peak 3.   
Figure 4-11 SEC purification of DOCK4-SH3 and DOCK9 PCIP-DHR1 peptides 
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To determine whether the DOCK4 SH3 domain binds directly to the DOCK9 PCIP 
residues and/or the DHR1 domain, 50μM of DOCK4 SH3-His peptides were combined with 
50μM of DOCK9 PCIP DHR1-His peptides.   
Combined peptides were diluted with non-denaturing elution buffer and 
fractionated through SEC into aliquots based on size, with larger proteins being eluted first. 
The concentration of peptide particles within each 1ml fractions was determined by UV light 
spectroscopy (mAU), generating a line graph that indicates concentration of each fraction 
with peaks signifying the UV absorbance and therefore hydrodynamic volume of the polymer 
molecules. Should the proteins interact and have formed a complex, the peak, currently 
indicated in figure 4.12 A3, would have shifted to the left; indicating complex of the two 
proteins resulting in a larger molecule, and an earlier elution of the proteins.. However, the 
peaks generated by elution of the combined lysates indicate lack of interaction between the 
two peptides, with each protein eluting separately with peaks that reflected the peaks 
generated by SEC of the individual peptides. Proteins collected in fractions represented by 
the two large peaks were resolved on an SDS PAGE gel and visualised with Coomassie blue. 
Peptides of the correct molecular weight for DOCK4 SH3-His and DOCK9 PCIP DHR1-His were 
confirmed (figure 4.12 B, wells 3 and 4). These results show lack of direct interaction between 
the DOCK4 SH3 domain and the DOCK9 p.PCIP627-630 residues encompassing PRR 3, nor the 
DOCK9 DHR1 domain encompassing PPR 4. This result also nullifies the hypothesis that the 
DOCK9 binding small molecule inhibitor QL-47 disrupts the DOCK4-DOCK9 interaction 





Analysis of DOCK4 SH3 and DOCK9 PCIP-DHR1 interaction using SEC followed by 
confirmation using SDS PAGE gel confirmation. (A) Affinity chromatography purified DOCK4 
SH3 and DOCK9 PCIP-DHR1 peptides were separated by size through SEC, using a Superdex® 
75 10/300 GL column connected to an ÄKTA pure protein purification system (GE 
Lifesciences). (Blue line) 100μM of DOCK4 SH3 peptides in 1ml of lysate were loaded onto a 
Superdex® 75 10/300 GL column through a 500μl loop. Peptides were resolved through SEC 
and detected based on size. (Orange line) 100μM of DOCK9 PCIP-DHR1 peptides in 1ml of 
lysate were loaded onto a Superdex® 75 10/300 GL column through a 500μl loop. Peptides 
were resolved through SEC and detected based on size. (Green line) 50μM of DOCK4 SH3 
and 50μM of DOCK9 PCIP-DHR1 peptides were combined to a volume of 1ml of lysate then 
loaded onto a Superdex® 75 10/300 GL column through a 500μl loop. Peptides were resolved 
through SEC and detected based on size. Right peak indicates DOCK4 SH3 domain peptides. 
Left peak indicated DOCK9 DHR1 peptides. (B) Peptides eluted by SEC were resolved on a 
SDS PAGE gel followed by Coomassie blue. Peptides in eluents corresponding to SEC peaks 
were confirmed as DOCK4 SH3 and DOCK9 PCIP-DHR1 peptides based on molecular weight: 
DOCK4 SH3 domain peptides (11kDa; blue line) indicated on Coomassie gel (B) lane 1. DOCK9 
DHR1 domain peptides (25kDa; orange line) indicated on Coomassie gel (B) lane 2. DOCK4 
SH3 domain peptides (right peak, green line) indicated on Coomassie gel (B) lane 3. DOCK9 
DHR1 domain peptides (left peak, green line) indicated on Coomassie gel (B) lane 4. 
 
 
Figure 4-12 SEC interaction analysis of DOCK4 SH3 and DOCK9 PCIP-DHR1 purified peptides 
A    
25 kDa 
11 kDa 
1     2      3     4      
B    
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4.3 Discussion 
The interaction analysis carried out within this study were unable to elucidate the 
DOCK9 residues which serve as the binding site of the DOCK9 interaction with the DOCK4 
SH3 domain (figures 4.3-4.7). The DOCK9 binding small molecule QL-47 was unable to disrupt 
the DOCK4-DOCK9 interaction within Co-IP assays, indicating that the p.C628 residue of 
DOCK9 may not be involved in a direct interaction between the two proteins (figures 4.8). 
Further to this, the truncated peptides DOCK4 SH3 and DOCK9 PCIP-DHR1 were found to not 
directly interact within SEC analysis (4.12). 
The signalling pathways that are activated in ECs during angiogenesis are complex 
and not entirely understood. The ability to dissect and gain further understanding of the 
events that drive blood vessel growth, will give further insights into dysregulation of the 
process during pathological angiogenesis and may identify new therapeutic targets for those 
pathologies. This study has set out to further understand the RhoG-DOCK4-RAC1-DOCK9-
CDC42 signalling pathway recently identified (Abraham et al., 2015). Previous work had 
demonstrated that the DOCK4-DOCK9 complex acts as an effector downstream of RhoG 
signalling (Abraham et al., 2015). Rho GEF proteins can heterodimerise as well as 
homodimerise. The ability of these proteins to form such complexes indicates their potential 
to act in-concert to finely tune Rho GTPase activity, throughout the highly organised and 
dynamic cellular events that take place during sprouting angiogenesis and lumen formation 
(Abraham et al., 2015). Different GEFs may modulate activation and inactivation of Rho 
proteins at key stages of blood vessel development, while also regulating other protein-
protein interactions and protein localisation (Barlow and Cleaver, 2019). The function of 
DOCK4 and DOCK9 are required for the outgrowth of lateral filopodia along sprouting vessels 
in 3D tissue culture (Abraham et al., 2015). This function has been stipulated as necessary 
for lumenisation and therefore functionality of newly forming blood vessels (Abraham et al., 
2015). The ability for DOCK4 and DOCK9 to heterodimerise during angiogenesis may be 
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required for signalling mechanisms involved in development of lateral filopodia. Elucidating 
how these two proteins interact will allow for further understanding of the signalling 
mechanisms involved in angiogenesis. 
 DOCK4-DOCK9 interaction 
Purified GST-tagged DOCK4 SH3 domain has been demonstrated as capable of 
pulling down endogenous WT DOCK9 from HEK 293T cellular lysates (Abraham et al., 2015). 
Currently the specific DOCK9 site that interacts with the DOCK4 SH3 domain has not yet been 
determined. Initial attempts in this study to utilise the commercially available GFP-trap, to 
identify a putative PRR within DOCK9 that mediates the interaction with DOCK4, have been 
convoluted. DOCK9 mutations within PRRs identified as DOCK9 PRRs 2 and 9 demonstrated 
little effect on DOCK4-DOCK9 interaction, leading to the hypothesis that these PRRs are not 
required for the interaction (figures 4.4, 4.6, and 4.7). Mutations within the PRRs identified 
as DOCK9 PRRs 3, 4, and 5 were found to yield somewhat conflicting results via western blot 
analysis of the Co-IP of DOCK4 and DOCK9 proteins (figures 4.4, 4.5, and 4.7). Co-IP of EGFP-
DOCK4 and Flag-DOCK9 PRR 3 and 4 mutants yielding the most varied results with EGFP-
DOCK4 showing the least affinity for binding DOCK9 PRR 4 when compared to the control, 
and the other DOCK9 PRR mutants, however this result was not statistically significant 
through colorimetric analysis (figure 4.7); although it should be noted that the profoundly 
strong GFP signal detected through Western blot within the TL samples led to oversaturation 
which may not present a true representation of the level of GFP expression within the GFP 
TL samples, thus potentially confounding any differences in DOCK4 expression between 
samples. This may be corrected by testing repeat blots of decreasing concentration of loaded 
protein in-order to create a gradient, and a more true representation of protein 
concentration (Ghosh et al., 2014). 
The variability of results indicates that Co-IP may not be sensitive enough to detect 
the loss of interaction between the two proteins. A number of elements within this model 
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should be considered and addressed, should this experiment be carried out for future 
purposes. Firstly, non-specific binding of the Flag-tag of the DOCK9 proteins should be 
investigated to determine if this epitope binds either the DOCK4 protein or GFP tag, as Flag-
tags have been previously described to bind a number of proteins non-specifically (Free et 
al., 2009). Consideration should also be given to the level of protein expression of both 
DOCK4 and DOCK9, as both proteins are large proteins with similar sequence homology, and 
both capable of homodimerisation, there is potential that over-expression may lead to non-
specific interaction. It should be noted that the GFP tag was determined to not bind the 
DOCK9 protein non-specifically, as seen in the EGFP-EV samples (figure 3.3, 3.4, and 3.5).  
As both DOCK4 and DOCK9 proteins possess structural similarities, both with the 
ability to homodimerise, overexpression within HEK 293T cells may likely result in forced and 
non-sensitive interaction (Sommer et al., 2014; Marcotte and Tsechansky, 2009). Through 
optimization of the Co-IP experiments, the concentration of transfected plasmid was tittered 
to reduce the level of protein expression, in-order to overcome false interaction. However, 
both the CMV promoter of the pC3 EGFP-DOCK4 plasmid and EF-1α promoter of the pEF4 
Myc-Flag-DOCK9 plasmid both induce a high level of expression which may maintain too high 
a level protein expression (Xia et al., 2006), it may therefore be necessary to use expression 
vectors with a weaker, or less active, promoter in order to better control the level of 
expression. The Co-IP approach also lacks the ability to detect direct interaction, which may 
be overcome by purified fusion protein-pull down experiments or SEC of purified proteins 
(Hall, 2005). Further to this, detection of interacting proteins via Western blot lacks 
sensitivity and produces unreliable results that may not distinguish between genuine 
interaction and non-specific interaction (Zhu et al., 2017).  
In an attempt to overcome the variability in results, the initial protocol TLs were also 
optimized to reduce detection of non-specific interaction. The TL buffer (RAC lysis buffer) 
was optimised with an increase in sodium chloride concentrations in an attempt to further 
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disrupt any non-specific binding of proteins. These experiments ultimately showed 
inconsistent results, with little or no difference in the binding ability of EGFP-DOCK4 to Flag-
DOCK9 PRR 3 and 5 mutants when compared to the control, EGFP-DOCK4 binding to WT Flag-
DOCK9 (figures 4.4, 4.5 and 4.7). In regards to the DOCK9 PRR 4 mutant, analysis of lysates 
from the optimised Co-IP experiment yielded results similar to the previous experiments, 
with EGFP-DOCK4 having a reduced affinity for binding DOCK9 PRR 4 mutant when compared 
to the WT and other DOCK9 mutants (figure 4.5 and 4.7), however this result was not 
significant and it was also noted that DOCK9 PPR 4 mutant appeared to express less total 
protein when compared to TL of HEK 293T transfected with the other 4 DOCK9 mutant 
constructs (figure 4.4 and figure 4.6). The variability within those results led to the 
consideration that the experimental design may not be suitable for demonstrating loss of 
DOCK4 and DOCK9 interaction, perhaps due to forced interaction of the two large 
overexpressed proteins (Sommer et al., 2014; Marcotte and Tsechansky, 2009). 
Furthermore, the ability for mutations within 3 separate PRRs to show some level of 
disruption of the DOCK4-DOCK9 interaction may suggest that more than one PRR binding 
site may be required for the interaction, a concept which could be further explored through 
inclusion of wider protein domains within interaction analysis.  
 The effect of QL-47 on the DOCK4-DOCK9 interaction 
Within the interim of the DOCK4-DOCK9 PRR mutant Co-IP experiments, a small 
molecule compound, QL-47, was identified by Nathanial Gray’s research group as a DOCK9 
binding compound. QL-47 specifically binds to the cysteine residue p.C628 within the PRR 3 
(p.PCIP627-630). Experiments reported within the previous results chapter of this thesis 
(figure 3.8 and 3.9) established that QL-47 disrupts correct sprouting angiogenesis and 
promotes an angiogenic phenotype. For the aforementioned reasons, it was considered that 
the phenotypic effect of QL-47 may involve disruption of DOCK4 and DOCK9 interaction.  
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To test this hypothesis the EGFP-DOCK4 Flag-DOCK9 co-expression and Co-IP 
analysis was carried out in the presence of QL-47, at a concentration of 5μM, equal to the 
concentration required to induce a phenotypical effect on angiogenesis in vitro. In separate 
experiments cells were either treated with QL-47 before transfection with the EGFP-DOCK4 
and Flag-DOCK9 expression vectors, or prior to cell lysis. Using anti-Flag and anti-GFP 
Western blot analysis it was not possible to conclusively demonstrate any disruption to the 
DOCK4-DOCK9 complex (figure 4.8).  
The results of the DOCK4-DOCK9 PRR mutant Co-IP experiments in combination with 
the QL-47 supplemented DOCK4-DOCK9 Co-IP experiments substantiated that the Co-IP 
approach may not provide a reliable experimental model for investigating the interaction. 
To remedy the influence of potential variables within the live cell cultures, an experimental 
approach utilising only purified DOCK4 and DOCK9 peptides was carried out.  
 SEC analysis of DOCK4 SH3 domain interaction with the DOCK9 DHR1 domain 
The previously mentioned experiments demonstrated that investigation of the wider 
domains of DOCK9 may be required to elucidate the binding site for DOCK4. In order to 
investigate this, SEC was carried out using specific domains of DOCK4 and DOCK9. SEC 
analysis of protein interactions is a robust and widely used technique for determining 
whether two proteins interact directly (Bloustine et al., 2003; Busch et al., 2017).   
Constructs were generated with the gene sequence for expression of a truncated 
DOCK9 protein, cloned into a pOPINF expression vector (plasmid maps can be found in 
Appendix 7.1.2). A truncated portion of DOCK9 was cloned into the pOPINF expression 
vector, and included only the DHR1 region, which encompasses PRR4, and the PPR region 
directly upstream of the DHR1 binding domain, identified as PRR 3 (p.PCIP627-630). The 
DOCK4 SH3 domain gene sequence was also cloned into a pOPINF expression vector. Both 
the DOCK4 SH3 and DOCK9 PCIP-DHR1 construct incorporate a histidine tags. Both the 
DOCK4 SH3 and DOCK9 PCIP-DHR1 truncated proteins were successfully expressed in BL21 
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(DES) competent cells. Bacterial cultures were lysed and proteins purified using affinity 
chromatography (figures 4.9 and 4.10). Proteins were then further purified using SEC (figure 
4.11)  
To determine whether the SH3 domain of DOCK4 directly binds to either/or both of 
the DOCK9 PRRs 3 and 4 equal concentrations (approx. 50μM) of purified protein samples 
were resolved using SEC, under non-denaturing conditions (figure 4.11). In-order to establish 
a size-based peak, 100μM of each protein were first resolved individually, and then 
combined and resolved via SEC, under non-denaturing conditions. Proteins capable of 
binding one another would be expected to remain bound during SEC, however the results 
demonstrated that the DOCK4-SH3 domain does not bind DOCK9 PRR3-DHR1 peptides 
directly. SEC of DOCK4-SH3 and DOCK9 PCIP-DHR1 was repeated, in-order to confirm the 
absence of direct interaction (Figure 4.12). The repeat experiment yielded the same result, 
strongly suggesting that the DOCK9 PRR3 and PRR4 are not involved in a direct interaction 
between the DOCK4-SH3 domain and DOCK9. Furthermore, it is likely that the DOCK4-SH3 
domain does not interact directly with the DHR1 domain of DOCK9.  
While this experiment indicates that the DOCK4 SH3 domain residues do not bind 
directly to residues within the DOCK9 DHR1 domain, it does not give consideration to the 
requirement of secondary structures within the interaction, as the purified peptides may lack 
the correct folding of the native proteins. As the full structure of DOCK9 as not yet been 
determined  
In consideration of the overall outcome of these experiments, it can be concluded 
that the experimental design for elucidating the site of DOCK9 which binds the DOCK4 SH3 
domain would need to be further optimised in-order to yield a more reliable result. The 
acquired results indicate that the DOCK4-SH3 domain does not directly bind to the DOCK9 
DHR1 domain, and is unlikely to interact with the DOCK9 PRRs 2, 3, 4, 5 and 9, however this 
cannot be considered a conclusive result. It can however suggest that it is likely that the small 
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molecule QL-47 does not disrupt DOCK4 and DOCK9 interaction, as there was no apparent 
binding of the DOCK4 SH3 domain to an individual residue of the DOCK9 p.C628. Therefore 
the phenotypic effects of QL-47 on sprouting angiogenesis in vitro are unlikely to be due to 
disruption of the interaction of DOCK4 with DOCK9.  
Additional experiments will be required in-order to further understand the precise 
nature of the DOCK4-DOCK9 interaction. Generation of expression constructs which 
encompass wider regions of DOCK9 would be ideal for encapsulating which wider region of 
the protein truly binds DOCK4. Data of the DOCK4 and DOCK9 interaction partners, identified 
through previous work in the laboratory, could help elucidate how these two proteins 
interact potentially via an indirect mechanism (Abraham et al., 2015). Defining true binding 
partners of these two DOCK180 family members will afford a more in-depth understanding 
of their function, while also potentially shed more light into the purpose of the DOCK4-















5 Results chapter III: Dock4 genetic deletion impairs vascular 
recovery following an ischemic event in vivo 
5.1 Introduction 
The GEF DOCK4 is essential for correct vascular growth during sprouting 
angiogenesis in vitro (Abraham et al., 2015). Depletion of DOCK4 expression results in growth 
of less dynamic vascular structures in vitro, and impaired lumenisation both in vitro and in 
vivo (Abraham et al., 2015). The DOCK4 effector protein, RAC1, is a multifunctional dynamic 
Rho GTPase which has been implicated as an essential component for blood vessel growth, 
during development and post developmental sprouting angiogenesis (Ramo et al., 2016; Cao 
et al., 2017). RAC1 drives directional migration and correct vascular patterning via regulation 
of the actin polymerisation required for lateral filopodia production, during sprouting 
angiogenesis (Abraham et al., 2015). Understanding how blood vessels grow in response to 
oxygen deprivation is imperative for deciphering the mechanisms that underpin vascular 
pathologies, which result from inadequate angiogenic response (Ramo et al., 2016; Cao et 
al., 2017).  
To expand upon current knowledge of the function of DOCK4 in angiogenesis, a 
global Dock4 heterozygous knockout C57BL/6J murine model (which will be referred to as 
Dock4 het throughout this chapter) was employed. This Dock4 het mouse model overcomes 
embryonic lethality of homozygous Dock4 deletion, and was used for analysis of Dock4 
function in vivo. The Dock4 het murine model was previously demonstrated to express only 
50% of the normal expression level of DOCK4 (Abraham et al., 2015). An EC specific 
conditional Dock4 knockout murine model, iVEC-cre+ve; Rosa26-lsl-Tomato; Dock4f/f mice, 
was also employed, to allow for inducible deletion of endothelial Dock4 (which will be 
referred to as EC Dock4 KO throughout this chapter).  
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To investigate how DOCK4 functionality influences vascular response and recovery, 
under pathological conditions of ischemia in vivo, the global heterozygous DOCK4 knockout 
model, and EC Dock4 KO model, were both employed in a HLI assay in vivo. The HLI model 
provides a model of arteriogenesis and angiogenesis within the hind limbs of mice, and is a 
widely performed and validated model of ischemia (Hellingman et al., 2010). All surgical 
procedures carried out by Dr Nadira Yuldasheva. 
LDI was utilised to monitor vascular recovery and response, following removal of a 
portion of the femoral artery (figure. 5.1). The moorLDI2-HIR High Resolution Laser Doppler 
Imager allowed for deep penetrative imaging of small blood vessels, ideal for detecting blood 
flow within solid tissues. 
Loss of blood flow through the femoral artery leads to redirection of blood flow via 
the pre-existing collateral arteries, and subsequent arteriogenesis and widening of the 
collateral arteries (van Royen et al., 2001; Limbourg et al., 2009). While blood flow through 
the collateral arteries allows some circulation to the lower appendage. Inadequate level of 
blood perfusion induces a strong angiogenic response within the muscles of the lower limb, 
the gastrocnemius and soleus (Limbourg et al., 2009; Niiyama et al., 2009). The strong 
angiogenic response within the gastrocnemius makes the muscle ideal for histological 
analysis of vascularity (Limbourg et al., 2009; Niiyama et al., 2009). Antibody staining of the 
endothelial specific surface protein, CD31, allows for visualisation of the blood vessels within 
the gastrocnemius and thus provides a method of comparative analysis of vascularisation of 
the gastrocnemius of the injured leg, compared to that of the un-injured leg (Hellingman et 
al., 2010). 
Gastrocnemius and soleus muscles of the mouse hind limbs were harvested, 
embedded in paraffin wax, sectioned and stained for DOCK4, the vascular specific marker, 
CD31, and RFP (for confirmation of the Td Tomato reporter for EC DOCK4 deletion in the 
inducible DOCK4 KO mouse). IHC stained muscle sections were electronically scanned and 
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analysed using ImageJ, in-order to quantify the vascularity of the tissue and analyse key 
features of the vascular structures.  
Numerical data generated through LDI detection of cell velocity, within the hind 
limbs of mice, was statistically analysed using a one-way analysis of variance (ANOVA), blood 
flow area under the curve, and linear regression and slope intersect analysis, to determine 
significant changes in vascular recovery. 
Overall this chapter will provide evidence that the RAC1 GEF, DOCK4, is required for 
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Figure 5-1 Schematic of the HLI model 
The HLI surgery removes a portion of the left femoral artery. The femoral artery is 
separated from the iliac vein, encircled with 8.0 Vicryl sutures, and the intervening arterial 
segment is excised. 
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5.2 Results 
 Dock4 het mice have lower gross body weight compared to WT littermate control mice 
Gross body weight of each mouse was tracked and recorded through-out the 
duration of the HLI experiment (table 5.1). Body weight was monitored to ensure each 
mouse was healthy and thriving throughout the duration of all murine experiments. Both 
male and female Dock4 het mice were found to have typically lower body weights, when 
compared to the WT littermate mice, at each time point. The reason for the lower body 
weight was not further investigated and has not yet been elucidated.  
 
 
DOCK4 het WT littermates 
ID Day 0 Day 7 Day14 Day 21 ID Day 0 Day 7 Day14 Day 21 
608 16g 17g 18g 17g 611 16g 16g 17g 17g 
609 16g 16g 17g 17g 631 19g 19g 20g 20g 
610 18g 18g 20g 20g 632 17g 18g 19g 19g 
630 17g 17g 17g 17g 641 20g 20g 20g 20g 
638 16g 16g 16g 16g 642 19g 19g 20g 20g 
645 15g 15g 15g 15g 643 19g 19g 19g 20g 
614 22g 23g 24g 24g 612 26g 27g 29g 28g 
633 24g 24g 25g 26g 613 22g 23g 24g 24g 
634 20g 21g 22g 23g 635 27g 28g 29g 29g 
636 20g 21g 22g 22g 637 25g 26g 29g 29g 
639 23g 23g 23g 23g 640 27g 27g 27g 27g 
646 23g 23g 24g 24g 647 26g 26g 26g 26g 
Table 5-1 Weight of each mouse in grams 
Table of the weight of each mouse, in grams. Each mouse was weighed directly 
before LDI was carried out. ID= Identification number of each mouse. Numbers highlighted 
in pink are female mice. Numbers highlighted in blue are male mice. 
 Dock4 het mice show reduced rate of hind limb mobility recovery compared to WT 
littermates 
Response to HLI was studied in the Dock4 het mice, following surgical removal of a 
portion of the femoral artery. Hind limb mobility of each mouse was monitored following 
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surgery, in order to determine if any differences in loss of hind limb mobility and recovery 
could be observed between the experimental groups. Immediately following HLI both the 
WT mice and Dock4 het mice demonstrated substantial loss in left hind limb mobility 
(qualitative observations). Over 28 days post-surgery WT mice began to regain mobility of 
the injured hind limb, while Dock4 het mice were observed to have less mobility of the 
injured limb by comparison to the WT littermate controls. By day 21, WT mice regained full 
mobility of their hind limb, and no longer appeared to be physically impacted by loss of the 
portion of the femoral artery. Dock4 het mice continued to experience loss of full leg 
extension and flexibility, with the injured left hind limb being held in a retracted position 
with full manual extension of the hind limb not possible.  
 
 Dock4 het mice develop necrosis of the ischemic foot  
Throughout the experiment all mice were monitored for any signs of necrosis of the 
ischemic limb, representative images and all recorded results are given in figure 5.2. Out of 
twelve Dock4 het mice, eleven experienced necrosis within the ischemic foot, which ranged 
from mild necrosis (blackening of the toe tips) to profound necrosis (auto-amputation of the 
ischemic foot). Three Dock4 het mice experienced auto-amputation of toe tips and an 
additional two Dock4 het mice experienced auto-amputation of toes. One Dock4 het mouse 
experienced auto-amputation of the affected foot (figure 5.2B). In summary, 5 out of 12 
Dock4 het mice experienced some form of auto-amputation. There was no auto-amputation 
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 Dock4 het mouse hind limb blood flow is equal to the hind limb blood flow of WT 
littermates under physiological conditions 
The hindlimb blood flow of the uninjured leg of both experimental groups were 
analysed through LDI, to determine whether any differences in hindlimb blood flow could be 
detected between the two experimental groups (figure 5.3 and 5.4). Blood flow of the 
uninjured limbs of both experimental groups followed the same trend (figure. 5.3 and 5.4), 
with blood flow appearing higher immediately following surgery, then decreasing each week 
post operation. Higher levels of post-operative blood flow were most likely due to mice being 
maintained on a heated surface prior to LDI.  
Comparative analysis of blood flow to the non-injured limbs of Dock4 het mice to 
WT littermates determined there was no significant difference between the normal hind 
limb circulation of the two experimental groups before ligation of the left femoral artery 
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Figure 5-3 Effect of Dock4 het deletion on hind limb vascular recovery following surgical 
ligation of the femoral artery  
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Representative images of LDI detected mean/area of blood flow perfusion in the 
hind limbs of Dock4 het mice and WT littermates, in a supine position, over a 21 day time 
period, following HLI surgery. Surgery to ligate and transect the left femoral artery was 
carried out to occlude blood flow to the left hind limb. Blood flow was analysed using LDI on 
day 0 (2 hours post-surgery), 7, 14, 21, and 28 following surgical ligation of the left hind leg 
femoral artery on day 0. (A) Experiment 1: WT mice (n=4) Dock4 het KO mice (n=4). (B) 
Experiment 2: WT mice (n=5); Dock4 het KO mice (n=4). (C) Experiment 3: WT mice (n=3) 














































Figure 5-4 Quantification of LDI of non-injured hind limbs of Dock4 het KO mice during 
ischemia recovery 
Combined data of blood flow perfusion detected by LDI in the hind limbs of WT mice 
(n=12) versus Dock4 heterozygous mice (n=12) following HLI surgery. A portion of the left 
femoral artery of each mouse was removed on day 0. Blood flow to the lower extremities of 
both injured and non-injured limbs of each mouse was monitored using LDI immediately 
following surgery, then every 7 days for a 21 day duration. Values plotted are mean blood flow 
perfusion divided by the area of each non-injured limb. Linear regression of Dock4 het mice was 
compared to the linear regression of the WT mice to detect differences in recovery over time. 
One-way ANOVA with Tukey’s multiple comparisons was carried out to compare mean blood 
perfusion by area of Dock4 het mice to WT mice at each time point showed no significant 
differences at any time point.  
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 Global heterozygous deletion of Dock4 resulted in a significant reduction in blood flow 
recovery following HLI surgery.  
Response to HLI was studied in the Dock4 het mice, following surgical removal of a 
portion of the femoral artery. LDI was carried out to determine velocity of motile cells, and 
thus blood perfusion, in the dermal tissue of the mouse hind limbs. Three separate HLI 
experiments were conducted to compare blood flow recovery of Dock4 het mice to the WT 
littermate controls, with a combined N number of 24 mice for each of the experimental 
groups.  
LDI data was generated over 3 separate HLI experiments, each for a duration of a 21 
day time period, following femoral artery ligation of the left hind limb in order to monitor 
the recovery of blood flow following femoral artery ligation (figure. 5.4, and figure. 5.5).  
LDI of blood flow to the left (injured) hind limbs of the 12 Dock4 het mice and 12 WT 
littermates immediately following hind limb surgery, on day 0, showed a loss of blood flow 
to the left hind limb in all 12 Dock4 het mice and 12 WT mice (figure. 5.3 and figure. 5.5). 
There was no significant difference in blood flow to the injured limbs of the Dock4 het mice 
when compared to the WT littermates (figure. 5.3 and figure 5.5) immediately following HLI 
surgery.  
LDI analysis of injured hind limbs on day 7 showed no significant difference in blood 
flow between the two experimental groups (figure. 5.4 and figure 5.5). 
However, by 14 days post operation, the global Dock4 het mice had a significantly 
lower level of blood flow to the ligated limbs when compared to the WT littermates 
(P=0.0047) (figure. 5.4 and figure 5.5). The lower level of blood flow to the hind limbs, of 
Dock4 het mice when compared to the WT, was also observed on day 21, however the 
difference was not statistically significant.  
The overall blood flow recovery following femoral artery ligation was reduced in the 
Dock4 het mice when compared to WT littermate controls. Analysis of the area under the 
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curve demonstrates a significant difference (P<0.005) between the WT data set and the 
Dock4 het deletion data set, signifying a significant impact of reduced Dock4 expression on 
blood flow recovery following removal of a portion of the femoral artery. 
Using linear regression analysis, the slope of the lines of best fit of the WT data set 
and the Dock4 het deletion data set are not significantly different, but only marginally not 
significant (P=0.056). However, the intercept of these two lines are significantly different 
(P=0.016). This signifies that the trend of vascular recovery between the WT and Dock4 het 
mice was similar, however the increase in blood perfusion over time was significantly higher 
in the WT mice when compared to the Dock4 het mice. 
Overall the data generated through LDI analysis indicate an impairment in recovery 
from HLI surgery when global levels of Dock4 are reduced. This loss in Dock4 results in a delay 





Figure 5-5 Quantification of LDI of injured hind limbs of Dock4 het KO mice during ischemia 
recovery 
Combined data of LDI detection of blood flow perfusion in the hind limbs of WT mice 
(n=12) versus Dock4 het KO mice (n=12) following HLI surgery. A portion of the left femoral 
artery of each mouse was removed on day 0. Blood flow to the lower extremities of each mouse 
was monitored using LDI immediately following surgery, then every 7 days for a 21 day duration. 
Mean blood flow perfusion divided by the area of each injured limb was normalized to the non-
injured limb, then calculated as a percentage. One-way ANOVA with Tukey’s multiple 
comparisons were carried out to compare mean blood perfusion by area of Dock4 het mice to 
WT mice at each time point. Significant differences indicated by asterisks: ***=P value equal to 
or lower than 0.005. 






























 IHC analysis of vasculature within the gastrocnemius tissue of Dock4 het mice following 
HLI 
The hindlimb muscles of all experimental mice were posthumously fixed and 
harvested for the purpose of analysing and comparing the vasculature of the hind limb 
tissues of each experimental group. One hour following the final LDI scan all mice were 
exsanguinated through ligation of the major vena cava. Whole animal fixation of each mouse 
was carried out through administration of 4% PFA through the left ventricle. The 
gastrocnemius and soleus muscles were harvested from both the injured and non-injured 
hind-limbs of each mouse and placed in 4% PFA for 24 hours before being transferred to 70% 
ethanol. Following fixation, gastrocnemius muscle tissue from both the injured and non-
injured legs were imbedded in paraffin wax in a longitudinal orientation. The muscle was 
then section into 50 x 5μm thick sections using a floating sectioning technique.  
Every 10th section from each muscle block was selected and IHC stained with an anti-
CD31 antibody. Slides were electronically scanned and imaged. Imagescope software was 
utilised to randomly select 8 500μm x 500μm boxes per muscle section (figure. 5.8). ImageJ 
analysis software was employed to quantify the length of every detectable CD31 stained 
vessel and number of branch points per 500μm x 500μm area of analysis. The mean values 
of TVL and BPI (number of branch points/TVL) were then calculated per muscle section for 
both the injured and non-injured limbs of both Dock4 het mice and their WT littermates. 
Data was analysed using a One-way ANOVA with Tukey’s multiple comparisons. 
The TVL of non-injured gastrocnemius of the Dock4 het mice were compared to the 
mean values of TVL generated from the non-injured gastrocnemius of the WT littermates 
Statistical analysis demonstrated no significant difference between the TVL of CD31 stained 
vasculature of the non-injured limbs of the Dock4 het mice when compared to their WT 
littermates (figure. 5.4, 5.6, and 5.9).  
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Analysis of the gastrocnemius muscle sections from the injured legs of the two 
experimental groups demonstrated a significant increase in TVL within the muscle sections 
from the Dock4 het mice when compared to the WT littermates (p=0.043) (figure 5.5, 5.7, 
5.9).  
When comparing the BPI of the gastrocnemius sections from the non-injured limbs 
between the two experimental groups, there was a significant decrease in BPI of Dock4 het 
CD31 stained gastrocnemius sections compared to the WT littermates gastrocnemius 
sections (p=0.046), signifying a less branched vascular phenotype in the gastrocnemius of 
the non-injured Dock4 het mice (figure. 5.4, 5.6, and 5.10). However, in gastrocnemius of the 
injured limbs, there was no significance in the BPI between the two experimental groups 
(figure. 5.5, 5.7, 5.10). 
To summarise the findings: IHC analysis detected differences between the pre-
existing vasculature of the Dock4 het mice and the wild-type littermates. While the 
gastrocnemius of both experimental groups appeared to have a similar overall level of 
vascularisation, the reduction in branching of the Dock4 het experimental group indicates 
patterning differences in the pre-existing vasculature.  
The vasculature within the gastrocnemius of the injured limbs also differed between 
the two experimental groups. However, following hind limb ischemia there was no significant 
difference between the BPI of the Dock4 het mice injured legs compared to the WT. 
Differences did however occur in the overall level of vascularisation between the two 
experimental groups, with the Dock4 het mice developing a much greater increase in TVL 
following vascular injury than was seen in the WT control group (figure. 5.7; figure. 5.9). 
These results were unexpected considering the reduction in blood flow to the injured hind 









Wild Type Dock4 het KO 
Figure 5-6 CD31 IHC staining of non-injured hind limb gastrocnemius muscle sections 
comparing DOCK4 het verses WT littermates. 
Representative images of gastrocnemius muscle harvested from non-injured hind limbs 
of Dock4 het KO and WT littermates, 21 days post HLI operation. Muscle from 24 Dock4 het mice 
and 24 WT littermates were fixed in 4% paraformaldehyde, embedded in paraffin wax. 8 Dock4 
het mice and 8 WT littermate muscle blocks were sectioned into 5μm floating sections and IHC 
stained using an antibody against CD31.  Slides were scanned using an Apeiro AT Virtual Slide 





Wild type Dock4 het KO 
Figure 5-7 CD31 IHC staining of injured hind limb gastrocnemius muscle sections comparing 
DOCK4 het KO mice versus WT littermates. 
Effects of het DOCK4 depletion on angiogenesis within the gastrocnemius following 
ligation and transection of the left femoral artery of global DOCK4 het deleted mice and WT 
littermates. Representative images of gastrocnemius muscle harvested from injured hind limbs 
of Dock4 het mice and WT littermates 21 days post HLI operation. Muscle from 24 Dock4 het 
mice and 24 WT littermates were fixed in 4% paraformaldehyde, embedded in paraffin wax.  
Muscle blocks of 8 Dock4 het mice and 8 WT littermates were sectioned into 5μm floating 
sections and IHC stained using an antibody against CD31.  Slides were scanned using an Apeiro 









Figure 5-8 Selection for analysis and quantification of gastrocnemius section regions following 
anti-CD31 IHC staining. 
(A) Representation diagram of anatomical location of gastrocnemius muscle in the 
hindlimb of mice. (B) Representative image of selection of area for analysis of IHC anti-CD31 
immuno-stained 5μm thick floating sections of gastrocnemius muscle from injured and non-
injured hind limbs of Dock4 het mice and WT littermate controls. Slides were electronically 
scanned using an Apeiro AT Virtual Slide scanner and characterised using Apeiro ImageScope 
software was utilized to randomly select 8 500x500m boxes per muscle section. 
 























































Figure 5-9 Quantification of CD31 IHC staining of hind limb gastrocnemius muscle sections 
comparing TL of WT versus DOCK4 het vessels detected in tissues sections 
Combined data of quantification of total vessel length measured from anti-CD31 stained 
gastrocnemius muscle sections harvested from the injured and non-injured limbs of global 
DOCK4 heterozygote deleted mice and WT littermates 21 post HLI surgery. Gastrocnemius 
muscle fixed in 4% paraformaldehyde was harvested from non-injured and injured hind limbs of 
DOCK4 heterozygous and WT littermates, 21 days post HLI operation. Muscle was imbedded in 
paraffin wax and sectioned into 5μm floating section then immuno-stained using a CD31 
antibody. IHC anti-CD31 sections were scanned using an Apeiro AT Virtual Slide scanner and 
characterised using Apeiro ImageScope software. Sixteen 500μm x 500μm areas of analysis were 
randomly selected. TVL of CD31 stained vessels within the 500μm x 500μm areas were 
quantified using ImageJ analysis. Histogram shows total vessel length per section SEM. N=3 
sections per mouse with 4 mice per condition. *P<0.05; **P<0.01; **P<0.001 by one-



















































Figure 5-10  Quantification CD31 IHC staining of hind limb gastrocnemius muscle sections 
comparing BPI of WT versus DOCK4 het mouse. 
Combined data of quantification of BPI (number of branch points/total vessel length) 
measured from anti-CD31 stained gastrocnemius muscle sections harvested from the injured 
and non-injured limbs of global DOCK4 heterozygote deleted mice and WT littermates 21 post 
HLI surgery. Gastrocnemius muscle fixed in 4% paraformaldehyde was harvested from non-
injured and injured hind limbs of DOCK4 heterozygous and WT littermates, 21 days post HLI 
operation. Muscle was imbedded in paraffin wax and sectioned into 5μm floating section then 
IHC stained using a CD31 antibody. IHC anti-CD31 sections were scanned using an Apeiro AT 
Virtual Slide scanner and characterised using Apeiro ImageScope software. Sixteen 500μm x 
500μm areas of analysis were randomly selected. CD31 stained vessels and vessel branch points 
within the 500μm x 500μm areas were quantified using ImageJ analysis software. Histogram 
shows BPI calculated as the number of total number of branches per section divided by the total 
tubule length SEM. N=3 sections per mouse with 4 mice per condition. *P<0.05; **P<0.01; 















































 Tamoxifen induced EC specific Dock4 deletion does not impact on blood flow recovery 
following HLI surgery.  
In-order to analyse whether the reduction in blood flow recovery following femoral 
artery ligation, detected in the Dock4 het mice, was due to reduction in endothelial specific 
Dock4 expression, an EC Dock4 KO model was used within the HLI experiment. Two separate 
HLI experiments were conducted using EC Dock4 KO mouse model in-order to study the 
effect of an endothelial specific homozygote Dock4 deletion on the recovery of blood flow 
to the hind limb following femoral artery ligation. In-order to deplete Dock4 expression EC 
Dock4 KO mice (n=9), and, iVEC-cre-ve; Rosa26-lsl-Tomato; Dock4f/f mic (which will be 
referred to as Cre-negative mice from this point forward) (n=8), underwent daily 
intraperitoneal injections of a 2mg dose of tamoxifen for 5 consecutive days. Tamoxifen 
induced Cre expression, leading to targeted deletion of the Dock4 gene, which was flanked 
by the Cre targeted lox sites (Dock4f/f). Seven days following the final tamoxifen dose, all 
mice underwent a HLI operation to surgically ligate and transect the left femoral artery. LDI 
was carried out immediately following surgery, then 7, 14, and 21 days post hind limb 
surgery. Comparative One-way ANOVA analysis of percentage of blood flow to the injured 
hind limb, normalised to the non-injured limb, was calculated for each weekly time point, in 
addition to linear regression analysis, and area under the blood flow curve.  
LDI data was generated over 2 separate HLI experiments, each for a duration of a 21 
day time period, following femoral artery ligation of the left hind limb. Each of the two 
experiments demonstrated no significant difference in blood flow of the non-injured hind 
limb of the 9 analysed EC Dock4 KO mice when compared to the 8 Cre negative control 
littermates (figure. 5.12). Each of the two experiments also demonstrated no significant 
difference in blood flow recovery of the injured hind limb of the 9 analysed EC Dock4 KO 
mice when compared to the 8 Cre negative control littermates (figure. 5.13) at any of the 4 
time points. 
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From visual analysis of the linear regression of the rate of blood flow recovery 
between the analysed EC Dock4 KO mice and the 8 Cre negative control littermates (figure. 
5.13) it can be noted that the level of detected blood flow of the mice with an inducible 
Dock4 deletion have a lower level of blood flow in comparison to the Cre negative control 
group. However, using linear regression analysis the slope of the lines of best fit, of the Cre 
negative data set and the EC Dock4 KO mice data set, were not significantly different 
(p=0.155). The intercept of the two lines representing the different data sets were also not 
significantly different (p=0.093). This signifies that while the Cre neg control group appear to 
recover marginally faster than the EC Dock4 KO experimental group, data analysis does not 
detect a significant difference between the rates of recover of the two experimental groups. 
Area under the blood flow curve analysis supported the linear regression analysis and found 































Figure 5-11 Effect of EC specific inducible Dock4 deletion on hind limb vascular recovery 
following surgically induced HLI  
Representative images of Laser Doppler detected mean/area of blood flow 
perfusion in the hind limbs of tamoxifen Cre neg control and EC Dock4 KO mice, in a supine 
position, over a 21 day time period, following HLI surgery. EC Dock4 KO mice and cre-
negative control mice were treated with once daily intraperitoneal injections of 2mg of 
tamoxifen for 5 consecutive days. Surgery to ligate and transect the left femoral artery of 
9 mice was carried out 7 days prior to tamoxifen treatments to occlude blood flow to the 
left hind limb. Blood flow within the hind limbs was analysed using LDI on day 0, 7, 14, 
and 21, following surgical ligation of the left hind leg femoral artery on day 0. Cre negative 








Figure 5-12 Quantification of LDI of EC Dock4 KO non-injured hind limbs during ischemia 
recovery 
Combined data LDI detection of blood flow perfusion in the uninjured hind limbs 
of EC Dock4 KO mice (n=9) versus Cre-negative control littermates (n=8) following HLI 
surgery. EC Dock4 KO mice and Cre-negative control mice were treated with once daily 
intraperitoneal injections of 2mg of tamoxifen for 5 consecutive days. Surgery to ligate 
and transect the left femoral artery of 9 mice was carried out 7 days prior to tamoxifen 
treatments to occlude blood flow to the left hind limb. Blood flow within the hind limbs 
was analysed using LDI on day 0, 7, 14, and 21, following surgical ligation of the left hind 
leg femoral artery on day 0. (Cre neg) Cre negative control (n=8) (Cre pos) EC Dock4 KO 
mice (n=9). 



































Figure 5-13 Quantification of LDI of EC Dock4 KO mice injured hind limbs during ischemia 
recovery 
Combined data of LDI detection of blood flow perfusion in the injured hind limbs 
of EC Dock4 KO mice (n=9) versus Cre-negative control littermates (n=8) following HLI 
surgery. EC Dock4 KO mice and Cre-negative control mice were treated with once daily 
intraperitoneal injections of 2mg of tamoxifen for 5 consecutive days. Surgery to ligate 
and transect the left femoral artery of 9 mice was carried out 7 days following tamoxifen 
treatments to occlude blood flow to the left hind limb. Blood flow within the hind limbs 
was analysed using LDI on day 0, 7, 14, and 21, following surgical ligation of the left hind 
leg femoral artery on day 0. (Cre neg) Cre negative control littermates (n=8) (Cre pos) EC 
Dock4 KO mice (n=9). 































 Tamoxifen treatment of EC Dock4 KO mice successfully depleted Dock4 expression 
The hindlimb muscles of all experimental mice were posthumously fixed and 
harvested, for the purpose of analysing and comparing the vasculature of the hind limb 
tissues of each experimental group. One hour following the final LDI scan, all mice were 
exsanguinated through ligation of the major vena cava. Whole animal fixation of each mouse 
was carried out by administration of 4% PFA, through the left ventricle. The gastrocnemius 
and soleus muscles were harvested from both the injured and non-injured hind-limbs of each 
mouse, and placed in 4% PFA for 24 hours, before being transferred to 70% ethanol. 
Following fixation, gastrocnemius muscle tissue from both the injured and non-injured legs, 
were imbedded in paraffin wax in a longitudinal orientation. The muscle was sectioned into 
5μm thick sections using a floating sectioning technique.  
Muscle section slides were selected from each experimental group and were IHC 
stained with an anti-DOCK4 antibody to detect presence of absence of Dock4 expression and 
RFP to detect the Td Tomato reporter; indicating successful tamoxifen induced depletion of 
DOCK4 (figure 5.14). Analysis of the anti-RFP stained muscle sections indicated Td Tomato 
expression within the vasculature of EC Dock4 KO mice, but not in Cre negative control 
littermates (figure 5.14). Dock4 expression was detected in the Cre negative mouse, anti-
DOCK4 stained gastrocnemius muscle sections, but was not detected in the Cre positive 























Figure 5-14 IHC staining of hind limb gastrocnemius muscle sections detecting vascular specific 
expression of DOCK4 
Representative images of anti-RFP and anti-DOCK4 IHC stained gastrocnemius muscle 
sections of the hind limbs of tamoxifen treated (A) EC Dock4 KO mice and (B) Cre neg control 
littermates. Mice were treated with once daily intraperitoneal injections of 2mg of tamoxifen 
for 5 consecutive days. Muscles were fixed in 4% paraformaldehyde, embedded in paraffin wax, 
sectioned into 5μm floating sections and IHC stained using an antibody against RFP or DOCK4. 







Understanding the complex cellular signalling mechanisms which underlay the 
dynamic process of angiogenesis, in response to a hypoxic environment, is imperative for 
furthering the knowledge of vascular pathologies that relate to the dysregulation of 
angiogenesis, such as peripheral ischemia. The ability to identify proteins essential for the 
growth of fully functional, normal blood vessels, is key for understanding how blood vessels 
form and grow in response to oxygen deprivation and other extracellular cues. In addition to 
expanding the understanding of vascular cell signalling mechanisms, the identification of 
potential therapeutic targets may also lead to improvement in the approach to treating such 
vascular pathologies. 
In the current study, global Dock4 het deletion severely impacted upon the vascular 
response to the loss of blood flow in a model of HLI, leading to inadequate vascular perfusion 
when Dock4 expression was reduced (figure 5.5). Reduction of Dock4 expression affected 
the mobility of the ischemic murine hind limbs, leading to necrosis of the toes and loss of the 
foot, in 2 out of 12 Dock4 het mice (figure 5.2). Thus, adequate levels of global Dock4 
expression are important for functional blood vessel growth following an ischemic event. 
Laser Doppler analysis of murine hind limbs following transection and removal of a 
portion of the femoral artery, inducing HLI, demonstrated that WT mice recovered from HLI 
within 21 days post operation (figure 5.5). This is in agreement with previous studies 
describing the expected normal response to HLI (Hellingman et al., 2010). However, global 
Dock4 het depleted littermates did not adequately recover from HLI (figure 5.5), as assessed 
by laser Doppler analysis of perfusion. Indicating that unlike controls, blood flow in the Dock4 
het mice had not recovered by day 21.  
When a conditional EC Dock4 KO model was employed, a trend towards reduced 
perfusion and vascular recovery from femoral artery ligation in response to HLI was 
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observed, however the level of reduction was not statistically significant (figure 5.13). This 
was unexpected as a complete ablation of Dock4 expression in ECs in the conditional 
knockout model had been hypothesised to re-capitulate, or exaggerate, the impaired 
recovery from HLI observed in the global het deletion model. This unexpected result may 
have been due to a number of different reasons: A potential inadequate knockdown of Dock4 
expression, and the efficiency of the RFP reporter system, Td Tomato. Although IHC 
assessment did indicate a successful depletion of Dock4 expression and expression of Td 
Tomato, in the EC Dock4 KO model (5.14). Isolation and culturing of ECs from experimental 
mice, for example pulmonary ECs, could be utilised for genetic confirmation of DOCK4 KO via 
analysis of the level of DOCK4 RNA within the ECs (Fehrenbach et al., 2009). However, 
isolation of pulmonary ECs from the DOCK4 het and conditional KO mice, used within this 
thesis, had been attempted but found to be unsuccessful. This was likely due to the age of 
the mice used within this thesis (24 weeks at the point of sacrifice). It has previously been 
reported that isolated pulmonary ECs harvested from adult mice have a reduced ability to 
proliferate, with an increase in susceptibility for fibroblast overgrowth (Fehrenbach et al., 
2009).  
Consideration also needs to be given to any compensatory cellular mechanisms 
which occur in response to Dock4 depletion. Cells may evoke transcription and post-
transcription mechanisms to overcome loss of an individual protein (El-Brolosy and Stainier, 
2017). When comparing genetic knockout and knockdown, of the same protein within a 
mouse model, phenotypical differences can arise (De Souza et al., 2006). The differences 
observed between a knockout and a knockdown can be attributed, in part, to compensatory 
mechanisms of the cell in response to ablation of a protein (De Souza et al., 2006). 
Considering such evidence in light of the conditional EC specific Dock4 deletion, which 
experiences a knockout of Dock4 expression, there may be potential for an endothelial 
compensatory mechanisms to overcome the loss of Dock4 expression within the adult 
193 
mouse, thus caution should be used when interpreting the findings of the HLI results in 
comparison to the Dock4 het mouse. 
Furthermore, global Dock4 het deletion affected Dock4 expression throughout the 
duration of development, unlike the conditional endothelial specific Dock4 deletion, which 
deletes Dock4 in the adult following tamoxifen treatment. The significant reduction in the 
vascular branching of the gastrocnemius of non-injured limbs of the Dock4 het mice (figure 
5.10) supports this concept as this observation indicates that 50% reduction in global Dock4 
expression, throughout development and post-developmental growth, impacts on vascular 
patterning.  
However, it should be noted that the EC DOCK4 KO mice did experience a reduction 
in the rate of vascular recovery compared to the control littermates, however, the difference 
between the two experimental groups was not statistically significant (figure 5.13). 
Expanding this study to include larger number of mice may have been necessary for the 
experiment to reach statistical significance. 
The significant difference in body weight between the global Dock4 depleted mice 
in comparison to their WT littermates indicates reduction in Dock4 expression has a greater 
over-all effect on the developing mouse, which may go beyond the vascular response to 
ischemia. This is also evident through many other studies which implicate DOCK4 
dysregulation in a number of pathologies; such as neural developmental functions of DOCK4 
(Ueda et al., 2013; Xiao et al., 2013) cancer (Yajnik et al., 2003; Hiramoto-Yamaki et al., 2010; 
Yu et al., 2015), and mental health related effects of DOCK4 mutations (Pagnamenta et al., 
2010; Alkelai et al., 2012). Thus demonstrating that DOCK4 depletion affects more biological 
mechanisms than is currently understood.   
It is also noteworthy that the heterozygous deletion is also global, unlike the 
conditional endothelial specific deletion. The potential involvement of non-endothelial 
Dock4 expression in driving the phenotypical effects seen in the global Dock4 KO model, but 
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not the EC DOCK4 KO mouse, should also be considered. Other requirements of DOCK4, such 
as for stromal cell paracrine signalling to the endothelium, or for the correct recruitment of 
perivascular cells, may also be relevant when considering the differences in impact of global 
versus EC Dock4 KO. However such functions have not yet been explored in relation to 
DOCK4, but may be of interest in fully understanding the function of DOCK4 in angiogenesis. 
Within normal vascular models, ischemia prompts a significant increase in total 
amount of vasculature. IHC CD31 staining of gastrocnemius muscle harvested from the hind 
limbs of global Dock4 het depleted mice and WT littermates, 21 days post HLI surgery, 
indicated distinct difference in the vascular growth in both the injured and non-injured hind 
limbs of the Dock4 het deleted mice and the WT littermates (figures 5.3-5.7). Dock4 depleted 
mice were found to have a normal amount of pre-existing vasculature in tissue harvested 
from the non-injured limbs in comparison to the wildtype littermates, although there may 
potentially be differences in patterning of the vasculature in Dock4 het mice, as they were 
found to have a less branched vasculature phenotype (figures 5.6, 5.9). Angiogenesis in 
response to ischemia was increased significantly in Dock4 depleted mice when compared to 
the WT littermates, as Dock4 het mice were found to have an increase TVL in the 
gastrocnemius following HLI in comparison to the wildtype littermates (figures 5.7 and 5.9)
 The findings indicate the DOCK4 depleted mice potentially experience differences in 
vascular patterning during development and/or during post developmental growth 
unrelated to HLI. The differences detected in vascular growth between the two experimental 
groups show that Dock4 depletion drives an increase in angiogenesis within the lower limbs. 
This may be due to blood vessel elongation as opposed to lateral branching, the latter of 
which is reduced by DOCK4 depletion in vitro(Abraham et al., 2015). However, BPI was not 
significantly impacted by Dock4 depletion following loss of blood flow. Similar phenotypes 
have been observed in other HLI model studies, which have investigated disruption of 
signalling mechanisms implicated in regulating angiogenesis that leads to an increase in 
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vascular structures but reduction in blood flow reperfusion (Ramo et al., 2016; Dor et al., 
2002; Clayton et al., 2008; Herold et al., 2017).    
Roma et al. found disruption of the MLK-JNK signalling pathway during development 
led to increased sprouting angiogenesis in conjunction with an inadequate response to HLI 
(Ramo et al., 2016). Interestingly, disruption of the signalling pathway in adult mice prior to 
hind limb surgery resulted in no significant difference in the recovery of hind limb blood flow. 
Impairment of hindlimb vascular of JNK deficient mice was only observed in mice which had 
experienced JNK protein depletion throughout development. This affect was attributed to 
the irregular growth of the collateral arteries during development, leading to loss of 
compensatory collateral blood flow in response to femoral artery ligation (Katoh et al., 2006). 
As the collateral arteries of either the Dock4 het or EC Dock4 KO experimental mice were not 
analysed, the findings of this study cannot be attributed to differences in vascular patterning 
or arteriogenesis of the collateral arteries. However, while this study investigates a non-
Dock4 related pathway, their results demonstrate how a genetic depletion can impact on 
vascular recovery to hind limb ischemia, when the depletion is present throughout 
development and adulthood, but for the same genetic depletion to have no impact on 
vascular recovery when induced only during adulthood. This finding offers potential insight 
to the differences observed between the global Dock4 het mouse recovery to hind limb 
ischemia when compared to the inducible EC Dock4 KO model. Further exploration into the 
impact of Dock4 expression on the hindlimb vasculature would be of great interest in 
understanding the true role of Dock4 within vascular biology.  
Data generated from LDI and IHC analysis together suggest reduction in Dock4 
expression impacts upon functionality of the vasculature, which grows through angiogenesis 
in the lower limbs or arteriogenesis in the upper limbs, in response to loss of the femoral 
artery. Despite the increase in angiogenesis within the gastrocnemius of the injured limbs, 
the global Dock4 het deleted mice appeared more physically impacted by the femoral artery 
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ligation, resulting in limited mobility, differing levels of necrosis, and a reduced rate of blood 
flow recovery to the injured limb when compared to the WT mice.  
The observation of increase in angiogenesis within the gastrocnemius, despite less 
blood flow to the hind limbs of Dock4 het mice compared to WT, may potentially be due to 
differences in the arteriogenesis within the collateral arteries. An investigation into the role 
of exogenous factor VII activating protein in vascular recovery, found application of 
exogenous factor VII activating protein inhibited arteriogenesis of the collateral arteries, 
resulting in an impairment in blood flow to the hind limbs and a pronounced increase in 
angiogenesis of the gastrocnemius. This effect was determined to be due to sustained 
hypoxia of the lower limbs due to a decrease in blood flow through the collateral arteries 
(Herold et al., 2017).  
Considering the wider implications of the combined Dock4 het deletion data it is 
possible to speculate that Dock4 depletion impacts upon the development of the pre-
existing vasculature of the hind limb. It is also possible to hypothesis that Dock4 depletion 
may impact on the ability to form functional vasculature in response to ischemia, leading to 
an overgrowth of less functional vasculature structures, as DOCK4 depletion in vitro results 
in loss of lumenisation of EC cords during angiogenesis (Abrahams et al. 2015). Abraham et.al 
(2015) demonstrated that Dock4 expression was found to be required for lumenisation and 
growth of functional vasculature. Abraham et.al described how Dock4 deletion within an 
organotypic angiogenesis co-culture in vitro resulted in long unbranched cords of ECs unable 
to form a lumen.  
This current study therefore supports the findings that DOCK4 is required for 
formation of functional vasculature during blood flow recovery following ischemia. 
Investigation into Dock4 function during vasculogenesis and angiogenesis during 
development would be of key interest to understand how DOCK4 impacts upon the growth 
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of functional blood vessels. Further investigation into the patterning of the collateral arteries 
may also add further insight into the role of DOCK4 function.  
The study demonstrates the requirement for Dock4 signalling in growth and 
formation of functional vasculature, with reduction in global Dock4 expression impacting on 



















6 Overall Discussion 
Sprouting angiogenesis describes the dynamic outgrowth of new blood vessels from 
existing vasculature in response to external stimuli. Chemotactic initiated sprouting 
angiogenesis integrates a dynamic repertoire of external stimuli, driving complex 
intracellular remodelling to permit growth of new vascular sprouts. The VEGFA driven small 
Rho GTPase signalling module SGEF-RhoG-DOCK4-RAC1-DOCK9-CDC42 is an important 
component for development of lateral filopodia and vessel lumenisation in vitro, and thus is 
likely to be required for correct patterning and functionality of newly sprouted vasculature 
(Abrahams et al., 2015). Depletion of the endothelial expression of RAC1 GEF, DOCK4, results 
in loss of filopodia along the lateral edge of newly forming vascular sprouts, leading to 
deficiencies in tube formation (Abraham et al., 2015). As dysregulation in vascular patterning 
and tube formation impairment are characteristics of some pathological angiogenesis driven 
disorders (Matucci-Cerinic et al., 2013; Maruotti et al., 2006; Maruotti et al., 2008; Cantatore 
et al., 2017), expanding upon the understanding of DOCK4 function within angiogenesis 
could lend insight into mechanisms affected during pathological angiogenesis. This study 
strove to expand upon the understanding of the DOCK4-DOCK9 interaction, while also 
investigating whether DOCK4 activity was required for pathological angiogenesis.  
The small molecule inhibitor QL-47 was demonstrated to be a potent anti-angiogenic 
compound with VEGFA stimulated ECs being particularly sensitive to QL-47 (figures 3.7-3.9). 
However, it is highly unlikely that the anti-angiogenic effects are due to disruption of a direct 
DOCK4-DOCK9 interaction at this site, as in this study no evidence was obtained that the 
p.C628 cysteine residue was found to bind the DOCK4 SH3 domain (figure 4.12). It is largely 
plausible that the QL-47 inhibitor disrupts DOCK9 through non-DOCK4 specific mechanism; 
perhaps through disruption of localisation, or inhibition of interaction with other DOCK9 
binding partners. Abraham et al (2015) described an extensive list of proteins which 
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specifically bind DOCK9. Repetition of the Abraham et al (2015) Co-IP with LC-MS/MS 
Orbitrap Elite mass spectrometer and MASCOT analysis of DOCK9 binding partners in the 
presence of QL-47 would potentially elucidate which DOCK9 interaction partners may be 
disrupted by the small molecule inhibitor. 
The specific site of DOCK9 which interacts with the SH3 domain of DOCK4 was not 
elucidated during this study, the results suggested that DOCK9 PRRs identified as PRR 2,3,4, 
5, and 9 were unlikely to serve as singular points of direct interaction between the two 
proteins (figures 4.3-4.12). Use of the Co-IP overexpression system and SEC of truncated 
peptides both present discrepancies which may have confound results. Forced interaction 
between the two large GEFs within an overexpression system within HEK 293T cells may have 
yielded non-specific interaction and a false positive pull down of Flag-DOCK9 due to non-
specific interaction of the peptide tags (Free et al., 2009), excessively high level of protein 
expression due to overly active promoters (Xia et al., 2006), and also the lack of sensitivity of 
the Western blotting technique which lacks sensitivity, with the potential to produce 
unreliable results that may not distinguish between genuine interaction and non-specific 
interaction (Zhu et al., 2017).  
Detecting an interaction between two truncated peptides using SEC may also prove 
difficult as the peptides may not provide a true representation of the secondary structures 
of the complete protein and thus they may lose the potential binding affinity between the 
site of interaction (Wingfield, 2015). 
Use of a MultiBac™ system designed to co-express both DOCK4 and DOCK9, followed 
by trypsin digest to expose crosslinking residues, and cryoEM analysis would allow for 
detection of the interacting residues of the two large proteins, with cryoEM providing an 
optimal technique for structural analysis of two large proteins within a complex (Serna, 
2019). Such an approach would offer a more highly sensitive approach for elucidating the 
site of interaction between the two proteins. 
200 
Through this study, DOCK4 was demonstrated as being a potential component of 
FGF2 stimulated angiogenesis under hypoxia in vitro, (figure 3.5 and 3.6) indicating DOCK4 
as important for mechanisms involved in the angiogenic response to ischemia.  
FGF2 has a protective effect during wound healing, and when used as a treatment 
improves outcomes of cardiac ischemia (Unger et al., 2000; Laham et al., 1999), and the 
peripheral circulation of people suffering from claudication (Lazarous et al., 2000). Such 
effects of FGF2 signalling may be attributed to the GFs function in EC proliferation and 
elongation in angiogenesis in response to vascular pathologies in vivo (Unger et al., 2000; 
Laham et al., 1999). The protective mechanisms of FGF2 has been indicated to occur in a 
RAC1 and CDC42 dependent mechanism (Lee and Kay, 2006). As DOCK4 is an activator of 
RAC1, it can be considered that DOCK4 may serve as a potential component in conferring the 
FGF2 protective response to pathological angiogenesis, a concept which has been supported 
by the results presented throughout this thesis. 
This finding was further supported through in vivo analysis of blood flow recovery in 
the hind limbs of het global DOCK4 deleted mice following femoral artery ligation. LDI of 
injured mouse hind limbs demonstrated a reduction in global Dock4 expression results in 
impairment of blood flow recovery (Figures 5.3 and 5.5). The reduction in blood flow 
recovery of the EC Dock4 KO mice was also seen to be impaired, but to a much lesser and 
non-significant degree (figures 5.11 and 5.13). This finding may potentially indicate 
additional non-EC functions of DOCK4 during pathological angiogenesis. The data also 
indicates that Dock4 may be required for the growth and correct patterning of hind limb 
vasculature during development (figure 5.4 and 5.10), with Dock4 deficiencies leading to 
differences in pre-existing vasculature in the mature mice; findings which are similar to other 
proteins which are not required for normal vasculature but impact on an adequate vascular 
response to hind limb ischemia (Herold et al., 2017; Ramo et al., 2016). 
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The IHC analysis of muscle tissue from the ischemic hind limbs of DOCK4 deficient 
mice indicated DOCK4 depletion may impair vessel functionality, as an increase was 
observed in the overall abundance of vascular structures despite a reduction in blood flow 
(Figures 5.4 and 5.9). This finding was in line with in vitro analysis of the impact of DOCK4 
depletion on sprouting angiogenesis, with loss of DOCK4 resulting in growth of less dynamic 
vascular structures with impaired tube formation (Abraham et al., 2015).  
In light of previous studies, which highlight the importance of correct vascular 
patterning of the collateral arteries during development for a proficient response to HLI 
(Ramo et al., 2016; Dor et al., 2002; Herold et al., 2017), consideration should be given to the 
effect of Dock4 depletion on the correct vascular patterning of the collateral circulation. Pre-
existing defects in the collateral vascular patterning, or arterogenesis response to ischemia, 
have both been observed to induce a similar phenotype to the global Dock4 depletion, in 
response to hind limb ischemia; with loss of blood flow recover to the hind limbs combined 
with an increase in angiogenesis detected in the gastrocnemius (Ramo et al., 2016; Dor et 
al., 2002; Herold et al., 2017). The detected difference in vascular recovery between the 
Dock4 het mouse model and the EC Dock4 KO mouse model may potentially indicate Dock4 
vascular signalling as being required for developmental blood vessel development, but not 
adult angiogenesis. Thus the collateral arteries of the Dock4 deficient mice should be further 
explored in future experiments to determine whether DOCK4 may be involved in collateral 
artery development, patterning, and/or arteriogenesis.  
MicroCT imaging of hind limb vasculature of both the DOCK4 het and EC Dock4 KO 
mouse lines, following HLI, would allow for analysis of intact whole leg vascular structures, 
including the collateral arteries, and would perhaps give insight into non-luminized 
structures when comparing Micro-fil perfused vessels to those detected through IHC analysis 
(Schaad et al., 2017). Comparison of Dock4 het mouse whole leg vasculature to that of non-
202 
Dock4 depleted littermates whole leg vasculature, would lend an interesting insight into how 
vascular Dock4 impairs recovery of blood flow following an ischemic event.  
The accumulated results of this thesis have strongly indicated that DOCK4 is a critical 
component of the vascular response to ischemia driven angiogenesis. Further investigation 
of DOCK4 function during development, formation of collateral arteries, correct 
lumenisation in vivo, and within the context of pathological angiogenesis during peripheral 
ischemia, would be required to determine how aberrant DOCK4 expression and regulation 
may underlie angiogenesis driven pathologies, such as peripheral ischemia. However, these 
finding highlight the importance of DOCK4 in growth of healthy vasculature that is capable 
of adequately responding to critical ischemia. Elucidating the vascular function of DOCK4 
during development and within the response to ischemia may further our understanding of 
how blood vessels grow, and expand our understanding of how angiogenesis may differ 













7.1 Appendix 1. Nucleotide sequences of primers for Sanger sequencing and 
Expression vector cloning  
 Primer design for Sanger sequencing 
1 pBABE Flag-DOCK forward 1 5’-GTTCAGTGAATCAGAAC-3' 
2 pBABE Flag-DOCK forward 2 5’-GGATGAAGGACGTGAAG-3' 
3 pBABE Flag-DOCK forward 3 5’-TTTCTCATGGAGTATCC-3' 
4 pBABE Flag-DOCK forward 4 5’-AGTAAAGTTTCTGCAGG-3' 
5 pBABE Flag-DOCK forward 5 5’-AAGGACCTGATCATGTG-3' 
6 pBABE Flag-DOCK forward 6 5’-CAGCCAGATCTTCGGAATG-3' 
7 pBABE Flag-DOCK forward 7 5’-CCAGCAACGTCTTGAAC-3' 
8 pBABE Flag-DOCK forward 8 5’-AGCTGATGCTTGAGCAG-3' 
9 pBABE Flag-DOCK forward 9 5’-AGAACATGTCGGATAGTG-3' 
10 pBABE Flag-DOCK forward 10 5’-AGTTGCTGATCTAAAACGC-3' 
Table 7-1 Primer sequences for Sanger sequencing of the pBabe puro Flag-DOCK4 plasmid 
construct designed for expression of human DOCK4.  
Human DOCK4 expression vector pBABE puro Flag- DOCK4; a plasmid gifted by Dr 
Vijay Yanik (Harvard Medical School, Massachusetts, USA) was sequenced using Sanger 








1 pEF4 Myc-Flag-DOCK9 forward 1 5’-ACTATAGGGAGACCCAAGCTG-3' 
2 pEF4 Myc-Flag-DOCK9 forward 2 5’-CTGGCAAAGCCAAAGCTAATTGAG-3' 
3 pEF4 Myc-Flag-DOCK9 forward 3 5’-CTTCCCTTACGATGACTTTCAGAC-3' 
4 pEF4 Myc-Flag-DOCK9 forward 4 5’-AAACCTATAACTCTGACTGGCATC-3' 
5 pEF4 Myc-Flag-DOCK9 forward 5 5’-AAAGTTCAGACTCTTCTAAGGTGG-3’ 
6 pEF4 Myc-Flag-DOCK9 forward 6 5’-CAAGGACATTGTTTAAGGATGC-3’ 
7 pEF4 Myc-Flag-DOCK9 forward 7 5’-GCTCAAGTTACTTGCAGACTTTCG-3’ 
8 pEF4 Myc-Flag-DOCK9 forward 8 5’-AAACTCCCATCACGTTTGAAG-3’ 
9 pEF4 Myc-Flag-DOCK9 forward 9 5’- GACCCAAAGACCCTCTTTGAATAC -3’ 
10 pEF4 Myc-Flag-DOCK9 forward 10 5’-GGGCATGACTGTGAAGGATG-3’ 
Table 7-2 Primer sequences for Sanger sequencing of the pEF4 Flag-DOCK9 plasmid 
construct designed for expression of human DOCK9.  
Human DOCK9 expression vector pEF4 Myc-Flag–DOCK9 (Meller et al., 2008); a 
plasmid gifted by Professor Martin Schwartz (University of Virginia, USA) was sequenced 

















Figure 7-1 Plasmid vector map of pOPINM DOCK9 
Full length DOCK9 was sub-cloned into pOPIN3SC HIS6-SUMO-3C-POI with ampicillin 
resistance gene sequence.  Full length DOCK9 gene inserted in recombinant plasmid vectors 
designed for expression of full length DOCK9 was PCR amplified from the template plasmid pEF4 
Myc-Flag–Dock9 (Meller et al., 2008) using the primer sequences described in Table 7.1. Plasmid 
map generated using Snapgene software. 
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Figure 7-2 Plasmid vector map of pOPINF PH-PCIP-DOCK9 
DOCK9 PH-PCIP-DHR1 domain PCR fragments were sub-cloned into a modified a 
pOPINF HIS6-3C-POI vector with ampicillin resistance gene sequence. DOCK9 gene fragments 
inserted in recombinant plasmid vectors designed for expression of full length DOCK9 was 
PCR amplified from the template plasmid pEF4 Myc-Flag–DOCK9 (Meller et al., 2008) using 





Figure 7-3 pOPINF PCIP-DHR1-DOCK9 
DOCK9 PCIP-DHR1 domain PCR fragments were sub-cloned into a modified a pOPINF 
HIS6-3C-POI vector with ampicillin resistance gene sequence. DOCK9 gene fragments inserted 
in recombinant plasmid vectors designed for expression of full length DOCK9 was PCR amplified 
from the template plasmid pEF4 Myc-Flag-DOCK9 (Meller et al., 2008) using the primer 




Figure 7-4 pOPINF DOCK4-SH3 
DOCK4 SH3 domain PCR fragments were sub-cloned into a modified a pOPINF HIS6-
3C-POI vector with ampicillin resistance gene sequence. DOCK4 gene fragments were PCR 
amplified, using the described primer sequences, from the template plasmid pBABE puro 
Flag- DOCK4; a plasmid gifted by Dr Vijay Yanik (Harvard Medical School, Massachusetts, 








Figure 7-5 pOPINF DOCK4-DHR2 
DOCK4 DHR2 domain PCR fragments were sub-cloned into a modified a pOPINF HIS6-
3C-POI vector with ampicillin resistance gene sequence. DOCK4 gene fragments were PCR 
amplified, using the described primer sequences, from the template plasmid pBABE puro 
Flag- DOCK4; a plasmid gifted by Dr Vijay Yanik (Harvard Medical School, Massachusetts, 









Figure 7-6 pGIPz lenti viral plasmid for DOCK4 shRNA expression 
Plasmid map of pGIPz lenti viral vector backbone with Dock4 SHRNA and non-
silencing pGIPZ nucleotide sequence.  Plasmid map generated using Snapgene software. 
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Figure 7-7 pEF4 Flag-DOCK9 plasmid map 
PEF4 Myc-Flag–DOCK9 (Meller et al., 2008) was obtained from Professor Martin 












Figure 7-8 psPAX plasmid map 
Plasmid psPAX plasmid map, generated by Snapgene software. 
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Figure 7-9 pMD2.G plasmid map 












Figure 7-10 The small molecule inhibitor QL-47 and YKL-04-126 
Molecular structure of the (A) covalent small molecule inhibitor QL-47 and (B) a 
tagged form of the covalent QL-47 inhibitor YKL-04-126. QL-47 is a compound developed by 








Figure 7-11 Covalent inhibitor target-site-identification and Liquid chromatography–mass 
spectrometry of QL-47 targeted proteins  
Inhibitor competition assay between a tagged (YKL-04-126) form of the covalent QL-47 
inhibitor and QL-47. This assay screen 1656 proteins for QL-47 specific binding. Purified tagged 
inhibitor peptides were identified via Liquid chromatography–mass spectrometry (LC-MS/MS) 
to distinguish between true targets of QL-47 and non-specific interactions. DOCK9 was detected 
to have a very high degree of competitiveness for QL-47. QL-47 was determined to bind 
irreversibly to distinct cysteine residues on target proteins. For DOCK9 this residue is cysteine 
628. Assays carried out and diagram generated by Dr Christopher Browne, of Prof. Nathanael 
Gray’s research group (Dana Farber Cancer Institute Harvard Medical School, MA). 
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Figure 7-12 Proteins identified as targets of QL-47 through Covalent inhibitor target-site-
identification and Liquid chromatography–mass spectrometry 
Purified tagged inhibitor peptides were identified via Liquid chromatography–mass 
spectrometry (LC-MS/MS) following an inhibitor competition assay between a tagged (YKL-
04-126) form of the covalent QL-47 inhibitor and QL-47; to distinguish between true targets 
of QL-47 and non-specific interactions. DOCK9 was detected to have a very high degree of 
competitiveness for QL-47. Of 1656 proteins screened, 9 were found as specific targets of 
QL-47. QL-47 was determined to bind irreversibly to distinct cysteine residues on DOCK9. 
Assays carried out by, and histogram generated by, Dr.Christopher Browne of Prof. 















DOCK9 ZAK VPS4A NT5DC1 HGD FAM8A1 LYRM7 SNX8 PFKFB2






7.3 Appendix 3. DOCK4 murine line genetic background 
Figure 7-13 Retroviruses used in the in vivo tumour co-injection model and generation of 
the Dock4 het mouse line. 
Schematic diagram showing the WT and the targeted KO Dock4 alleles. In the 
targeted allele, exons 3-5 were replaced by the targeting cassette for frameshift of the open 
reading frame. Yellow boxes show exons, main black lines show homology regions, grey lines 
show homology outside of the targeting vector. SA = Splice Acceptor, IRES = Internal 
Ribosomal Entry Site, β Gal= Beta galactosidase. Black boxes show position of the Southern 
probe that detects bands shown upon NsiI digestion for the purpose of genotyping. Figure 










Figure 7-14 Schematic showing the EC Dock4 KO alleles and excision site of Dock4 exon 6. 
Diagram depicting the targeted strategy for the EC Dock4 KO model, generated by Ozgene. 
Dock4f/f mice were crossed with VE-cadERT2-CreTd tomato gene carrying mice. FRT sites 
flanking, SA (splice acceptor), IRES (internal ribosomal entry site), β Gal (Beta galactosidase). 
Expression of FLP recombinase enzymes targets FRT sites, deleting the internal 
compartment. Cre recombinase expression, under the control of the VE-Cadherin reporter, 
targets and deletes the LoxP sites flank the Dock4 exon 6, and also Lox. The Td Tomato gene 
lies downstream of a transcriptional/translational-floxed stop cassette, allowing for strong 
expression of the Td Tomato gene in the presence of Cre recombinase expression. The VE-
cadERT2-CreTd tomato mouse line was originally generated by the lab of Prof. Ralf Adams 
(London Research Institute), and is commercially available via purchase from Taconic 
Biosciences (Germantown, NY USA). VE-cadERT2-CreTd tomato mouse line carries a gene for 
tamoxifen inducible Cre recombinase expression, under the control of the VE-Cadherin 
reporter. VE-cadERT2-CreTd tomato alleles not depicted within this diagram. Black boxes 
show exons, main black lines show homology regions. SA = Splice Acceptor; IRES = Internal 
Ribosomal Entry Site; B-gal = β-galactosidase; FR= FLP recombinase; PGK: Neo= 
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